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Chapter 1: General Introduction
von Hippel-Lindau disease: mutation 
spectrum suggests a specific role for the 
p30 isoform in tumor suppression
Giles RH, Lolkema MP, and Voest EE
submitted
8Inactivating mutations of the von Hippel-Lindau gene (VHL) on chromosome 3p 
have been associated with the autosomal dominant VHL disease, characterized 
by extensively vascularized tumors and cysts in different organs, as well as the 
vast majority of conventional kidney cancers. The VHL gene product regulates the 
ubiquitination and subsequent degradation of hypoxia inducible factor (HIF), an 
important transcriptional activator of the genetic program triggered by hypoxia. 
The absence of functional VHL, thus, artificially stabilizes HIF and induces a cel-
lular response to perceived low-oxygen tension. This illegitimate HIF signalling 
under normoxic conditions is likely to contribute to the extensive vascularization 
observed in VHL-related lesions. Here, we examine the evidence supporting the 
role of HIF as an oncogene, but also examine data suggesting the presence of al-
ternative functions of VHL. For example, a subset of disease VHL alleles retains the 
ability to regulate HIF. We closely examine the VHL mutation spectrum in familial 
and sporadic tumors, which provides unique insights into several new functions 
ascribed to this tumor suppressor protein.
von Hippel-Lindau disease: mutation spectrum suggests a specific 
role for the p30 isoform in tumor suppression
Giles RH, Lolkema MP, and Voest EE
          submitted 
VHL disease
The von Hippel-Lindau (VHL) disease (MIM 
#193300) is an autosomal dominant disorder 
in which affected individuals have a propensity 
for developing both benign and malignant 
tumors in many organ systems. VHL patients 
develop vascular neoplasia, hemangioblas-
tomas of the central nervous system and/
or retina, clear cell renal cell carcinomas 
(ccRCCs), endocrine neoplasia of the adrenal 
gland (pheochromocytomas) and low-grade 
adenocarcinomas of the temporal bone, 
known as endolymphatic sac tumors. Less 
commonly, epididymal or broad ligament 
cystadenomas and pancreatic tumors are 
observed in VHL patients. In addition to the 
inherited risk for developing cancer, VHL pa-
tients develop cystic disease in various or-
gans including the kidney, pancreas, and liv-
er. VHL disease affects 1 in 36,000 individuals 
 worldwide, with similar prevalence in both 
genders and across all ethnic backgrounds (1). 
Age at diagnosis for VHL varies from infancy 
to the seventh decade of life, with an aver-
age age at diagnosis of 26 years.
The morbidity of VHL varies, depending on 
the particular organ system involved. The 
malignant degeneration of renal cysts is 
commonly believed to be the most serious 
VHL manifestation. Approximately 75% of 
patients demonstrate multiple renal cysts. 
Renal cysts are common in the general pop-
ulation and are seldom clinically significant; 
however, in VHL patients they have a 
significant predilection to degenerate to 
clear cell (cc) RCC (lipid-containing clear 
cells arranged in nests and tubules) (2). It 
is currently unknown whether all ccRCCs in 
VHL patients originate from cysts. ccRCC is 
the leading cause of death in patients with 
VHL disease, with 35-75% prevalence in one 
autopsy series (http://www.emedicine.com/
ped/topic2417.htm#section~bibliography). 
RCC develops in VHL patients at an aver-
age age of 44 years, which is significantly 
younger than the average age of 62 years 
at which sporadic RCC develops in the gen-
eral population. In addition to simple cysts 
and RCC, a number of other renal lesions 
are seen, such as angiomas and benign 
adenomas. To prevent the development of 
ccRCC in VHL patients, close surveillance us-
ing ultrasound, MRI, or CT-scan is indicated. 
For lesions larger than 2 cm minimal inva-
sive and nephron-sparing surgery has been 
suggested to be the treatment modality of 
choice, although new technologies such as 
ultrasound guided radiofrequency ablation 
could become the new standard for the VHL 
patients (3,4). This approach potentially 
delays the necessity for kidney-function re-
placement therapy such as dialysis or trans-
plantation for VHL patients. 
The most common –and often earliest- 
manifestations of VHL disease in 83% of 
patients (5,6) comprises the second most 
common cause of morbidity and mortality: 
retinal or CNS hemangioblastomas. CNS 
hemangioblastomas are typically located 
in the cerebellum but can also occur at the 
brainstem, spinal cord and very rarely at the 
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to diagnosis. Accepted criteria for diagnosis 
are (1) more than one angioblastoma in the 
CNS or retina, (2) a single angioma of the 
CNS or retina plus a visceral complication 
(multiple renal, pancreatic, or hepatic cysts; 
pheochromocytoma; renal cancer), or (3) 
a family history plus any one of the above 
manifestations. VHL gene mutation analysis 
is recommended when one of the following 
criteria are met: a patient with classic VHL 
disease and/or first-degree family members; 
a person from a family in which a germline 
VHL gene mutation has been identified (pre-
symptomatic test); a VHL-suspected pa-
tient, i.e., one with multicentric tumors in 
one organ, bilateral tumors, two affected 
organ systems, one VHL-associated tumor 
at a young age (<50 years for hemangio-
blastoma and  pheochromocytoma or <30 
years for ccRCC); or a patient with family 
history of hemangioblastoma, renal cell 
carcinoma, or pheochromocytoma (10). 
Regular surveillance is strongly suggested for 
at-risk individuals starting from age four, or 
until genetic testing excludes the presence 
of the familial mutant allele in an individual.
VHL is a tumor suppressor 
VHL patients are highly susceptible to tu-
mor development because they already 
carry one mutated VHL allele in all of their 
cells. The chance inactivation of the second 
allele in a single cell is capable of initiating 
neoplastic growth. However, while VHL 
disease is rare, biallelic loss of VHL in certain 
tumor types is quite common. Not surprisingly, 
the tumor types most likely to harbor two 
independent inactivating VHL mutations, are 
also the same tumor types most frequently 
observed in VHL patients. For example, about 
50% sporadic CNS and retinal hemangio-
mas also show biallelic loss of VHL (11,12). 
Most strikingly, it is estimated that 80% of 
sporadic ccRCCs –the 7th most common 
cancer of any type- have acquired biallelic 
VHL mutations, implying that the function 
of VHL is especially important for curtailing 
neoplasia of the kidney (reviewed in: 
(13,14)). Mouse xenograft studies have dem-
onstrated that reintroduction of wild-type 
VHL into patient-derived ccRCC cells inhibits 
the ability of these cells to form tumors (15). 
Tumor suppressor genes form an arbitrary 
group of proteins whose biallelic inactivating 
mutation ultimately results in neoplastic 
transformation (16). Thus VHL is consid-
lumbosacral nerve roots and supratentorial. 
These lesions are rarely malignant, however 
enlargement or bleeding within the CNS can 
result in neurological damage and death. 
Retinal hemangioblastomas can likewise 
result in considerable morbidity through 
retinal detachment or visual loss often lead-
ing to blindness. Typically, hemangioblasto-
mas are cystic tumors containing a mural 
nodule formed by noninvasive, vacuolated 
stromal cells that are embedded in a network 
of capillaries. Ocular hemangioblastomas 
can be treated using laser coagulation, cryo-
therapy, and vitrectomy. Recently anti-VEGF 
(vascular endothelial growth factor) therapy 
has been show to be beneficial in the treat-
ment of these lesions, offering a new thera-
peutic option for therapy-resistant cases (7). 
CNS hemangioblastomas pose a significant 
challenge for neurosurgeons and new treat-
ment modalities such as cryotherapy and lo-
cal coagulation are being tested. The main 
goal of therapy for CNS hemangioblastomas 
is to minimize the local pressure effects of 
the lesions and to minimize destruction of 
normal brain tissue incurred by the treat-
ment (8,9).
Neoplastic lesions in the adrenal glands 
(pheochromocytoma) appear histologically 
as an expansion of large chromaffin positive 
cells.  Development of pheochromocytoma 
is extremely rare in the general population, 
but occurs in 19% of all VHL patients. With-
out treatment, hypertension resulting from 
pheochromocytomas can lead to acute heart 
disease, brain edema and stroke. The risk 
of VHL patients developing pheochromocy-
tomas (usually benign) appears to hinge on 
the precise nature of the mutation respon-
sible for VHL disease in a specific family (dis-
cussed in more detail below). 
The recognition and screening of other less 
frequently occurring tumors associated 
with the VHL disease remain a clinical di-
lemma. However, as the life expectancy of 
VHL patients improves through timely rec-
ognition and treatment of the most com-
mon VHL-associated neoplasms, the less 
frequent tumors gain in clinical importance. 
Future clinical trials will elucidate the optimal 
management of this disease.
Diagnostic criteria 
Since VHL disease is a multi-organ disease 
with great variability in clinical presentation, 
a combination of manifestations may lead 
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ered to belong to the family of classic tumor 
suppressor proteins, and is often dubbed the 
“gatekeeper” of the kidney. 
The molecular mechanism of VHL func-
tion: its role in oxygen sensing
The best-known function for VHL is its role 
in the oxygen-sensing pathway. A wide 
variety of symptoms associated with the 
VHL disease and ccRCC such as increased 
angiogenesis and polycythemia suggested a 
correlation between the function of VHL and 
the adaptive response to oxygen deprivation 
(17).  However, insight into the molecular 
mechanism came from a landmark study 
in C. elegans, in which substantial pheno-
typic overlap was observed between genetic 
mutants for the orthologs of VHL and prolyl 
hydroxylases (PHDs), suggesting a common 
pathway (18). This genetic insight linked 
several pieces of loose data into a simple 
but elegant mechanism for the biological 
oxygen sensor. Multiple lines of evidence 
had indicated that the hypoxia-inducible 
factor α (HIFα) was subject to PHD-mediated 
hydroxylation under normoxic conditions, 
requiring the presence of iron, 2-oxogluta-
rate, PHDs, and most importantly, oxygen. 
Once modified by the -OH group, HIFα can 
be captured by VHL, which then delivers HIFα 
to an E3-ubiquitin ligase complex, thereby 
targeting HIFα for degradation by the 
proteasome (19-25). The interplay of these 
proteins, centered around the presence of 
an -OH group, results in a direct molecular 
oxygen sensor. The absence of oxygen, 
and thus -OH modification of HIFα, simply 
abrogates the ability of VHL to recognize 
HIFα. HIFα levels are thus transiently stabi-
lized, causing accumulation in the cytoplasm 
and ultimately translocate to the nucleus 
where it functions as a transcription factor. 
VHL mutations, by allowing inappropriate 
stabilization of HIFα, result in illegitimate 
hypoxic signaling in the presence of oxygen. 
The activation of HIF-mediated transcription 
accounts for a large number of phenotypes 
ascribed to VHL: e.g. the presence of elevated 
angiogenesis, altered extracellular matrix 
interactions, and the sporadic presence of 
polycythemia (2).
HIF- and VHL-related target gene expression 
has been studied extensively and has led to 
the recognition of a large set of hypoxia- 
responsive genes (26-29). The genes that 
are upregulated in the absence of VHL or 
the presence of HIF are indeed involved 
in the promotion of the adaptive response 
to hypoxia and can be classified into a 
few functional classes of genes: oxygen 
transport genes (e.g. EPO), promoters of 
angiogenesis (e.g. VEGF, PAI-1), and anaerobic 
energy metabolism (e.g. GLUT-1, LDH-A) 
(30). The affected genes are by large thought 
to promote tumor growth, with some notable 
exceptions. Pro-apoptotic proteins and growth 
inhibitory proteins Bnip3, cyclin G2, and 
DEC1 are upregulated by HIF transcription 
but their function would predict them to be 
less favorable for tumor growth. Thus there 
seems to be a subtle balance between the 
growth promoting and apoptotic effects of 
HIF target genes in oxygen homeostasis. 
However, in tumorigenesis, HIF seems to 
tip towards growth stimulatory functions 
(31). Furthermore, it has been reported that 
paralogs HIF1α and HIF2α have different 
functions, favoring a role for HIF2α in the 
development of ccRCC (32). 
VHL gene. 
The human VHL gene spans 3 exons residing 
on the short arm of chromosome 3 (3p25) 
and encodes a ubiquitously expressed 4.7-
kilobase messenger RNA. The first exon 
encodes the N-terminal half of the VHL 
protein which contains the sequences that are 
reported to be crucial for the recognition 
of hydroxylated HIF by VHL (Ser111 and 
His115), and the second exon encodes the 
α-domain important for the binding between 
VHL and Elongin C. This interaction occurs at 
residues 157-171 and forms the connection 
of VHL to the E3-ubiquitin ligase complex 
involved in the poly-ubiquitination of HIFα 
subunits (33). The third exon contributes to 
the structural beta domain complementing 
the region important for HIF binding. Two 
protein products are encoded by VHL, a 30kD 
full-length protein (p30, 213 amino acids), 
and a 19 kD protein (p19, 160 amino acids) 
generated by alternative translation initiation 
of an internal methionine at position 54 
(34,35) (Fig. 1). Both the p30 and p19 
isoforms were shown to suppress tumor 
formation in nude mice and both are fully 
capable of targeting HIFα subunits to the 
proteasome (34,36,37). The first 53 residues 
of p30 contain eight repetitions of a five-res-
idue acidic repeat, which collectively form 
an N-terminal acidic domain of unknown 
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function. The remaining functions of residues 
54-213 appear to be identical between p30 
and p19 (34). p30 is found primarily in 
cytoplasm, whereas p19 is also present in 
the nucleus (35,38). However, this difference 
 in localization has not yet led to differences 
in known VHL functionality, raising the issue 
of the biological relevance of the acidic 
domain. 
Germline inactivating mutations of a single 
VHL allele co-segregate with VHL disease (39). 
Mechanisms of VHL inactivation have been 
described to include intragenic mutations, 
mitotic recombination events, and 
hypermethylation of the promoter region. 
Mutations in virtually every of the 213 resi-
dues have been reported in three excellent 
databases (see VHL mutation databases). 
Global mutation analysis of 823 patient 
records identifies 36% as frameshifts, (28.5% 
deletions, and 7.5% insertions), 60% point 
mutations (48% missense, 12% nonsense), 
with the remaining mutations categorized as 
complex (Fig. 2). Nonsense mutations are 
far less likely to occur in exon 2 than exon 
3.
Most clinical genetic facilities screen VHL 
mutations by direct sequencing of the three 
exons. Single exon or larger deletions of VHL 
can best be detected by rapid quantitative 
RT-PCR assay (40). Somatic inactivation of 
the wild type VHL allele is believed to be the 
initial transforming event in all VHL disease-
associated neoplasms, although additional 
mutations are probably necessary for pro-
gression in carcinogenesis. 
The VHL gene - the p19 isoform in partic-
ular- has been conserved throughout evo-
lution and can be found in all multicellular 
organisms examined to date. Sequence 
analysis shows a striking conservation of 
amino acids that are crucial for HIFα binding 
(Fig. 3a) and the association with elongin C 
as part of the E3 ligase complex (Fig. 3b). 
These data suggest that the role for VHL in 
regulating HIF levels seems to be conserved 
through evolution. However there appears 
one or more hypoxia-independent functions 
for VHL as well; analysis of VHL in C. elegans 
has produced the strongest evidence to date 
that a group of genes is regulated by VHL 
in a manner independent of oxygen levels 
(41). Furthermore, multiple groups have re-
ported microarray analyses in mammalian 
 cell lines that indicate a role for VHL in tran-
scriptional regulation, independent of its 
interaction with HIF (26-28,42,43). Thus, 
while the role of VHL in the regulation of the 
cellular response to oxygen remains the best 
characterized and is likely to contribute to 
its tumor suppressor function, one or more 
additional functions may exist. 
Genotype-phenotype correlation: a 
strong case for a HIF-independent func-
tion for VHL
Different genetic mutations in VHL give rise 
to consistent disease manifestations, sug-
gesting that some genotype-phenotype 
correlations exist. For example, missense 
mutations in residues 74-90 confer 75% 
genetic susceptibility for RCC (44). Like-
wise, VHL kindreds with a deletion or protein 
truncation mutation of the VHL gene have 
less than 10% risk for developing pheochro-
mocytoma, while the risk is 50% in kindreds 
with a missense mutation (Fig. 2). From the 
mutation in the VHL gene, one can make 
informed predictions as to which tumors will 
develop in a particular family. Accordingly, 
patients are clinically categorized based on 
their predisposition to pheochromocytoma: 
type 1 patients have low incidence of 
pheochromocytomas, whereas type 2 families 
are defined by the presence of pheochro-
mocytoma (45). Type 2 VHL disease can be 
further subclassified into type 2A, type 2B 
and type 2C ((46) and Table 1). While type 
2A patients have only a small chance of 
developing ccRCC, they may develop any of the 
other visceral complications associated with 
Fig. 1. Cartoon of VHL protein domains.
VHL contains two functional translational initiation 
sites resulting in 2 VHL isoforms; a full-length 
protein (VHLp30) with an N-terminal acidic 
domain of unknown function, and a downstream 
reading frame (VHL p19) starting at methionine 
54. Both isoforms contain sequences responsi-
ble for binding to HIF-α and Elongin C (EloC). 
Although the vast majority of VHL mutations are 
downstream of the second initiation site, thereby 
altering both isoforms, 8% of unique mutations 
have been described that are not predicted to 
affect the structure or function of the smaller p19 
isoform. 
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the disease. One large family originally from 
the Black Forest region of Germany carrying 
a missense mutation (Y98H) comprises a 
significant portion of patients with this 
subtype, and it has been suggested that the 
mortality rate for those carrying this mutation 
was much lower than in unselected VHL 
mutations (47). Type 2B families are 
susceptible to all VHL-related tumors, but 
are always characterized by the presence 
of angiomas and ccRCC in addition to 
pheochromocytoma. Zbar et al. confirmed 
previous observations that germline VHL 
mutations at codon 167 (R167Q, R167W) 
convey a much higher risk for the development 
of pheochromocytoma (64%) and RCC 
than families without a mutation at codon 
167 (7%) (48). The reported reduced risk 
for RCC in individuals with a complete dele-
tion of VHL (49) possibly defines a new VHL 
phenotype, characterized by a low risk for 
both RCC and pheochromocytoma.
The only disease manifestation families with 
type 2C disease develop is pheochromocyto-
ma (13,14). The best characterized type 2C 
allele cosegregating with the syndrome con-
tains both P81S as well as L188V mutations 
(50). Other typical type 2C mutations include 
R64P, V84L, and F119S. Of great interest is 
the fact that type 2C mutant alleles retain 
their ability to regulate HIF-α levels (51,52). 
Whether the regulation of HIF by type 2C-
VHL alleles is empirically comparable to wild-
type VHL in vivo remains yet to be validated 
in target tissue (e.g.. in a type 2C patient’s 
pheochromocytoma). Some very recent 
evidence regarding pheochromocytoma de-
velopment places VHL together with all other 
known familial pheochromocytoma genes 
in a common pathway involving succinate 
dehydrogenase components (enzymes 
of the energy and respiratory system in 
mitochondria). By suppressing transcription 
factor JunB, VHL promotes apoptosis in 
sympathetic neuronal precursor cells (53). 
VHL mutant alleles, including type 2C variants, 
abolished this function of VHL, suggesting a 
HIF-independent role for this pathway in at 
least pheochromocytoma generation, if not 
Fig. 2.  Distribution of mutation types in VHL 
families.
VHL families can be grouped by their propensity 
to develop pheochromocytomas. Top panel, all 
families taken together give a fairly even distribu-
tion of mutation events. Middle panel, almost all 
families with pheochromocytomas (type 2 dis-
ease) are characterized by missense mutations. 
Bottom panel, families with pheochromocytomas. 
Modified from the National Cancer Institute.
Type Pheochro- Angioma RCC   HIF regulation
 mocytoma   
1 No    Yes Yes Defective
2A Yes    Yes No Diminished  
   (MT stability defect)
2B Yes    Yes Yes Defective
2C Yes    No No Normal
Table 1. VHL disease subtypes
RCC, Renal cell carcinoma; MT, microtubule
all VHL-related tumorigenesis.  Alternative-
ly, another recent paper details how loss of 
either succinate dehydrogenase subunits B or 
D, respectively associated with two distinct 
pheochromocytoma syndromes, triggers 
a HIF1α response, just like VHL-loss. The 
researchers further establish that high HIF1α 
levels can suppress the B subunit in a regu-
latory loop (54). These apparently conflicting 
data make it difficult to completely exclude a 
role for HIF activation in pheochromocytoma 
development. 
A few years ago, recessive “mild” mutations 
of VHL were discovered in polycythemia 
patients in the Chuvash Repub-
lic, formerly of the Soviet Union. 
This distinct congenital syndrome 
13
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AA1  DNA  Protein  p19 CNS or Other  reference
 mutation mutation  altered? retinal  Phenotype
     angioma?
1 3G>A M1I  No No RCC  (77)
10 28G>T E10X  No N/A Sp. RCC  (78)
 28G>T E10X  No N/A Sp. RCC  (78)
14 42insA Frameshift res14 No Unknown RCC  (79)
18 52G>A A18T  No No RCC  (80)
252  73C>T P25L  No Unknown RCC  (81)
 73C>T P25L  No N/A Sp. Pheochrom (82)
 73C>T P25L  No Yes Unknown  (83)
 73C>T P25L  No Yes Kidney/pancreatic cysts (84)
38 112T>C S38P  No No RCC, Pheochrom (85)
40 119_118dup
  Frameshift res40 No Unknown Type 1  (86)
46 136G>T E46X  No No Type 1  (87)
52 154G>A E52K  No Late-onset Type 1  (87)
53 159-168del Frameshift res53 Yes Yes N/A  (81)
 160-175del Frameshift res53 Yes N/A Sp. RCC  (88)
54 162-166del Frameshift res54 Yes N/A RCC   (89)
 162insT Frameshift res54 Yes N/A Pheochrom (87)
 162delG Frameshift res54 Yes N/A RCC  (77)
 162G>C M54I  Yes Yes Pheochrom Personal Communication3 
55 163-164del Frameshift res55 Yes N/A RCC  (78)
 165dup Frameshift res55 Yes Yes Unknown  (86)
 163delG Frameshift res55 Yes Yes Unknown  (90)
 163delG Frameshift res55 Yes Yes Unknown  (91)
 163delG Frameshift res55 Yes N/A Pheochrom (92)
56 167insA Frameshift res56 Yes Yes Unknown  (86)
 166-178del Frameshift res56 Yes Yes RCC  (93)
59 175-183del In-frame Δ59-61 Yes N/A Sp.RCC  (88)
 176-177del Frameshift res59 Yes N/A RCC  (77)
 175delC Frameshift res59 Yes Yes Type 1  (86)
Table 2. N-terminal VHL mutations
 1 Abbreviations: AA, amino acid; RCC, renal cell carcinoma; Pheochrom, pheochromocytoma; Sp., spo-
radic; N/A, not applicable; Type 1, VHL subtype without pheochromocytoma.
 2 The P25L mutation is of questionable pathogenicity; it has been found in 2/500 (0.4%) alleles in the 
non-affected population. 
 3 Personal Communication, RB van der Luijt, UMC Utrecht, the Netherlands
was characterized by a constitutively 
homozygous VHL missense R200W 
mutation (55). Since then, four other 
missense VHL mutations have been iden-
tified in congenital polycythemia: D126Y, 
V130L, H191D, and P192S (56,57). Pastore 
et al. (2003) conclude that homozygous 
or compound heterozygous VHL mutations 
are the most frequent cause of congenital 
polycythemia (56). VHL polycythemia 
patients manifest thrombosis and vascular 
abnormalities, due to elevated normoxic 
levels of HIFα commensurate with their 
elevated serum erythropoietin and VEGF 
concentrations. However, despite upregu-
lated HIFα levels, Chuvash polycythemia 
patients are not predisposed to cancer (57). 
The existence of this syndrome suggests 
that upregulation of HIFα alone does not ap-
pear to be oncogenic in humans. However, 
the elevated HIF levels in polycythemia pa-
tients are possibly below a threshold neces-
sary to initiate tumor growth. Alternatively, 
comparing polycythemia patients to VHL 
patients might suggest that tumors in VHL 
patients might arise through an alternate, 
HIF-independent tumor suppressor function 
of VHL. 
Elucidating the crystal structure of VHL 
allowed significant insight into the correlation 
existing between genotype and phenotype 
in VHL. It began with the identification of 
two very well conserved residues, H115 and 
S111, that are essential in the binding of VHL 
to HIF by forming hydrogen bonds with a 
hydroxylated proline (58-60). These critical 
VHL residues are encoded by the second 
exon and contribute to a β-sheet structure. 
The third exon of VHL encodes an α-helical 
structure important for the binding of Elongin 
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C (residues 157-171) (33) and is frequently 
altered in naturally occurring VHL mutations 
(48,61-63). The crystal structure predicts 
that VHL L158 and C162 directly contact 
elongin C, whereas Q164 and R167 stabi-
lize the VHL interface without direct contact. 
Mutations affecting L158 and C162 completely 
abrogate elongin binding, wheras mutations 
affecting Q164, V166, and R167 alter VHL 
conformation sufficiently to lead to a partial 
loss of elongin-binding activity. Alleles Y98H 
and W117R do not compromise binding to 
the elongins and Cul2, but do allow HIF 
accumulation through an unknown mecha-
nism. By contrast, type 2C mutant L188V 
retains the ability to bind to elongins and 
Cul2 and HIF is regulated apparently nor-
mally (33).  
Is HIF an oncogene?
Multiple studies have shown increased HIF 
expression among various tumors such as 
breast, colon, head and neck and cervix 
(64,65). Moreover, in breast cancer the 
patient prognosis seems to correlate with 
the expression of HIF (66,67). Therefore it 
seems plausible that HIF plays a prominent 
role in the development of renal cell 
carcinoma. Several research groups have 
addressed this role; collectively, these 
articles suggest that HIF2α (and not HIF1α) is 
the main effector of tumorigenesis upon VHL 
loss. Using a xenograft model of 786-O VHL-
deficient ccRCC cells genetically engineered 
to re-express VHL, the first of these studies 
examined whether overexpressed stabilized 
HIF can counteract tumor suppression by VHL. 
When subsequently engineered to express 
HIF2α with a point mutation in the amino 
acid crucial for the oxygen dependent 
prolyl-hydroxylation (68), these cells were 
able to override the VHL-mediated tumor 
suppression. However, similar experiments 
using HIF1α did not result in a similar 
abolition of VHL mediated tumor suppression 
(69). Although these studies suggest a role 
for HIF2α in tumorigenesis, they do not 
address the more physiologically relevant 
question of whether the suppression of 
endogenous HIF2α would be sufficient to 
abrogate tumor development in these patient- 
derived renal cell carcinoma cells. By knocking 
down HIF2α by RNAi, data supporting a 
putative oncogenic role for HIF2α was 
generated (70,71). These experimental 
data do not, however, exclude additional 
tumor suppressor functions for VHL. The in 
vivo experiments described in these papers 
were terminated after 8-10 weeks, whereas 
recent experiments demonstrate that beyond 
this time point 786-O cells engineered to 
express a mutant VHL that is still capable of 
controlling HIF levels fails to suppress tumor 
formation (72). We conclude that, although 
HIF regulation certainly seems to be an 
attractive candidate, additional VHL-func-
tions are likely to participate in VHL-medi-
ated tumor suppression.
Candidate HIF-independent functions 
for VHL
 
Ohh et al. described the first E3 ligase-in-
dependent function for VHL: binding to 
fibronectin (73). To date, all tested VHL point 
mutants have shown reduced binding to 
intracellular fibronectin which is presumably 
responsible for the observation that cells 
lacking VHL are defective in proper depo-
sition of the extracellular fibronectin. Post-
translational neddylation of VHL seems to 
regulate the binding of fibronectin to VHL and 
subsequent deposition (74). Furthermore, 
fibronectin expression at the mRNA level is 
regulated by VHL in a hypoxia-independent 
fashion (42). These observations, however, 
are largely correlative; the exact molecular 
mechanisms by which VHL stimulates 
fibronectin deposition have yet to be eluci-
dated. 
Recently, residues 95-123 of VHL have been 
described to be important in the stabilization 
of the microtubule cytoskeleton (38). This 
novel VHL function is independent of its 
participation in E3 ligase complexes. Because 
microtubule dynamics are potentially 
important in regulating cancer-related 
processes including chromosomal stability, 
migration, and polarity, this VHL function 
might contribute to its ability to suppress 
tumor formation. Interestingly, type 2A 
VHL mutations Y98H and Y112H (as well as 
one type 2C allele) abrogate the protein’s 
ability to stabilize microtubules (38).Yet 
these alleles are associated with a low risk of 
RCC, a conundrum that has been difficult to 
resolve. 
The 5’ prime acidic domain of VHL: a 
region important in HIF-independent 
function?
The 5’ acidic domain of VHL is relatively new 
15
Chapter 1: General Introduction
in evolution, and may be unique to mammals. 
Composed of tandem copies of the pentameric 
repeat GXEEX, mice have only a single copy 
while the marmoset (New World Monkey) 
bears three. In baboons, chimpanzees, 
gorillas, and humans, the VHL gene con-
tains 8 acidic repeats (75) (Fig. 3c). The 
amplification of the number of acidic repeats 
might reflect increasing functionality 
of the acidic domain of VHL in higher 
mammals. The fact that the p19 isoform of 
VHL is still expressed in mammals in addi-
tion to the longer isoform containing acidic 
repeats, suggests that the two isoforms may 
have separate, non-overlapping functions.
We performed literature and database 
searches for VHL mutations in familial and 
sporadic tumors (VHL mutation databases) 
and found 32 familial and sporadic mutations 
reported in the first 59 residues of p30 (Ta-
ble 2), comprising 8% of unique mutations. 
Strikingly, 12 mutations are predicted to 
only affect the p30 isoform, i.e. translation 
of p19 should not be affected as a result 
of the mutation. Five missense mutations 
disrupting negatively charged or hydrophobic 
residues in the acidic domain might interfere 
with as yet unidentified protein binding partners 
or alter p30 conformation. It should be noted, 
however, that it is unclear whether the P25L 
mutation is a rare naturally occurring poly-
morphism (that happens to segregate with 
the disease in four families) or a true disease- 
associated allele. Three nonsense mutations 
and two frameshifts are predicted to produce 
a truncated N-terminal fragment in addition 
to unaffected p19 from the same allele, raising 
the possibility of a dominant negative 
function for the N-terminal sequences. 
Additional nonsense mutations in the first 
53 residues exist but have not yet been 
reported (personal communication, S. Rich-
ard). One additional mutation replaces me-
thionine 1 with an isoleucine, abrogating all 
translation of p30 specifically. None of the 
studies reporting these mutations mentions 
the relevance of these mutations with regard 
to p19. It is possible that mutations lying 5’ 
to the p19 coding region could alter mRNA 
stability or translation efficiency; no study 
has examined expression level of the two 
isoforms as a result of these mutations. 
Theoretically, however, p19 expression will 
not be affected by acidic domain mutations; 
consequently, mutations in the first 159 
nucleotides of the open reading frame of VHL 
should not be considered null alleles. Since 
wild-type expression of p19 is equivalent 
to p30, (35) mutations affecting p30 only -
even if the other allele carries an inactivating 
mutation affecting both p19 and p30- can 
be predicted to retain at least 25% of HIF 
regulation due to the single remaining allele 
encoding p19 (76). Moreover, because these 
tumors will not harbor biallelic inactivating 
mutations of p19, the p19 isoform of VHL 
fails to conform to the classic definition of a 
tumor suppressor protein (16). 
Recently, we have found that phosphorylation 
of VHL seems to be dependent on the pres-
ence of the acidic domain (72). Our data 
demonstrate that acidic domain phosphory-
lation does not affect HIFα regulation, but is 
important for proper binding with fibronectin. 
Moreover, a phospho-defective mutant fails 
to suppress tumor formation in nude mice 
indicating the need for a fully functional 
acidic domain in VHL mediated tumor 
suppression. This finding connects one of 
the candidate HIF independent functions 
Fig. 3. Conservation of VHL functional do-
mains.
Sequence alignment of four primates (Human, 
chimpanzee, gorilla and marmoset), mouse, frog 
(Xenopus), puffer fish (Fugu), fruit fly (Drosophi-
la), and C. elegans (worm). (A) The HIF-α binding 
domain; (B) the Elongin C binding domain; (C) 
the acidic domain is only present in mammals. 
Position numbers refer to the human residue 
number.
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for VHL to the function of the acidic domain 
and strengthens the notion that the acidic 
domain is important for the role VHL has in 
humans.
Hypothesis
 
Examination of the VHL mutation spectrum 
in familial and sporadic tumors suggests 
that mutations specifically occurring in the 
p30 isoform of VHL do not necessarily affect 
HIF regulation and are sufficient for 
tumorigenesis. Accordingly, it is interesting 
to note that the most common and early 
neoplasm accounting for the first manifestation 
of the disease in 83% of VHL patients (5,6) 
–retinal or CNS hemangiomas- appear to be 
absent or occur with late-onset in patients 
with p30-specific mutations (Table 2). The 
under-representation of angiomas implies 
that upon somatic inactivation of the second 
VHL allele, the p19 allele produced from 
an allele with a 5’ mutation is sufficient to 
suppress hemangioma development (76). 
Our analysis supports the notion put forth 
by a number of groups that VHL-mediated 
tumor suppression is HIF-independent, 
mediated by an unknown function of the 
N-terminal acidic domain. 
Concluding remarks
Clinical hallmarks of VHL disease are devel-
opment of retinal and central nervous sys-
tem (CNS) hemangiomas, pheochromocy-
tomas, multiple cysts of the pancreas and 
kidneys, and a high potential for malignant 
transformation of renal cysts into carcinoma. 
Given the wide age range and pleiotropic 
manner in which VHL disease can be mani-
fested, diagnosis of VHL disease and treat-
ment of patients and their at-risk relatives 
are challenging. Each different type of VHL-
related neoplasm is associated with a differ-
ent histology and different clinical course, 
and might respond to different forms of 
therapy. Understanding the genetic basis of 
VHL disease coupled with an understanding 
of the particular anatomical venue provides 
a unique opportunity for the development of 
allele-specific forms of therapy.
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The von Hippel-Lindau (VHL) tumor suppressor gene regulates the extracellular 
matrix by controlling fibronectin deposition. To identify novel VHL-target genes, 
we subjected mRNA from VHL deficient RCC cells (786-0-pRC) and a transfectant 
re-expressing wildtype VHL (786-0-VHL) to differential expression profiling. Among 
the differentially expressed genes, we detected that fibronectin is upregulated 
in the presence of VHL, while not affected by hypoxia. Thus regulation of fibronectin 
deposition by VHL occurs at the transcriptional level, irrespective of oxygen 
levels.
Introduction
Von Hippel-Lindau disease is caused by in-
activation of the von Hippel-Lindau (VHL) 
tumor suppressor gene, and is characterized 
by the formation of hypervascularized 
neoplasms, including virtually all sporadic 
and inherited renal cell carcinomas (RCCs) 
(1,2).
VHL functions as the substrate recognition 
moiety of the E3 ubiquitin ligase complex, 
VCB-CUL2 E3 that targets the α-subunit of the 
hypoxia-inducible factor (HIF) for degradation 
by the proteasome under normoxic conditions 
(3). HIF is a transcription factor regulating 
genes encoding proteins that function to 
increase O2 delivery, allow metabolic adap-
tation and promote cell survival (4). RCCs 
lacking functional VHL exhibit high levels of 
stabilized nuclear HIF, resulting in excessive 
transcription of HIF target genes, the best 
documented of which being the vascular 
endothelial growth factor (VEGF) (5,6). HIF-
independent functions of VHL have been 
described in recent literature. VHL binds 
the extracellular matrix protein fibronectin; 
VHL-deficient cells show impaired fibronectin 
deposition possibly contributing to 
tumorigenesis and directly influencing the 
behavior of tumor cells (7). 
We and others have previously demonstrated 
that VHL appears to control extracellular 
matrix (ECM) degradation by regulating 
both metalloproteinases –2 and –9 and their 
inhibitors (8), as well as the urokinase-type 
plasminogen activator system (9,10). In 
addition, by promoting the assembly of actin 
and vinculin, VHL was found to affect 
cytoskeletal organization, focal adhe-
sion formation and cell motility (11). VHL 
influences effects on proliferation, cell cycle 
progression, as well as alterations of the 
extracellular matrix interactions. Further-
more, fibronectin gene (FN1) expression has 
been correlated with increased tumor cell 
growth and invasiveness of VHL-defective 
RCCs (12). 
To identify novel VHL-target genes, we 
subjected VHL-deficient RCC cell line (786-0-
pRC) and transfectants re-expressing wild-
type VHL cDNA (786-0-VHL) to differential 
expression profiling and identified a group 
of 16 genes that were either negatively or 
positively regulated by VHL. Of these genes 
two interesting features were noticed. 
The first was a group of genes positively 
regulated by VHL. Our results confirmed and 
expanded on earlier reports using differential 
hybridization (11, 13-16). Interestingly, we 
identified the gene encoding fibronectin, 
FN1, as a gene positively regulated by VHL, 
whose transcription levels are unaltered by 
hypoxia. These data support the hypothesis 
that VHL also regulates transcription in a 
HIF-independent manner. Secondly, our data 
suggest that VHL regulates fibronectin mRNA 
levels. This knowledge, taken together with 
the fact that VHL binds fibronectin, increases 
our understanding of how VHL regulates 
fibronectin deposition.
Material and Methods
Cell lines
Stable transfectants of 786-0 cells express-
ing vector backbone alone (786-0-RC) or 
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wild type VHL (786-0-VHL) (obtained from 
W. Kaelin, Dana Farber Cancer Institute, 
USA) were grown in DMEM (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% 
fetal calf serum (FCS) (Invitrogen, Carlsbad, 
CA, USA), L-glutamine (2 μM), penicillin (50 
IU/ml), and streptomycin sulphate (50 μg/
ml) (Invitrogen, Carlsbad, CA, USA).
RNA isolation
Total RNA was isolated using RNAzol B as 
described by the manufacturer (Campro Sci-
entific, Veenendaal, The Netherlands) and 
dissolved in DepC-treated milliQ H20. Poly 
A+ RNA was extracted and purified using 
the oligotex mRNA Mini kit (Qiagen, Valen-
cia, CA, USA).
Microarray analysis
1 μg of poly A+ RNA of each sample was 
reverse transcribed into cDNA using a re-
verse transcription kit (Invitrogen, Carlsbad, 
CA, USA) in combination with an oligo-dT15 
primer (Invitrogen, Carlsbad, CA, USA) and 
amino allyl containing dUTPs (Sigma, St. 
Louis, MO, USA). cDNAs were fluorescently 
labeled with either Cy3 or Cy5 (Amersham 
Biotech, Buckinghamshire, UK). Chroma-
spin columns were used to remove unincor-
porated Cy-dyes (Clontech, Palo Alto, CA, 
USA). Labeled cDNAs (100 ng per sample 
in hybridization buffer) were subjected to 
competitive hybridization on a 1.7K human 
microarray (obtained from the Microarray 
Facility of University of Toronto; http://www.
uhnres.utoronto.ca/services/microarray). 
Hybridization buffer contained 25% for-
mamide, 2.5X SSC, 0.2% SDS, 100 μg/ml 
herring sperm DNA and 200 μg/ml E. coli 
tRNA.  A coverslip (25X25 mm) was applied 
to the microarray after which 30 μl of hy-
bridization mix was applied to hybridize in a 
hybridization chamber (Corning, New York, 
USA) overnight in a 42OC water bath. Af-
ter hybridization, microarrays were washed 
at room temperature in 1XSSC with 0.2% 
SDS for four minutes, 0.1XSSC with 0.2% 
SDS for four minutes, and 0.1XSSC for four 
Accession number Gene ID                            Cy3/Cy5 Biological function
                           (Log2 ratio) 
AA099195 GDIB  GDP dissociation inhibitor B 1.2 Intracellular vesicle transport
AA136799 GADD45 Gene activated by   0.7 Stress response; cell cycle ar
   DNA-damage   rest; cell death 
AA195589 FN1 Fibronectin  1.6 Cellular adhesion
H07071  VCAM1 Vascular cell adhesion  0.8 Cellular adhesion
   molecule 1
R81846  FRIL Ferritin light chain  0.8 Metal transport; RNA stability
W69515  MKK2 MAP kinase kinase 2 0.8 Stress response; nuclear export; 
       cell growth
H52752  GR75 Heat-shock 70-KD protein 0.7 Stress response; cell growth;   
       cellular aging
AA023029 PPP5 Serine/threonine Protein  0.7 Mitosis; RNA biogenesis; tran
   phosphatase 5   scription
AA151568 TEGT Testis enhanced gene  0.7 Cell death
   transcript   
H02641  VHL Von Hippel-Lindau  0.9 
Accession number Gene ID                            Cy3/Cy5  Biological function
                           (Log2 ratio)
AA037034 COXA Cytochrome C oxidase  -1.0 Metabolic response; electron   
       transfer 
H86642  CERU Ceruloplasmin transport -1.0 Metabolic response; copper
N31417  IGFBP3  Insulin-like growth factor  -2.3 Cell growth
   binding protein 3
N40420  CGD1 Cyclin D1   -0.8 Cell growth; cell cycle regulator
N91060  VEGF Vascular endothelial growth  -0.9 Angiogenesis; cell growth
   factor   
N31209  NUP153 Nucleoporin 153  -0.8 Nuclear-cytoplasmic transport
R92231  TLE1 Transducin-like enhancer  -0.7 Cell differentiation; cell fate
   protein 1   
Table 1. VHL target genes
Upregulated
Downregulated
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minutes, successively. Subsequently, micro-
arrays were dried by centrifugation (5 min. 
at 124g) and scanned using a confocal laser 
scanner (Packard Scanarray 4000XL from 
Perkin Elmer, Boston, MA, USA ). Data were 
analyzed using Imagene software (Biodis-
covery Inc., El Segundo, CA, USA).
RT-PCR analysis
One and a half µg of total RNA was reverse 
transcribed to obtain cDNA for reverse tran-
scription polymerase chain reaction (RT-
PCR) using SuperScript II Rnase H- Reverse 
Transcriptase (according to manufacturer; 
Invitrogen, Carlsbad, CA, USA). Gene-spe-
cific cDNA fragments were amplified by 25 
cycles of PCR consisting of 1 min. at 95OC, 1 
min. at 55OC and 2 min. at 72OC. PCR frag-
ments were analyzed by DNA gel electropho-
resis. The following primers were used for 
RT-PCR: VEGF forward primer: 5’-cgaaac-
catgaactttctctgc, reverse primer: 5’-ccacttc-
gtgatgattctgc (127 bp product), Glucose 
Transporter-1 (GLUT-1) forward primer: 
5’-ttcaatgctgatgatgaacc, reverse primer: 
5’-gtacacaccgatgatgaagc (114 bp product), 
Insulin-like Growth Factor Binding Protein-3 
(IGFBP-3) forward primer: 5’-gaacttctcctcc-
gagtcc, reverse primer: 5’-ccttcttgtcacagtt-
ggga (136 bp product), FN1 forward primer: 
5’-caagccagatgtcagaagc, reverse primer: 5’-
ggatggtgcatcaatggca (138 bp product), 18S 
forward primer: 5’-agttggtggagcgatttgtc, re-
verse primer: 5’-tattgctcaatctcgggtgg (142 
bp product)
Western analysis
Approximately 1x106 cells were lysed in 400 
μl lysis buffer (20 mM Tris-HCl pH 8.0; 1% 
Triton-X-100; 140 mM NaCl; 10% glycerol; 
0.005% Bromo-Phenol-Blue; 8% β-mercap-
toethanol) containing the ‘complete’ cocktail 
of protease inhibitors (Roche, Basel, Swit-
zerland). Cell remnants were removed by 
centrifugation (5 min. at 16,100 g at 4OC) 
and cleared lysates were stored at –20OC. 
Approximately 20 μg of protein per lane 
were analyzed by SDS-PAGE followed by 
western blotting using a polyclonal antibody 
specific for IGFBP3 (1:200; kind gift from 
Dr. J. van Doorn, WKZ Utrecht, the Nether-
lands), and monoclonal antibodies for fibro-
nectin (1:500; M010, FN30-8, TaKaRa Bio-
medicals, Shiga, Japan) and for VHL (1:500; 
IG32, BD-Pharmingen, San Diego, USA), 
respectively. Antibodies were diluted in PBS 
containing 5% non-fat dried milk and 0.1% 
Tween-20. Swine anti-rabbit or rabbit anti-
mouse horseradish peroxidase (1:10,000; 
Pierce, Rockford, IL, USA) was used as a 
secondary antibody and enhanced chemi-
luminescence (Perkin Elmer Life sciences, 
Boston, MA, USA) was used for detection.  
IGFBP3 and fibronectin detection assays
Secretion levels of IGFBP3 in conditioned 
medium were determined as described pre-
viously (17). Secretion levels of fibronec-
tin were determined by sandwich enzyme-
linked immuno-sorbent assay (ELISA) (18) 
using a polyclonal antibody specific for fibro-
nectin and a monoclonal antibody against 
fibronectin (respectively M010 and FN30-8, 
TaKaRa Biomedicals, Shiga, Japan). Rabbit 
anti-mouse peroxidase was used as a third 
antibody for detection and quantification.
Figure 1: Fibronectin (FN1) gene expression 
is positively regulated by VHL.
Gene expression levels of CERU, IGFBP3, FN1, 
VEGF, VHL, and GAPDH were determined by RT-
PCR analyses. All panels show specific products 
for the indicated genes. Left lanes represent 
VHL-mutant cell line 786-0-RC (RC); right lanes 
represent the same cell line stably overexpressing 
VHL, 786-0-VHL (VHL). The housekeeping gene 
GAPDH functions as a control for loading. Previ-
ously reported in the literature, VEGF, CERU, and 
IGFBP3 are all negatively regulated by VHL. FN1 
expression, however, is regulated by VHL in the 
opposite manner.
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Real-Time PCR
Real-time PCR was performed using the iCy-
cler iQ real-time PCR detection system (Bio-
Rad, Hercules, CA, USA). An optical 96 well 
reaction plate (Bioplastics, North Ridgeville, 
OH, USA) and iCycler iQ sealing tape (Bio-
Rad, Hercules, CA, USA) was used for PCR 
amplification. The final reaction mixture of 
15 μl consisted of diluted cDNA, 1 X PCR buf-
fer (Amersham Biotech, Buckinghamshire, 
UK), 0.05 mM dNTPs (Amersham Biotech, 
Buckinghamshire, UK), 100 μM forward 
primer, 100 μM reverse primer and 0.375 
units Taq polymerase (Amersham Biotech, 
Buckinghamshire, UK). For detection of the 
PCR product in real-time, the SYBR Green I 
fluorophore (Roche, Basel, Switzerland) was 
used in a final 10,000-fold dilution. The cDNA 
was further diluted 6-fold or 2,000-fold pri-
or to PCR amplification of GLUT-1, IGFBP-3 
and FN1 or 18S, respectively. Gene-specific 
cDNA fragments, using the same primers as 
mentioned before, were amplified by 40 cy-
cles of PCR consisting of 30 sec. at 94OC, 30 
sec. at 58OC and 30 sec. at 72OC. For each 
assay, specific targets were amplified in trip-
licate with their respective standard curve. 
The equation of the standard curve was used 
to determine the starting quantity of the 
samples with the iCycler analysis software. 
All experimental samples were normalized 
to 18S quantities. 
Results and discussion
Identification of VHL-regulated genes by 
microarray analysis
In an attempt to identify novel VHL-target 
genes involved in tumorigenesis, we subjected 
mRNA from a VHL effective renal carcinoma 
cell line (786-0-pRC) and transfectants 
re-expressing a wildtype VHL allele (786-0-
VHL) to differential expression profiling. A 
glass-chip based cDNA array representing 
about 1700 distinct human genes was spotted 
in duplicate (obtained from the Microarray 
Facility of the University of Toronto: http://
www.uhnres.utoronto.ca/services/ microar-
ray). The cDNA made from purified mRNA 
from 786-0-VHL cells was labeled with Cy3 
and mixed with Cy5 labeled cDNA transcribed 
from 786-0-pRC purified mRNA. After 
normalization, the Cy3/Cy5 ratio of each 
gene individually was determined from three 
independent experiments and overlapping 
sets of genes were selected. In this way 
9 genes, with an average log2 ratio above 
0.7, were considered positively regulated by 
VHL, whereas 7 genes, that had an average 
log2 ratio of  -0.7 or below, were considered 
negatively regulated (Table I). The expression 
of the GAPDH gene was not regulated by 
VHL (not shown). In addition, the average 
Cy3/Cy5 log2 ratio of the VHL gene (as 
expected above 0.7) was used as an internal 
control as a measure of the reliability of the 
observed changes. 
Figure 2: Quantification of IGFBP3 and fi-
bronectin gene expression. 
(A) Levels of fibronectin mRNA expression were 
determined by real-time PCR. The amount of 
mRNA measured in the 786-0-VHL cell line (VHL) 
was normalized to 1 and the amount of mRNA 
in the 786-0-RC cell line (RC) is relative to this 
amount. Each individual point in the plot is an 
independent measurement. There is a statistically 
significant upregulation of fibronectin in the pres-
ence of VHL. (B) Quantification of IGFBP3 mRNA 
expression performed as described above shows a 
statistically significant decrease of mRNA levels in 
the presence of VHL.
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RT-PCR was performed as an independent test 
to confirm the differential expression of some 
of the genes identified by DNA microarray. 
As shown in Figure 1, the expression of FN1 
and VHL was shown to be higher in 786-
0-VHL cells than in 786-0-pRC cells. The 
opposite was true for CERU, IGFBP3 and 
VEGF. The expression of GAPDH was taken 
as an internal control. In conclusion, similar 
expression patterns of VHL-target genes 
were found when measured by these two in-
dependent methods. 
Using the Gene Ontology Consortium 
classification of biological processes, these 
target genes could be classified accord-
ing to their biological function (Table I). In 
this way, VHL was shown to be a negative 
regulator of genes involved in cell prolifera-
tion such as IGFBP3 and cyclinD1. More-
over, VHL appeared to positively regulate 
GADD45, a gene involved in cell cycle ar-
rest, as well as FN1 and VCAM1 (encod-
ing the vascular cell adhesion molecule), 
both of which have roles in cell adhesion. 
Literature searches revealed that eight 
of the VHL-target genes identified in our 
study (VEGF, CERU, COXA, IGFBP3, cyclin 
D1, GADD45, VCAM1, and FN1) have been 
previously implicated in the development 
of RCC (19-23). We further focused on 
fibronectin as this protein is reported to inter-
act with VHL and is believed to be regulated 
in a post-transcriptional manner by VHL. 
However, the transcriptional regulation of 
FN1 by VHL has not yet been reported.
Role of VHL in regulation of fibronectin
 
Levels of fibronectin mRNA increased 3.7-
fold in the presence of VHL as measured 
by repeated real-time PCR analyses (Fig. 
2), IGFBP3 was used to study the behavior 
of genes down-regulated by VHL. Protein 
expression levels were determined in whole 
cell lysates of 786-0-VHL versus 786-0-pRC 
cells by western analysis. Figure 3A correlates 
higher fibronectin levels with VHL in 786-0-
VHL cells.  In contrast, increased levels of 
IGFBP3 were detected in 786-0-pRC cells as 
compared to 786-0-VHL cells. Conditioned 
medium of 786-0-pRC and 786-0-VHL cells 
recapitulated the differential secretion of 
fibronectin and IGFBP3 (Fig. 3B). 786-0-
VHL cells secreted 15-fold more fibronectin 
than 786-0-pRC cells. Accordingly, IGFBP3 
secretion was relatively high (20-fold) in 
cultured medium from 786-0-pRC cells 
when compared to that of 786-0-VHL cells. 
Together, these data imply that aberrant 
production and secretion of fibronectin and 
IGFBP3 is directly related to VHL expression 
in RCC cell lines. It is worthy of noting that 
fibronectin mRNA levels are remarkably 
less sensitive to re-expression of VHL than 
detectable secreted protein levels (approxi-
mately 4-fold, discussion below). 
Fibronectin is an extracellular glycoprotein that 
binds to and signals through heterodimeric 
cell surface receptors known as integrins 
(24). Loss of fibronectin matrix assembly 
has been recognized as a feature of cellular 
transformation (25). Fibronectin has the 
ability to decrease the metastatic behavior of 
malignant cells by increasing the interaction 
between tumor cells and their micro- 
Figure 3: Secretion of IGFBP3 and fibronec-
tin are inversely regulated by VHL.
(A) Intracellular protein levels of IGFBP3, fi-
bronectin and VHL determined by western blot 
analyses. Left and right lanes contain protein 
lysates derived from 786-0-RC cell line (RC) and 
786-0-VHL (VHL) cell lines, respectively. Upper 
panel: fibronectin levels increase in the presence 
of VHL. Middle panel: less IGFBP3 is detected in 
the presence of VHL. Lower panel: VHL levels. (B) 
Levels of secreted IGFBP3 and fibronectin (FN) 
depicted left and right, respectively, in condi-
tioned medium from 786-0-RC (RC; black bars) 
and 786-0-VHL (VHL; gray bars) cell lines. Detec-
tion of secreted protein by ELISA was performed 
in at least three independent experiments.
environment via the integrin receptor fam-
ily (26). Furthermore, fibronectin can revert 
some aspects of the malignant phenotype 
of tumor cells, including proliferation and 
migration (27). Previous reports have 
described a physical interaction between 
VHL and intracellular fibronectin in vivo; this 
interaction affected the ability of cells to 
assemble an extracellular fibronectin matrix 
(7). We report here –using the same cell system 
used to determine VHL-fibronectin binding- 
that fibronectin mRNA levels are regulated 
by VHL. The difference in fibronectin 
secretion in our experiments could not 
be directly accounted for by mRNA 
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increase (15-fold vs. 3.7-fold). Our data 
thus does not exclude the notion that VHL 
binding to fibronectin regulates the amount 
of fibronectin deposition in a post-transcrip-
tional manner (7). However, we propose an 
additional way that VHL regulates fibronec-
tin: at the transcriptional level.
Effect of hypoxia on the VHL-target genes 
FN1 and IGFBP3
Because many of known VHL target genes 
(including VEGF) are regulated by the HIF 
transcription factors, we next determined the 
effect of hypoxia on the expression of FN1 
and IGFBP3. Therefore, we cultured 786-
0-VHL or 786-0-pRC cells under normoxic 
(20% O2) or hypoxic (1% O2) conditions 
for 18 hours. Total RNA was extracted from 
these cells and subjected to quantitative 
real-time PCR to follow the expression of 
GLUT-1 (which is a known hypoxia-inducible 
gene) (4), IGFBP3 and FN1. The expression 
of 18S (which is not affected by hypoxia) 
was taken as an internal control and used 
to normalize expression of GLUT-1, IGFBP3 
and FN1.
As shown in Figure 4A, hypoxia significantly 
induces the expression of GLUT-1 by 6.7-
fold in 786-0-VHL cells after 18 hours of 
hypoxic treatment (p = 0.025; Fig. 4A). In 
786-0-pRC cells the expression of GLUT-1 
mRNA was not significantly changed. Similar 
results were also shown for VEGF expression 
under these conditions (data not shown). 
As expected, hypoxia also induced IGFBP3 
mRNA expression (approximately 5-fold; p 
= 0.029) in 786-0-VHL cells, whereas in the 
absence of functional VHL (i.e. 786-0-pRC), 
IGFBP3 expression did not significantly dif-
fer (Fig. 4B). This implicated a role of HIF in 
the regulation of the IGFBP3 gene by VHL. 
Although the expression of both GLUT-1 and 
IGFBP3 in 786-0-pRC was not significantly 
altered by hypoxia, a trend towards induction 
of transcription was present (Fig. 4A and B). 
In contrast, FN1 expression was not affected 
by hypoxia in 786-0-VHL cells as well as in 
786-0-pRC cells, and suggested a HIF-inde-
pendent mechanism of regulation by VHL. To 
chemically mimic the effect of hypoxia we 
administered cobalt chloride to these cell 
lines, thereby artificially stabilizing HIF and 
stimulating HIF-mediated transcription (28). 
This method was able to reproduce hypoxia 
Figure 4: Fibronectin is a hypoxia-independent target of VHL transcriptional regulation. 
Cells were either cultured under normoxia (20% O2; light bars) or hypoxia (1% O2; dark bars) for 20 
hours. The left two columns represent cDNA derived from the 786-0-VHL cell line (VHL) and the right 
two columns represent cDNA derived from the 786-0-RC (RC) cell line. These results represent the 
mean of six independent experiments in triplicate ± standard error of the mean. P-values were deter-
mined by paired, two-tailed t-test. (n.s., not significant). (A) GLUT-1 mRNA levels were measured by 
real-time PCR as a positive control for hypoxia-induction. As expected, GLUT-1 expression increases in 
response to hypoxia in the 786-0-VHL cell line. (B) Like GLUT-1, IGFBP3 mRNA levels are significantly 
regulated by hypoxia. (C) FN1 mRNA expression does not respond to hypoxia in either the 786-0-RC or 
in the 786-0-VHL cell lines.
26
Reference List:
(1) Kaelin, W. G., Jr. (2002) Nat.Rev.Cancer 2, 
673-682
(2) Ohh, M. and Kaelin, W. G., Jr. (1999) Mol.Med.
Today 5, 257-263
(3) Epstein, A. C., Gleadle, J. M., McNeill, L. 
A., Hewitson, K. S., O’Rourke, J., Mole, D. R., 
Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, 
A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaak-
kola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., 
Pugh, C. W., Schofield, C. J. and Ratcliffe, P. J. 
(2001) Cell 107, 43-54
(4) Semenza, G. (2002) Biochem.Pharmacol. 64, 
993-998
(5) George, D. J. and Kaelin, W. G., Jr. (2003) 
N.Engl.J.Med. 349, 419-421
(6) Yang, J. C., Haworth, L., Sherry, R. M., Hwu, 
P., Schwartzentruber, D. J., Topalian, S. L., Stein-
berg, S. M., Chen, H. X. and Rosenberg, S. A. 
(2003) N.Engl.J.Med. 349, 427-434
(7) Ohh, M., Yauch, R. L., Lonergan, K. M., Wha-
ley, J. M., Stemmer-Rachamimov, A. O., Louis, 
D. N., Gavin, B. J., Kley, N., Kaelin, W. G. and Jr., 
Iliopoulos, O. (1998) Mol.Cell 1, 959-968
(8) Koochekpour, S., Jeffers, M., Wang, P. H., 
Gong, C., Taylor, G. A., Roessler, L. M., Stear-
man, R., Vasselli, J. R., Stetler-Stevenson, W. G., 
Kaelin, W. G., Jr., Linehan, W. M., Klausner, R. D., 
Gnarra, J. R. and Vande Woude, G. F. (1999) Mol.
Cell Biol. 19, 5902-5912
(9) Los, M., Zeamari, S., Foekens, J. A., Gebbink, 
M. F. and Voest, E. E. (1999) Cancer Res. 59, 
4440-4445
(10) Zatyka, M., da Silva, N. F., Clifford, S. C., 
effects on GLUT-1, VEGF, IGFBP3 and FN1 
expression (data not shown). 
Our data demonstrate positive regulation 
of FN1 by VHL thereby suggesting the exis-
tence of a HIF-independent pathway of tran-
scriptional control by VHL. Our findings sup-
port the hypothesis that VHL is positioned 
in both HIF-independent and HIF-dependent 
pathways that are involved in extracellular 
matrix deposition (14,29).  HIF-independent 
VHL transcriptional targets provide a pos-
sible link with the tumor suppressor mecha-
nism of VHL. It is tempting to speculate that 
the induction of genes in the presence of 
VHL and the downregulation of these genes 
in the absence of VHL both play a role in the 
development of the malignant properties of 
RCCs.
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The tumor suppressor function of the von Hippel-Lindau protein has previously 
been linked to its role in regulating hypoxia inducible factor levels. However, VHL 
gene mutations suggest a hypoxia inducible factor-independent function for the 
N-terminal acidic domain in tumor suppression. Here we report that phosphorylation 
of the N-terminal acidic domain of the von Hippel-Lindau protein by casein kinase 2 
is essential for its tumor suppressor function. This post-translational modifica-
tion does not affect the levels of hypoxia inducible factor, however it does change 
the binding of the von Hippel-Lindau protein to another known binding partner: 
fibronectin. Cells expressing phospho-defective mutants cause improper fibronec-
tin matrix deposition and demonstrate retarded tumor formation in mice. We pro-
pose that phosphorylation of the acidic domain plays a role in the regulation of 
proper fibronectin matrix deposition and that this may be relevant for the develop-
ment of VHL-associated malignancies.
Introduction
In some anatomical venues neoplastic 
transformation occurs upon biallelic inacti-
vation of the von Hippel-Lindau gene (VHL) 
(1). In their lifetime, patients carrying 
a mutated VHL gene are predisposed to 
multiple tumors in a number of organs 
including the retina, cerebellum, spinal cord, 
adrenal gland, and kidney. Despite this 
phenotypicheterogeneity, VHL patients can 
be segregated based on their likelihood of de-
veloping pheochromocytoma.  That is, Type 
1-VHL patients are at low risk of developing 
pheochromocytoma, but do develop 
clear-cell renal cell carcinoma (CC-RCC). 
Type 2 patients develop pheochromocytoma 
and are further subdivided; Type 2A patients 
have low risk for CC-RCC, and Type 2B patients 
have high risk for CC-RCC. Types 1, 2A and 2B 
patients all develop the two cardinal features 
of the VHL disease, namely retinal and central 
nervous system (CNS) haemangioblastoma. 
However, Type 2C patients exclusively develop 
pheochromocytoma (2,3).
pVHL forms a multiprotein complex (VEC) 
with elongin C, elongin B, Cul-2, and Rbx-
1 (reviewed in: (4)). VEC functions as an 
E3 ubiquitin ligase to target the α subunit 
of a heterodimeric transcription factor called 
HIF (hypoxia-inducible factor) for polyubiq-
uitination (5-7). The polyubiquitin-tagged 
HIFα is subsequently degraded by the 26S 
proteasome. pVHL functions as the target 
recognition moiety of the VEC complex and 
specifically recognizes prolyl-hydroxylated 
HIFα subunits (8,9). This post-translational 
modification of HIFα requires oxoglutarate, 
iron and oxygen (8-10). Thus, ubiquitin- 
mediated destruction of HIFα occurs selec-
tively under normoxic conditions. Accordingly, 
biallelic inactivation of the VHL gene through 
mutation, deletion, or promoter silencing 
generally leads to the stabilization of HIFα 
and thereby promotes the up-regulation of 
numerous HIF-target genes, resulting in an 
inappropriate triggering of the hypoxic 
response under normal oxygen tension (4). 
However, type 2C patient mutations do not 
affect E3 ligase function of pVHL and hence 
HIF regulation is normal, yet these patients 
nevertheless develop pheochromocytoma 
(3). Therefore we hypothesized that another 
function of pVHL is essential for its tumor 
suppressor activity.
The VHL gene produces two wild-type 
isoforms, the 30kD full-length pVHL30 and 
a shorter 19kD pVHL19 that is generated 
by an alternative translational initiation at 
methionine 54 (11-13).  Both pVHL30 and 
pVHL19 form an active VEC complex and 
both proteins independently have been 
shown to suppress tumor formation in nude 
mouse xenograft assays (12-14).  However, 
analyzing known mutations in VHL patients 
revealed a number of disease-associated 
mutations in the acidic domain that would 
not affect the transcription and function of 
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the pVHL19 isoform (VHL mutation data-
base; http://www.umd.be:2020/). Hence, 
although the functional significance of the 
extra N-terminal acidic domain of pVHL30 
remains unclear, this region in pVHL clearly 
contributes to the tumor suppressor function 
of pVHL. 
Here, we show that pVHL30 is phosphory-
lated within the N-terminal acidic domain 
by casein kinase (CK) 2. The phosphoryla-
tion status of pVHL30 does not affect the E3 
ubiquitin ligase function. Ablation of CK2-
specific phosphorylation sites or inhibition 
of CK2 activity increased affinity to fibronec-
tin, yet resulted in decreased deposition of 
extracellular fibronectin. Interestingly, cells 
expressing phospho-defective pVHL delay 
the onset of tumor formation in a SCID xe-
nograft assay. Hence, CK2-mediated phos-
phorylation represents a HIF-independent 
tumor suppressor function of the acidic do-
main of pVHL.
 
Methods and Materials
Cell culture 
Human kidney 293T cells and 786-O CC-RCC 
cells were cultured in RPMI 1640 or Dulbec-
co’s modified Eagle medium (DMEM) me-
dium containing 10% heat-inactivated fetal 
bovine serum (FBS) (Sigma, St. Louis, MO) 
supplemented with penicillin, streptomycin 
and glutamine and maintained at 37°C in a 
humidified 5% CO2 atmosphere. 786-O sub-
clones stably expressing HA-pVHL30(WT) 
(786-WT), HA-pVHL30(AAA) (786-AAA), or 
empty plasmid (786-MOCK) were generated 
as previously described (15).
Antibodies
Monoclonal anti-GAL4 (DBD; RK5C1 Santa 
Cruz Biotechnology, Santa Cruz, CA), anti-
HA (12CA5, hybridoma supernatant) (Roche, 
Basel, Switzerland), anti-VSV (P4D5, hy-
bridoma supernatant), anti-RPTPμ (3D7, 
hybridoma supernatant), anti-Cul2 (Zymed, 
San Francisco, CA), anti-α tubulin (Sigma, 
St. Louis, MO), polyclonal anti-GLUT1 (Al-
pha Diagnostics, San Antonio, TX), anti-CK2 
(Santa Cruz Biotechnology, Santa Cruz, CA) 
and anti-fibronectin (TaKaRa Biomedicals, 
Shiga, Japan) were obtained from the indi-
cated companies.
Plasmids 
pVHL30 and pVHL19 isoforms were cloned 
into a pcDNA3 vector (Stratagene, La Jolla, 
CA) containing an N-terminal VSV-or HA-
tag. Mammalian expression plasmid pRc-
CMV-HA-pVHL(WT) was described previously 
(15) and pRc-CMV-HA-pVHL(AAA) were gen-
erated using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). 
S33A, S38A, and S43A substitutions were 
generated using the following primer sets: 
5’-CGGGGAGGAGGCGGGCGCCGAGGAG-3’/ 
5’-CTCCTCGGCGCCCGCCTC CTCCCCG-3’, 
5’-GCGCCGAGGAGGCCGGCCCGGAAGAG-3’/ 
5’-CTCTTCCGG GCCGGCCTCCTCGGCGC-
3’, and 5’-GGCCCGGAAGAGGCCGGCCCG-
GAGG-3’/ 5’- CCTCCGGGCCGGCCTCTTCC-
GGGCC-3’, respectively. The authenticity of 
all plasmids was confirmed by direct DNA 
sequencing.
Immunoprecipitation and immunoblotting
For immunoprecipitations (IP), protein A/
G agarose beads (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and antibody were 
pre-coupled for 30 min and washed twice 
with Triton-lysis buffer (20mM TRIS pH 8.0, 
140mM NaCl, 10% glycerol, 1% Triton X-
100). Samples were added to the pre-cou-
pled beads and binding was allowed to occur 
for 90 min at 4°C, then washed 4 times with 
800 ml of Triton-lysis buffer, submitted to 
SDS-PAGE gel electropheresis and electro-
transferred onto a PVDF membrane (Bio-Rad 
Laboratories Inc., Mississauga, ON). Specific 
protein bands on Western blots were visual-
ized using the various indicated antibodies. 
All primary antibodies were diluted in PBS 
containing 5% non-fat dry milk and 0.1% 
Tween-20. Goat-anti-mouse-HRP or goat-
anti-rabbit-HRP (Pierce, Rockford, IL) was 
used 1:20,000 as secondary antibody after 
which enhanced chemiluminescence (Perkin 
Elmer Life Sciences, Boston, MA) was per-
formed for detection.
[32P]-orthophosphate labeling
786-WT or 293T cells were seeded in 6 well 
plates and grown to 80% confluency. Cells 
were washed once with phosphate-free me-
dium (ICN Biochemicals, Irvine, CA ) fol-
lowed by growth in phosphate-free medium 
supplemented with 200μCi of [32P]-ortho-
phosphate and labeled for 4 hours. Cells 
were transferred to ice, washed with ice-
cold PBS and then lysed using 500 μl of Tri-
ton-lysis buffer containing protease inhibitor 
mix (Roche, Basel, Switzerland) and phos-
phatase inhibitor mix (0.1mg/ml Na3VO4, 
0.1mg/ml β-glycerophosphate and 1mg/ml 
30
Na4P2O7). These lysates were then submitted 
for various immunoprecipitations.
In vitro kinase assay
Plasmids encoding wild-type or the indicated 
mutant pVHL were in vitro transcribed and 
translated using the TNT Quick-Coupled 
Transcription/Translation System (Promega, 
Madison, WI). 5U of recombinant casein 
kinase 2α (CK2α) (Promega, Madison, WI) 
with the recommended buffer and 1μl of in 
vitro translated protein were mixed in a re-
action volume of 50μl with 10μCi of [32P] g-
ATP (Perkin Elmer Life sciences, Boston, MA) 
for 30 min at 30°C. In vitro translated prod-
ucts were immunoprecipitated to increase 
the specificity of the signal. CK2 inhibitors 
daidzein (Sigma, St. Louis, MO) and 4,5,6,7-
tetrabromobenzotriazole (TBB, a kind gift 
from D. Shugar, Warsaw, Poland) were used 
at indicated concentrations during the incu-
bation with [32P] γ-ATP.
Gel filtration assay
The gel filtration assay was done using a 
column containing a biogel A15-m (Bio-Rad 
Laboratories Inc., Mississauga, ON). The 
column was equilibrated using PBS, pH7.4 
and 200μl of crude cell lysate in Triton-lysis 
buffer was run at 0.5 ml/min and samples 
of 0.5ml each were collected. The bed vol-
ume of the column used was 25ml. Fractions 
were collected and subsequently submitted 
to TCA precipitation. The precipitated pro-
teins were dissolved in 50μl of 1X sample 
buffer and used for western blotting.
In vitro ubiquitination assay
In vitro ubiquitination assay was per-
formed as previously described (6). Briefly, 
[35S]methionine-labeled  reticulocyte lysate 
HA-HIF1α[ODD] translation product (4μl) 
was incubated in RCC 786-O S100 extracts 
(100-150μg) supplemented with 8 μg/μl of 
ubiquitin (Sigma), 100ng/μl of ubiquitin-al-
dehyde (BostonBiochem, Cambridge, MA), 
and an ATP-regenerating system (20 mM 
Tris [pH 7.4], 2 mM ATP, 5 mM MgCl2, 40 mM 
creatine phosphate, 0.5 μg/μl of creatine ki-
nase) in a reaction volume of 20 to 30μl for 
1.5 h at 30 °C.
Metabolic labeling
Metabolic labeling was performed as previ-
ously described (16). In brief, radioisotopic 
labeling was performed by methionine star-
vation for 45 minutes, followed by growth in 
5 ml of methionine-free DMEM supplemented 
with [35S]-methionine (100μCi/ml medium) 
(Amersham Biotech, Buckinghamshire, UK) 
and 2% dialyzed-FBS for 3hr at 37 °C in a 
humidified 5% CO2 atmosphere. 
Fibronectin ELISA
Fibronectin ELISA was performed as previ-
ously described (2;16). In brief, cells (2 x 
103) were grown for 4 days in 96-well microti-
ter plates (Costar, Cambridge, MA) prior to 
cell removal with PBS containing 2mM EDTA. 
Complete removal of cells was visualized by 
phase microscopy. Plates were blocked with 
PBS containing 0.1% heat-inactivated BSA 
(Invitrogen, Carlsbad, CA, USA) for 1 hour 
at 37°C and subsequently incubated with 
10 μg/ml rabbit anti-fibronectin antibody in 
PBS/0.1% BSA for 1 hr. Plates were washed 
three times with PBS and alkaline phospha-
tase-conjugated goat anti-rabbit IgG (0.1 
μg/ml) was added for 1 hr at 37°C. Plates 
were washed three times with PBS and de-
veloped with 1.0 mg/ml p-Nitrophenyl Phos-
phate in 0.2 M Tris buffer (Sigma, St. Louis, 
MO). Reactions were stopped with 3 M NaOH 
and the OD at 405 nm was measured on a 
microplate reader.
SCID mouse xenograft assay
Multiple 786-O subclones expressing 
pVHL(WT), pVHL(AAA), or plasmid alone 
MOCK were grown to approximately 90% 
confluence in a humidified 5% CO2 atmo-
sphere at 37°C.  Cells were harvested with 
0.25% Trypsin/1 mM EDTA solution.  2x106 
cells in 50 μl of 1xPBS were injected intra-
muscularly into the left hind leg of SCID male 
mice (Charles River Lab).  Tumor growth was 
assessed and measured weekly by carefully 
passing the tumor-bearing leg through a se-
ries of holes of decreasing diameter (0.5 mm 
decrements) in a plastic rod. 
 
Results
The acidic domain of pVHL30 is phosphory-
lated by CK2
To determine whether the two naturally 
occurring pVHL isoforms are phosphorylated, 
293T cells were transfected with VSV-tagged 
pVHL30 and pVHL19, and metabolically labeled 
with [32P]-orthophosphate. Cells were 
then lysed, immunoprecipitated with anti-
VSV antibody, resolved on SDS-PAGE, and 
immunoblotted with anti-VSV antibody (Fig. 
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Figure 1: pVHL30, but not pVHL19, is phosphorylated. 
(A) 293T cells were transfected with VSV-pVHL30 or VSV-pVHL19 and metabolically labeled with [32P]-
orthophosphate. Cells were lysed, immunoprecipitated with anti-RPTPμ mAb as a negative control (left 
upper panels) and anti-VSV mAb (right upper panels), and immunoblotted with anti-VSV mAb. Lower 
panels, autoradiography of the immunoblot showing [32P] incorporation. (B) 293T cells were transfected 
with HA-pVHL30(WT) or HA-pVHL30(AAA) and metabolically labeled with [32P]-orthophosphate. Cells 
were lysed, immunoprecipitated with anti-RPTPμ mAb as a negative control and anti-HA mAb (up-
per panels), and immunoblotted with anti-HA mAb. Autoradiography of the immunoblot showing [32P] 
incorporation (bottom panels). (C) 293T cells were metabolically labeled with [32P]-orthophosphate. 
Cells were lysed, immunoprecipitated with anti-pVHL mAb or anti-HA mAb as a negative control, bound 
proteins were separated on SDS-PAGE gel electropheresis and submitted to autoradiography.  IB, im-
munoblot; AR, autoradiography; IP, immunoprecipitation; kDa, kilodalton 
1A). Autoradiography of the immunob-
lot demonstrates that while VSV-pVHL30 
incorporated [32P]-orthophosphate, VSV-
pVHL19 did not (Fig. 1A). Computer-based 
scanning of the full-length pVHL30 indicated 
multiple potential phosphorylation sites over 
the entire open reading frame and three pre-
dicted CK2-phosphorylation sites in the acid-
ic domain at S33, S38, and S43 (data not 
shown). Thus, we generated the triple mutant 
pVHL30(AAA) with serine (S) to alanine (A) 
substitutions at each of these positions and 
found that pVHL30(AAA) was no longer ca-
pable of incorporating [32P]-orthophosphate 
(Fig. 1B). These results suggest that in an 
overexpression system pVHL30, but not 
pVHL19, is phosphorylated at one or more of 
the serine residue(s) within the acidic domain. 
To determine the physiologic relevance of 
this finding we metabolically labeled 293T 
cells with [32P]-orthophosphate. Cells were 
then lysed, immunoprecipitated with anti-
pVHL antibody, resolved on SDS-PAGE and 
blotted (Fig. 1C). Autoradiography of this 
blot clearly showed a specific band at about 
30kD in the anti-pVHL immunoprecipitation 
32
Figure 2: CK2 phosphorylates pVHL30. 
(A) In vitro kinase assay (IVK) of in vitro translated VSV-pVHL30(WT) and HA-pVHL30(AAA). After 
translation proteins were immunoprecipitated with anti-VSV or anti-HA antibody, CK2α was added 
in the presence of [32P] γ-ATP. Immunoblots with an anti-VSV and anti-HA antibody (lower panel) 
and visualized by autoradiography (upper panel). Casein was used as a positive control. (B) In vitro 
translated HA-pVHL30 with the indicated mutations were immunoprecipitated with anti-HA antibody 
and treated as described above, CK2-mediated phosphorylation (Upper panel). Anti-HA immunoblot 
of the in vitro translated pVHL used in IVK assay (Lower panel). (C) 786-WT cell lysates were immu-
noprecipitated with anti-RPTP-μ mAb as a negative control and anti-pVHL mAb, bound proteins were 
separated on SDS-PAGE and immunoblotted with an anti-CK2 antibody (upper panel) or an anti-pVHL 
antibody (lower panel). (D) 293T cells were lysed and used for endogenous IP of CK2α, pVHL or RPTPμ 
(aspecific control). The samples were incubated with [32P] γ-ATP, separated on SDS-PAGE and blotted. 
Bands were visualized using autoradiography. (E) 293T cells were lysed and the lysate was submitted 
to gelfiltration. Fractions of different sizes were collected and after TCA-precipitation the proteins were 
submitted to western blot analysis using anti-CK2α and anti-pVHL. (F) 293T cells were transfected with 
HA-pVHL30(WT). IVK assay of anti-HA immunoprecipitations were performed without or with increas-
ing concentrations of the indicated CK2-specific inhibitors (Upper panel). Anti-HA immunoblot indicates 
equal loading (Lower panel). IVK, in vitro kinase assay; IP, immunoprecipitation; IB, immunoblot;  kDa, 
kilodalton; wcl, whole cell lysate; *, Antibody light chain.
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and not in the anti-HA control. From these 
data we concluded that the phosphorylation 
of pVHL30 as observed, occurs endogenously. 
To directly address whether CK2 is responsible 
for the phosphorylation of pVHL30 at the 
predicted serine residues, we performed 
an in vitro kinase (IVK) assay using in vitro 
translated VSV-pVHL30(WT) and HA-
pVHL30(AAA) with or without recombinant 
CK2α, the catalytic subunit of CK2 (Fig. 2A). 
Autoradiography of the IVK assay clearly 
demonstrates that pVHL30(WT), but not 
pVHL30(AAA), was phosphorylated by CK2α 
(Fig. 2A). Casein was used as a positive con-
trol for the CK2-mediated IVK assays (Fig. 
2A). To determine the exact site or sites of 
pVHL30 phosphorylation, single and double 
S to A mutants were generated and ana-
lyzed using the IVK assay (Fig. 2B). All in 
vitro translated single S to A mutants were 
phosphorylated by recombinant CK2α. It 
should however be noted that pVHL30(S38A) 
had noticeably weaker phosphorylation sig-
nal. All double S to A mutants showed signif-
icantly weaker phosphorylation profiles com-
pared to their wild-type counterpart (Fig. 2B). 
These data suggest that all three serine resi-
dues can serve as CK2-mediated phosphor-
ylation sites, and that the phosphorylation 
of any one site appears to be temporally and 
spatially independent of the other two sites’ 
phosphorylation status. 
During the course of these IVK assays, we ob-
served that even without adding exogenous 
CK2α, anti-pVHL30(WT) immunoprecipitates 
derived from 293T cells exhibited endogenous 
kinase activity capable of phosphorylating 
casein (data not shown). Likewise, 
immunoprecipitates of pVHL30(AAA), which 
themselves cannot be phosphorylated 
(Figs. 1A, 2A, 2B), were also capable of 
phosphorylating purified casein (data not 
shown). These data suggest that CK2 ex-
ists in a complex with pVHL30 irrespective 
of its phosphorylation status. To further ver-
ify that pVHL30-associated kinase is CK2α, 
786-O RCC subclones stably expressing 
HA-pVHL30(WT) (786-WT) were lysed and 
immunoprecipitated with an anti-pVHL an-
tibody, anti-CK2α antibody, and anti-RPTPμ 
antibody as a negative control (Fig. 2C). 
Bound proteins were resolved on SDS-PAGE 
and immunoblotted with an anti-CK2α anti-
body and anti-pVHL antibody, which showed 
that CK2a associates with pVHL30 (Fig. 
2C). To determine whether this interaction 
Figure 3: pVHL30(AAA) forms a functional E3 
ubiquitin ligase. 
(A) 786-O cells stably transfected with plasmids 
encoding HA-pVHL30(WT) (786-WT), HA-
pVHL(AAA) (786-AAA), or empty plasmid (786-
MOCK) were lysed and submitted to immunopre-
cipitation with anti-HA mAb. Bound proteins were 
separated on SDS-PAGE and immunoblotted with 
an anti-Cul2 antibody (upper panel) or an anti-HA 
antibody (lower panel). (B) In vitro ubiquitination 
of [35S]-labeled HA-hHIF-1α(ODD) was performed   
using S100 extracts generated from 786-MOCK 
(lanes 1-5), and S100 extracts derived from 786-
WT (lane 6). Reaction mixtures were supplement-
ed with increasing amounts of in vitro translated 
HA-pVHL30(WT) (2 and 4μL; represented by a tri-    
angle), in vitro translate HA-pVHL30(AAA) (2 and 
4μL; represented by a triangle), or mock translate        
(2μL), in the presence of purified PHD. All reaction         
mixtures were immunoprecipitated with anti-Gal4 
antibody. Bound proteins were then separated on 
SDS-PAGE and visualized by autoradiography. (C) 
Whole cell extracts prepared from the indicated 
786-O stable subclones were separated on SDS-
PAGE and immunoblotted with an anti-GLUT1 
antibody (upper panel), an anti-a tubulin antibody 
(middle panel) as a loading control, or an anti-HA 
antibody (lower panel). IP, immunoprecipitation; 
IB, immunoblot; kDa, kilodalton; R, S100 lysate 
derived from 786-MOCK cells; W: S100 lysate 
derived from 786-WT cells.
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occurs in the absence of overexpression, we 
performed an IP using an anti-CK2α anti-
body, an anti-pVHL antibody and anti-RPTPμ 
antibody as a negative control, which was 
followed by an IVK assay, resolved on SDS-
PAGE gel and visualized by autoradiography. 
Kinase activity was detected in immuno- 
precipitates of pVHL and CK2α, which showed 
phosphorylation of endogenous pVHL30 (Fig. 
2D, lanes 1 and 2). We also observed phos-
phorylated proteins co-migrating with CK2α, 
suggesting autophosphorylation of CK2α (Fig. 
2D). These results suggest that pVHL30 and 
CK2α interact under a physiologic condition. 
Furthermore we performed a size-gel 
filtration assay to separate endogenous 
multiprotein complexes from 293T lysate 
according to their size. After performing the 
Figure 4: Inhibition of CK2-mediated phosphorylation of pVHL30 increases binding to 
fibronectin. 
(A) The indicated 786-O subclones were radiolabeled with [35S]-methionine. Cells were lysed and im-
munoprecipitated with anti-HA antibody. The bound proteins were resolved on SDS-PAGE and visual-
ized by autoradiography. (B) The indicated radiolabeled cells were lysed in the presence of increasing 
amounts of purified recombinant fibronectin and immunoprecipitated with anti-HA antibody. Bound 
proteins were resolved on SDS-PAGE and visualized by autoradiography. (C) Densitometry of B. 100% 
binding represents pVHL30-bound fibronectin in the absence of competing exogenous purified fibronec-
tin. (D) 786-O subclones ectopically expressing HA-pVHL(WT) were radiolabeled with [35S]-methionine 
in the presence of increasing concentrations of specific CK2 inhibitor diadzein. Cells were lysed and im-
munoprecipitated with anti-HA mAb, resolved by SDS-PAGE, and visualized by autoradiography. Upper 
panel shows bands at the molecular weigth of fibronectin, lower panel shows bands at the molecular 
weight of pVHL indicating equal loading. IP, immunoprecipitation; kDa, kilodalton 
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gel filtration according to size, proteins were 
concentrated using TCA-precipitation and 
immunoblotted for pVHL and CK2α. In the 
fraction containing pVHL30 we do find CK2α, 
again supporting the notion that pVHL and 
CK2α are present in the same protein com-
plex (Fig. 2E). 
We next examined the effect of specific CK2 
inhibitors, daidzein and 4,5,6,7-tetrabromo-
benzotriazole (TBB), on the phosphorylation 
of pVHL30. To this end, anti-HA immuno-
precipitates from 293T cells transfected with 
HA-pVHL30 were prepared and used in an 
IVK assay in the presence of 0, 10, 30, and 
100μM daidzein or TBB (Fig. 2F). We observed 
dosage-dependent inhibition of pVHL30 
phosphorylation (Fig. 2F). Collectively, 
these results show that CK2α binds and 
phosphorylates pVHL30. 
VEC complex formation and function are 
independent of pVHL30 phosphorylation 
To address whether the pVHL30(AAA) mutant 
is capable of forming an E3 ligase complex, 
we tested the ability of pVHL30(AAA) to bind 
to Cul2, a component of the VEC complex 
that acts as a scaffold. 786-WT, 786-AAA, 
or 786-MOCK cells were lysed, immuno- 
precipitated with an anti-HA antibody, re-
solved on SDS-PAGE, and immunoblot-
ted with an anti-Cul2 antibody and anti-
HA antibody (Fig. 3A). This assay shows 
that pVHL30(AAA) bound Cul2 similar to 
pVHL30(WT). Furthermore, immunoprecipi-
tation of HA-pVHL30(AAA) from metabolically 
labeled 786-AAA cells co-precipitated 
elongin B, elongin C, and Cul2 (Fig. 4A). These 
results demonstrate that pVHL30(AAA) 
forms a VEC complex. 
We next asked whether pVHL30(AAA) can 
ubiquitinate HIF1α(ODD) by performing an 
in vitro ubiquitination assay. S100 extracts 
prepared from 786-MOCK cells lacking pVHL 
supplemented with in vitro translated empty 
plasmid failed to support the ubiquitination of 
[35S]-labeled HA-HIF1α(ODD) (Fig. 3B, lane 
1). However, S100 extracts supplemented 
with either increasing amounts of in vitro 
translated HA-pVHL30(WT) (Fig. 3B, lanes 
2 and 3) or increasing amounts of in vitro 
translated HA-pVHL30(AAA) (Fig. 3B, 
lanes 4 and 5) ubiquitinated [35S]-labeled 
HA-HIF1α(ODD). As expected, S100 extracts 
made from 786-WT cells supported the 
ubiquitination of [35S]-labeled HA-
HIF1α(ODD) (Fig. 3B, lane 6). Furthermore, 
Figure 5: pVHL30(AAA)-expressing RCC cells 
accumulate intracellular fibronectin. 
(A) Fibronectin deposited by 786-MOCK, 786-WT, 
and 786-AAA cells grown for 4 days in 96-well 
plates in octoplets were measured by fibronectin 
ELISA. Relative amounts of fibronectin deposited 
by cells were normalized against mean of read-
ings obtained from wells containing cell culture 
media alone for the indicated period. (B) 786-WT 
and 786-AAA cells were grown on coverslips for 
4 days, fixed using ice-cold methanol and stained 
for fibronectin. Thin slices (0,6μm) of the cells 
above the level of the matrix were taken using 
a confocal microscope. (C) 786-MOCK, 786-
WT and 786-AAA cells were grown for 4 days, 
whole cell lysates were prepared after 30 min of 
trypsin/EDTA treatment at 37ºC, then resolved on 
SDS-PAGE and immunoblotted for fibronectin (up-
per panel) and MAPK (lower panel) as a loading 
control. IB, immunoblot; kDa, kilodalton
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whole cell extract made from 786-AAA cells 
down-regulated the expression of HIF-target 
gene GLUT1 under normal oxygen tension 
similar to 786-WT cells (Fig. 3C). Whole cell 
extract made from 786-MOCK cells showed 
over-expression of GLUT1 under normal 
oxygen tension. These results indicate that 
phosphorylation of pVHL30 by CK2 is not 
required for participation in the VEC complex 
to ubiquitinate HIFα.
Phosphorylation of pVHL30 regulates binding 
and secretion of fibronectin into extracellular 
space
Interestingly, HA-pVHL30(AAA) bound 
strikingly more fibronectin (approximately 
3-fold, as measured by densitometry) than 
HA-pVHL30(WT) to fibronectin (Fig. 4A). 
Furthermore, the addition of increasing 
amounts of purified recombinant fibronectin 
during lysis of radio-labeled cells resulted 
in greater reduction of fibronectinbound 
to HA-pVHL30(WT) compared to HA-
pVHL30(AAA) (Fig. 4B and C).  For example, 
whereas no appreciable effect was observed 
on HA-pVHL30(AAA) binding to fibronectin, 
there was 40% reduction in fibronectin 
binding by HA-pVHL30(WT) upon the addition 
of 0.1 μg of purified fibronectin, 
as measured by densitometry (Fig. 4C). 
Addition of 1 μg of purified fibronectin 
almost completely competed against the 
binding of endogenous fibronectin to HA-
pVHL30(WT), but negligibly affected the 
binding of endogenous fibronectin to 
non-phosphorylatable HA-VHL30(AAA). 
Collectively these data imply that dephospho-
rylation of pVHL30 enhances its ability to bind 
fibronectin or reduces its ability to release 
fibronectin.
We next asked whether the inhibition of CK2 
activity would recapitulate the increased 
binding of pVHL30(WT) to fibronectin. 
During metabolic labeling, 786-WT cells 
were treated with increasing concentrations 
of CK2-specific inhibitor diadzein. Cells were 
then lysed, immunoprecipited with anti-
HA antibody, resolved on SDS-PAGE, and 
visualized by autoradiography. As predicted, 
the inhibition of CK2 by diadzein increased 
pVHL30(WT) binding to fibronectin (Fig. 4B). 
This effect was not simply due to increased 
expression of pVHL30(WT) in diadze-
in-treated cells, as noted by relative-
ly equal loading of de novo translated 
pVHL30(WT) (Fig. 4B). Treatment 
with staurosporine (a general serine/ 
threonine kinase inhibitor excluding CK2) 
had negligible effect on fibronectin binding 
(data not shown). These results suggest that 
a specific inhibition of CK2 enhances pVHL30 
binding to fibronectin.
We next asked what effect pVHL30 binding 
of fibronectin had on subsequent deposition 
of fibronectin in the extracellular space. Relative 
Figure 6: pVHL30(AAA) fails to suppress tumor development in SCID mice xenograft assay. 
(A) A graph of tumor-growth over time in mice injected with the indicated 786-O stable subclones. The 
total number of mice that grew tumor is indicated on the right. This is a representative experiment 
of three experiments. (B) Tumor-take in representative mouse injected with either 786-O cells stably 
expressing MOCK, pVHL30(WT), or pVHL30(AAA).
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amounts of fibronectin deposited by 786-
MOCK, 786-WT and 786-AAA cells grown on 
96 well plates for 4 days were measured by 
ELISA using anti-fibronectin antibody after the 
cells were removed using Trypsin-free ETDA 
solution to preserve any fibronectin that was 
deposited on plastic. As expected, 786-MOCK 
cells deposited significantly less fibronectin 
than 786-WT cells. However, the enhanced 
fibronectin binding by pVHL(AAA) resulted in 
less fibronectin deposition than 786-WT cells 
(Fig. 5A). Anti-fibronectin immunofluoresence 
using confocal microscopy demonstrated 
an expected fibronectin staining in the 
cytoplasm and along the cell periphery 
in 786-WT cells (Fig. 5B). However, 
786-AAA cells showed excessive perinuclear 
fibronectin staining as well as punctate 
staining along the cell cortex (Fig. 5B). 
Concordantly, 786-AAA cells showed more 
intracellular fibronectin expression than in 
786-WT cells (Fig. 5C). 786-WT and 786-AAA 
cells showed similar de novo translation of 
fibronectin as measured by [35S]-metabolic 
labeling (data not shown). These data suggest 
that although 786-AAA cells are capable of 
producing fibronectin, they are less capable 
of releasing fibronectin into the extracellular 
space, which would account for the increased 
intracellular accumulation of fibronectin.
Phosphorylation of pVHL30 is required for 
tumor suppression in SCID mice
To determine if phosphorylation plays a role 
in tumor suppression, multiple 786-O sub-
clones expressing pVHL(WT), pVHL(AAA), or 
plasmid alone (MOCK) were injected intra-
muscularly into the left hind legs of SCID 
mice.  Tumor-take and -size were monitored 
and measured weekly (Fig. 6).  After 
approximately 3-4 weeks, as expected, 786-
MOCK cells began to form tumors (15/15). 
The mice injected with 786-AAA cells began 
to develop tumors (15/15) after 7-8 weeks, 
while mice injected with multiple 786-WT 
subclones were tumor-free (0/14).  These 
results demonstrate that the phosphorylation 
of pVHL30 within the first 53 amino acids 
have a direct role in tumor suppression.
Discussion
 
Not all VHL disease-causing mutations result 
in the dysregulation of HIF activity (2;3;17). 
For example, Type 2C-associated mutations 
such as L188V or K159E have been shown 
to have wild-type or ‘normal’ E3 ubiquitin 
ligase activity to target HIFα subunits for 
oxygen-dependent polyubiquitination. How-
ever, every VHL disease-causing mutant 
tested to date has shown a failure to bind 
fibronectin, resulting in a reduction of extra-
cellular fibronectin matrix assembly (2;3;17). 
Here we show that inhibition of pVHL 
phosphorylation, either by serine to alanine 
substitutions or by treatment with CK2-specific 
inhibitors, results in markedly increased 
binding of pVHL30 to fibronectin, while 
maintaining wild-type E3 ligase function. 
This increased binding, however, led to 
reduced fibronectin deposition in the extra-
cellular space. The improper deposition of 
fibronectin into the extracellular space or 
interference with its proper function has been 
correlated with the development of dysplasia 
in Xenopus and fibronectin has been 
shown to influence the malignant behavior 
of tumor cells in experimental mouse models 
(18;19). Thus, we postulate that the tumor 
suppressor function of the phosphorylation 
of pVHL30 is related to the regulation of 
proper fibronectin deposition.
The tumor suppressor function of pVHL we 
describe here requires the N-terminal acidic 
domain and is independent of the regulation 
of HIFα. Multiple papers have recently been 
published regarding the role of stabilized HIF in 
tumorigenesis, using an identical cell system 
as we describe here. Collectively, these articles 
suggest that HIF2α is the effector of 
tumorigenesis upon loss of functional pVHL. 
In the first 2 studies, Kondo et al. (2002) 
and Maranchie et al. (2002) address whether 
overexpressed stabilized HIF can counter-
act tumor suppression by pVHL (20,21). 
Kondo et al.  (22) show that the 786-O cells 
expressing stable HIF2α are able to override 
the pVHL-mediated tumor suppression. 
However, these studies do not address the 
more physiologically relevant question of 
whether the suppression of endogenous 
HIF2α would be sufficient to abrogate tu-
mor development in these patient-derived 
renal cell carcinoma cells (786-O RCC). 
Kondo et al. and Zimmer et al. do address 
this question with HIF2α RNAi; their data 
indeed support an oncogenic role for HIF2α 
(22,23). These experimental data do not, 
however, exclude further tumor suppressor 
functions for pVHL. The in vivo experiments 
described in these papers were terminat-
ed after 8-10 weeks, whereas our experi-
ments demonstrate that this time point 
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is only when the 786-O cells deficient for 
CK2-mediated phosphorylation begin form-
ing detectable tumors (Fig. 6). Moreover, 
tumor growth in the absence of HIF2α is 
retarded, but not completely inhibited (22). 
On the basis of these findings and our data, we 
propose that although HIF2α is an important 
regulator of tumor growth, it is not the only 
effector of tumorigenesis in pVHL-deficient 
cancers. These data lead us to hypothesize 
that an additional tumor suppressor 
function is linked to the phosphorylation 
of the acidic domain of pVHL.
The regulation of fibronectin by pVHL is 
tightly linked to the development of VHL 
disease. It follows then that there are multiple 
levels of fibronectin regulation by pVHL30. 
First, pVHL30 positively regulates transcription 
of the gene encoding fibronectin, FN1, in 
a HIF-independent manner (24). Second, 
as shown here, phosphorylation of the 
N-terminal acidic domain of pVHL30 mediates 
the engagement and/or disengagement of 
fibronectin. Third, modification of pVHL30 
by ubiquitin-like molecule NEDD8 is linked 
to fibronectin binding, where the inhibition 
of pVHL30 neddylation prohibited fibronectin 
binding (18). Thus, fibronectin deposition by 
pVHL seems to be a highly regulated process 
and is unique to the pVHL30 isoform, as 
pVHL19 does not bind fibronectin (11). 
We show here that CK2 exists in a complex 
with pVHL30 and phosphorylates S33, S38, 
and S43 in the N-terminal acidic domain of 
pVHL30. CK2 is a hetero-tetrameric complex 
composed of two β and two α subunits (25). 
The two β subunits have no kinase activity, 
but are thought to have a regulatory role 
enhancing the catalytic activity of the α 
subunits (25). Differential gene expression 
profiling of chemically-induced kidney 
carcinoma cells of Eker rats demonstrated 
over-expression of CK2β subunits, indicating 
that amplification of CK2α function may be 
involved in renal carcinogenesis (26). In 
support of this notion, human kidney tumors 
have been shown to express elevated levels 
of CK2α and CK2β (27). Moreover, CK2 localizes 
and binds to microtubules and has been 
shown to phosphorylate various microtubule- 
binding proteins (28-31). Recently, pVHL has 
been shown to associate with microtubules 
(32), which raises the possibility that pVHL30 
and CK2 interact on microtubules. Taken 
together our data present a novel tumor 
suppressor function for the acidic domain 
of pVHL, which might help to elucidate the 
complex genotype-phenotype correlation in 
the VHL disease.
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The von Hippel-Lindau tumor suppressor protein influences 
microtubule dynamics at the cell periphery.
Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE
Exp Cell Res. 2004 Dec 10;301(2):139-46
The von Hippel-Lindau protein (VHL) protects microtubules (MTs) from 
destabilization by nocodazole treatment. Based on this fixed-cell assay with static 
end points, VHL has been reported to directly stabilize the MT cytoskeleton. To 
investigate the dynamic changes in MTs induced by VHL in living cells, we measured 
the influence of VHL on tubulin turnover using fluorescence recovery after photo-
bleaching (FRAP). To this end we engineered VHL-deficient renal cell carcinoma 
cells to constitutively incorporate fluorescently labeled tubulin and to inducibly 
express VHL. Induction of VHL in these cells resulted in a decrease of  tubulin 
turnover as measured by FRAP at the cell periphery, while minimally influencing 
MT dynamics around the centrosome. Our data indicates that VHL changes the 
behavior of MTs dependent on their subcellular localization implying a role for 
VHL in cellular processes such as migration, polarization and cell-cell interactions. 
Here we propose a complementary method to directly measure VHL-induced 
subcellular changes in microtubule dynamics, which may serve as a tool to study 
the effect of MT binding proteins such as VHL.
Introduction
In a recent publication, the von Hippel-Lindau 
(VHL) protein was described to stabilize 
microtubules (MTs) (1). This finding is 
significant because it ascribes a novel function 
for VHL and suggests a mechanism for its 
tumor suppressor activity. Biallelic in- 
activation of VHL results in multi-focal tumor 
formation and is present in the majority of 
sporadic and inherited renal cell carcinomas 
(2). MT cytoskeleton dynamics play an impor-
tant role in various physiological processes 
such as cell migration, establishing epithelial 
cell polarity, neurite formation and mitosis. A 
frequently applied assay to assess whether 
drugs or proteins affect MT stability uses the 
microtubule disrupting agent nocodazole. 
After nocodazole treatment, cells are fixed 
and stained for acetylated or detyrosinated 
tubulin to identify the remaining stable MTs. 
This assay does not depict the dynamic 
process that underlies MT-stability; rather, 
it shows an endpoint measurement after 
nocodazole treatment. The exact nature of 
the influence of VHL on the MT dynamics 
described by Hergovich et al. could not be 
deduced from the static assay as mentioned 
above (1). We hypothesized that detailing 
the precise changes in MT dynamics induced 
by VHL would lend insight to the functional 
consequences of VHL-loss in the early stages 
of renal cell carcinoma.
To measure the rate of MT turnover we 
adapted a well-defined method to study 
the dynamics of protein movement in living 
cells: fluorescence recovery after photo-
bleaching (FRAP) (3). This technique has been 
previously used to study the behavior of in-
dividual MTs using green fluorescent protein 
(GFP)-labeled α-tubulin (4). Furthermore, 
using FRAP to measure MT dynamics has been 
validated extensively in studies involving 
microinjection of fluorochrome-labeled tu-
bulin (5-8). However, FRAP has not yet 
been used to assess the effect of drugs or 
proteins on MT-stabilization. The advent and 
validation of GFP-labeled tubulin as a tool to 
study MT dynamics opens the door for study-
ing changes in global MT turnover (4), such 
as those induced by MT-stabilizing agents.
In this paper we describe a FRAP-based 
analysis of MT dynamics. We validate our 
adapted method by showing that (YFP)- 
labeled α-tubulin (hereafter, tubulin-YFP) 
incorporates into stable microtubules 
and that recovery of tubulin-YFP into the 
bleached region has kinetic properties that 
can be associated with the properties of 
microtubule dynamics as previously published. 
Using this assay we measured changes in MT 
dynamics by paclitaxel (commonly known as 
Taxol©), a drug known to influence MT stability. 
To investigate the role of VHL in MT dynamics, 
we constructed a stable human renal cell 
carcinoma cell line, which conditionally 
over-expresses VHL from a tetracycline 
responsive promoter. After expression of 
VHL was induced, we registered a change 
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in MT dynamics specifically at the cell 
periphery. Thus, we have developed a 
sensitive method to measure real-time 
changes in MT dynamics, which has allowed 
us to quantify the MT-stabilizing effect of the 
tumor suppressor VHL. 
Materials and Methods
Expression vectors and cell culturing
KC12 renal cell carcinoma cell line was gen-
erously provided by Dr. Oshimura (9) and 
propagated with RPMI-1640 containing 5% 
Fetal Calf Serum (FCS), penicillin and strep-
tomycin (Invitrogen Carlsbad, CA). The PC3 
Figure 1: Characterization of KC12RN cell line
(A) Western blot analysis for expression of VHL, HIF1α and HIF2α of whole cell lysates of KC12TR or 
KC12TR/VHL-TO cells stimulated for 16 hrs + or – doxycycline (dox). Upper panel shows western blot 
analysis of VHL. The second panel shows western blot for HIF1α with lysate of PC3 prostate carcinoma 
cell line treated with desferoxiamine as positive control and the third panel shows western blot of HIF2α 
with lysate of the VHL deficient 786-O renal carcinoma cell line as a positive control. For loading control 
the same lysates were submitted to western blot analysis for MAPK (lower panel). IB, immunoblot. (B) 
KC12 cells have biallelic deletion of VHL exon 1. PCR of genomic DNA with primers specific for the 3 
exons of VHL from KC12 and 293T cells. As a positive control for DNA loading a PCR for GAPDH was 
performed (lower panel). H2O, contamination control. (C) RT-PCR analysis of HIFα subunits in the KC12 
cells. Upper panel shows the RT-PCR for HIF1α with RNA from 293T cells as positive control. The third 
panel shows RT-PCR for HIF2α with RNA form 786-O cells as a positive control. 18S is amplified as RNA 
input control for each experiment (second and fourth panel). (D) KC12TR and KC12TR/VHL-TO cells, 
all exposed to doxycycline (+dox), were treated with or without nocodazole (noc) for 20 minutes, fixed 
with methanol and stained for acetylated tubulin. Representative images acquired with the confo-
cal microscope are shown. Noc., nocodazole. (E) KC12RN cells were fixed with methanol and stained 
for acetylated tubulin. Upper panel shows tubulin-YFP staining, middle panel shows acetylated tubulin 
staining and lower panel shows the overlay of the two images.  
44
prostate cancer and 786-O renal cell carci-
noma cell lines were obtained from the ATCC 
and cultured under the same conditions. The 
T-REX system (Invitrogen, Carlsbad, CA) 
was used according to the manufacturer’s 
instructions to generate doxycycline-induc-
ible VHL expressing cells. In short, 107 cells 
were transfected by electroporation with 20 
mg FspI linearized pcDNA6TR. After 3 weeks 
of selection, blasticidin (10μg/ml) resistant 
colonies were expanded and transfected with 
pcDNA4TO-Luciferase. Two clones showing 
the strongest induction were chosen. These 
were subsequently transfected with 20μg 
PvuI linearized full-length VHL, which had 
been cloned into pcDNA4TO. After selection 
on Zeocin (500μg/ml), resistant colonies 
were tested for VHL induction by immuno-
cytochemical staining and western blot af-
ter addition of doxycycline and selected for 
further studies.  Selected clones were then 
further transfected with α-tubulin-YFP (Invi-
trogen, Carlsbad, CA) and cultured selecting 
for neomycin (500 μg/ml) resistant clones.
 
Reagents and antibodies
Nocodazole, zeocin, blasticidin and neo-
mycin were purchased from Invitrogen, 
Carlsbad, CA. Further reagents used were: 
doxycycline (Sigma-Aldrich, St.Louis, MO), 
paclitaxel (Brystol-Meyers-Squibb, New 
York, NY), anti-acetylated tubulin (1:500) 
(monoclonal Ab, Sigma-Aldrich, St.Louis, 
MO), anti-HIF1α (1:200) (monoclonal Ab, 
Beckton Dickinson, San Jose, CA), anti-
HIF2α (1:200) (monoclonal Ab, Beckton 
Dickinson, San Jose, CA), anti-VHL (1:500) 
(monoclonal Ab, Beckton Dickinson, San 
Jose, CA), anti-MAPK (1:3000) (polyclonal 
Ab, gift of Dr. O. Kranenburg, Dept. of Sur-
gery, University Medical Center Utrecht, The 
Netherlands).
Western blotting
Samples were examined by SDS-PAGE and 
subsequent western blotting. Specific pro-
tein bands on the western blots were visu-
alized using the appropriate antibodies as 
indicated in the text. All antibodies were di-
luted in PBS containing 5% dried skim milk 
and 0.1% Tween-20. Rabbit anti-Mouse HRP 
(Pierce, Rockford, IL) (1:20,000) or Swine 
anti-Rabbit (DAKO, Glostrup, Denmark) 
(1:3000) were used as secondary antibody 
after which enhanced chemiluminescence 
(Perkin Elmer Life sciences, Boston, MA) was 
used for detection.
Genomic PCR
Genomic DNA was isolated using standard 
procedures and the PCR of the three exons 
of VHL was performed using the primers de-
scribed by Gnarra et al. (10) 
RT-PCR
RNA from cell lysates was extracted using 
RNAbee reagent following the protocol of 
the manufacturer (Campro Scientific, The 
Netherlands). cDNA was made using 2μg 
of total RNA and reverse transcribed using 
Superscript Reverse Transcriptase (Invitro-
gen, Carlsbad, US) and random hexamers. 
We used the following primers in our as-
says: HIF1α-Fw: 5’-gctgatttgtgaacccattcctc, 
HIF1α-Rev: 5’-gcagcaacgacacagaaact, 
HIF2α-Fw: 5’-gaggtgttctatgagctggccc, 
HIF2α-Rev: 5’-cttgaggttgacagtacggcc, 18S-
Fw: 5’-agttggtggagcgatttgtc, 18S-Rev: 5’-
tattgctcaatctcgggtgg.
Immunofluorescent staining
Cells were washed once with PBS and fixed 
with 100% ice-cold methanol for 2 minutes 
at RT, then washed again with PBS. Pri-
mary antibodies for staining were used as 
indicated in the text. Secondary antibodies 
were goat-anti-mouse Alexa488 (1:200) 
(DAKO, Glostrup, Denmark) and goat-anti-
mouse Alexa 568 (1:200) (DAKO, Glostrup, 
Denmark). All incubations were done in PBS 
containing 1% BSA at room temperature in 
a dark chamber. Staining was visualized on 
a Zeiss LSM510 confocal imaging unit (Jena, 
Germany).
Fluoresence recovery after photobleaching 
(FRAP)
Cells were cultured on 24 mm diameter 
round coverslips and prepared for imaging 
on the Zeiss LSM510 confocal imager in a cli-
mate box at of 37°C and humidified air con-
taining 5%CO2. The cells were imaged using 
the argon laser at approximately 15mW of 
energy. Images taken for monitoring fluo-
rescence intensity used less than 1% of the 
laser power and the high-intensity bleaching 
beam was used at 100% of the laser power 
in all channels for the argon laser (458nm, 
477nm, 488nm, 514nm). The pinhole was 
adjusted to record slices of approx. 3-6μm. 
In region B (at the cell periphery, see Fig. 2), 
selecting a larger pinhole resulted in higher 
percentage of interpretable FRAP patterns. 
Frames were recorded every 10 seconds for 
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the dynamics around the centrosome (region 
A), but taken every 5 seconds to accurately 
determine the half-life time for the dynam-
ics at the cell periphery (region B). Regions 
were selected for FRAP according to the car-
toon shown in figure 2A. Regions bleached 
were similar in size. For further calculations 
we used the parameters and formulas given 
in Table 1. To be able to determine half-life 
time we plotted the %Fi vs time and using 
Sigmaplot software (SPSS, Chicago, IL) we 
curve-fitted these data with the regression 
wizard. We chose the ‘rise to the max. func-
tion’ and performed the regression using 3 
variables (f= y0+a*(1-exp(-b*x))). From 
these data we calculated the half-life of fluo-
rescence recovery (t(1/2)) from the follow-
ing function: t(1/2) = ln(2)/b. To correct for 
loss of global fluorescence that inevitably 
occurs as a result of imaging, we normal-
ized our data using the mean fluorescence 
of the entire cell over the time imaged vs. 
our bleached region of interest (see Table 
1 for mathematical formulas). However the 
two variables occasionally result in a slight 
increase in the adjusted fluorescence that is 
measured in the region of interest. Because 
very mobile proteins will recover 100%, nor-
malizing the data to account for total loss of 
fluorescence might appear as >100% recov-
ery. All Mf and half-life time data were pooled 
from at least 3 independent experiments and 
statistical analyses were performed using a 
two-tailed Student’s T-Test.
Results and discussion
Induction of VHL in KC12 cells affects MTs
To determine the role of VHL in MT dynamics, 
we constructed cell lines carrying doxy- 
cycline-inducible expres-
sion plasmids encoding 
full-length VHL (KC12 TR/VHL-TO) or an 
empty plasmid (KC12TR). As the recipi-
ent cell line, we chose the human renal cell 
carcinoma line KC12, which has a known in-
activating VHL mutation (9) and is tumorigenic 
in mouse xenografts. Multiple clones wer-
isolated and tested for inducibility of VHL 
expression (Figure 1A). VHL protein was 
not detected in uninduced clones. However, 
KC12 cells contain a constitutive unbalanced 
chromosomal translocation resulting in 
chromosome 3p11-ter loss in one VHL allele 
in the T-lymphocytes from the VHL patient, 
and it is possible that the remaining VHL 
allele is intact. We thus reanalyzed these 
renal carcinoma cells for the presence of VHL 
mutations. To begin with, we analyzed the 
genomic DNA of this cell line by Southern blot 
analysis using hybridization probes for each 
three of the three exons of VHL. KC12 cells 
failed to hybridize a probe comprising the 
first exon of VHL (data not shown). Probes 
for the second and third exons, however, 
hybridized to KC12 genomic DNA. These 
data suggest that the VHL allele not affected 
by the t(3;5) has also acquired a somatic 
deletion of exon 1. Because the first exon 
of VHL contains the translation initiation 
site, these mutations would both constitute 
complete null-alleles. Because biallelic deletion 
of VHL should also be detectable by a more 
sensitive PCR amplification, we PCR amplified 
the 3 exons of VHL and confirmed that exon 
1 is deleted in the KC12 cells (Figure 1B). The 
remaining two exons amplified with expected 
efficiency (Figure 1B) and showed no sequence 
abnormalities (data not shown).  These data 
suggest that a somatic mutation occurring 
in the renal carcinoma of this VHL patient is 
limited to exon 1 of VHL. 
VHL-deficient cells normally express high 
levels of hypoxia inducible transcription fac-
tor alpha (HIFα) under normoxic conditions 
F(ROI)  Mean fluorescence intensity of region of interest (ROI)
F(total cell) Mean fluorescence intensity of the entire cell
Fi  Average fluorescence before bleaching (5 values averaged)
Fw  Mean fluorescence of last 10 time points recorded in experiments 
  reaching an equilibrium
F(t)n  Normalized fluorescence at time point (t) = Ft(ROI)/(Ft(total cell)/Fi(total cell))
F0  F0=F(t)n directly after bleach
%Fi  Percentage of initial fluorescence = 100-{(Fi(ROI)-F(t)n) / (Fi(ROI))*100}
Mf  (Fw - F0) / (Fi - F0)
t(1/2)  t(1/2) = ln(2)/b, b is derived from curve fitting as described in the text
Table 1. Formulas used for FRAP calculus
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(11). We thus determined the levels of HIF1α 
and HIF2α on western blots. Contrary to our 
expectations given the biallelic inactivation 
of VHL in KC12 cells we were unable to detect 
HIF1α or HIF2α (Figure 1A). We next 
performed an RT-PCR to detect whether 
HIF1α or HIF2α were detectable at mRNA 
levels and we were unable to detect mRNA 
specific for HIF1α or HIF2α in the KC12 cell 
line (Figure 1C). In this same assay we could 
readily show mRNA for HIF1α in 293T cells 
and HIF2α in 786-O renal carcinoma cells (Fig-
ure 1C). Several mechanisms like promotor 
methylation or chromosomal deletion could 
account for the observed lack of HIF. These 
data infer that KC12 cells system represent 
a unique cellular system in which to study 
the HIF-independent function of VHL, as it 
does not express HIF1α or HIF2α but is able 
to form tumors in nude mice (9). This finding 
supports the notion that VHL has a tumor 
suppressor function that is independent of 
its ability to regulate HIFα levels (12,13). 
However, other data has provided evidence 
for a causative role for HIF2α in tumorigenesis 
(14,15). We concluded that any effect of 
reconstituted VHL in this cell line would be 
HIF-independent. 
We next set out to confirm the positive ef-
fect of VHL on MT-stability using the exist-
ing method of scoring for stable MTs after 
nocodazole treatment. We treated KC12TR 
and KC12TR/VHL-TO cells with doxycycline 
for 16hrs and exposed them to nocodazole 
for 20 minutes, fixed them and stained for 
acetylated tubulin. This assay recapitulated 
the results of Hergovitch et al. (1), showing 
that induction of VHL resulted in an increase 
Figure 2: Paclitaxel affects tubulin-YFP turnover as measured by FRAP.
(A) Schematic representation of the regions that were used for FRAP experiments. Lines represent MTs 
and filled circle represents nucleus. (B) Typical FRAP patterns that were obtained in the different regions 
in untreated KC12RN cells. The squares are measured points. These are represented as % of initial 
fluorescence (Fi) vs time in seconds. The solid lines are the curve-fitted lines and are calculated values. 
(C) Typical FRAP pattern of KC12RN cells after paclitaxel treatment (10μM) in the different regions. 
The representation is identical to Fig. 2B. (D) Bar graph representation of Mf and t(1/2) of non-treated 
vs paclitaxel-treated cells of the different regions. The error bars represent the standard error of the 
mean. Statistics using two-tailed Student’s t-test are provided above the bars. ns, not significant 
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Figure 3: VHL shifts MT-stability towards the cell periphery
(A) Typical FRAP patterns of cells induced with doxycyline (dox) for 16hrs for regions. Every square rep-
resents a measurement and the data is given as %Fi vs time in seconds. The solid lines are the curve-
fitted lines and are calculated values. ns, not significant. (B) Bar graph representation of calculated Mf 
and half-life time (t(1/2)). Every bar represents at least 3 independent measurements FRAP region is 
depicted below the bars. Statistics using two-tailed Student’s t-test are provided above the bars. ns, not 
significant. (C) Confocal slices KC12RN cells. Upper panels: tubulin-YFP directly visualized in living cells. 
Middle panels: the same cells imaged using differential interference contrast (DIC) microscopy. Lower 
panels: overlay of tubulin-YFP and DIC image.
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of nocodazole resistant MTs as opposed to 
the KC12TR cells -which lacking the inducible 
VHL construct- failed to manifest any MT 
resistance to nocodazole upon exposure to 
doxycycline (Figure 1D). 
For FRAP analysis of MT dynamics we selected 
a KC12TR/VHL-TO clone that inducibly 
expresses VHL and stably transfected it with 
tubulin-YFP. We then selected clones with a 
uniform expression of tubulin-YFP. Tubulin-
YFP expression pattern largely co-localizes 
with the staining for acetylated tubulin in 
these cells, suggesting that tubulin-YFP is 
incorporated into stable MTs (Figure 1E). 
From these results we concluded that the 
KC12TR/VHL-TO/tubulin-YFP (dubbed 
KC12RN) cells represented a suitable model 
for testing global changes in MT dynamics. 
Applying FRAP to measure MT dynamics
To study the dynamic behavior of MTs we 
next set out to use FRAP of tubulin-YFP. In the 
KC12RN cells the MT dynamics appeared to 
differ according to the proximity of the MTs to 
the centrosome.  We thus defined two regions 
in which subsequent FRAP experiments 
could be stratified. The first region is defined 
as the region around the centrosome 
(region A); the second was defined as a 
region localized along the cell periphery 
(region B) (Figure 2A). The mobile fraction 
(Mf) of tubulin-YFP in cells lacking VHL does not 
show significant differences in the regions we 
measured. The half-life time of fluorescence 
recovery, however, showed a significant 
decrease in region B; we observed a half-
life time (+/-1xSD) ranging from 437+/-102 
sec. in region A to 78+/- 38 sec. in region B. 
These data support the notion that the MTs 
at the cell periphery are generally more 
dynamic than around the centrosome. 
Additionally, the subcellular localization of 
the MTs with a longer half-life time correlates 
with the acetylated tubulin staining (Fig-
ure 1F). Previously published data on the 
turnover of MTs during interphase using FRAP 
did not discriminate between different regions 
of the cell (4,7). Here we demonstrate 
for the first time a difference in tubulin turnover 
in different sub-cellular compartments as 
measured by the half-life time of fluores-
cence recovery. This finding and a recent 
publication on the local effects of stathmin 
on MT dynamics (16) underscore the 
importance for stratifying the results of MT 
turnover data according to their subcellular 
localization. 
We next addressed whether a known MT 
stabilizing agent, paclitaxel, could change 
the FRAP read-out of MT dynamics (17). 
After 1 hour of paclitaxel treatment we 
observed significant changes in MT dynamics. 
In region A as well as region B the Mf 
decreased significantly with no significant 
changes in half-life time after paclitaxel 
treatment (Figure 2C, D). These data show 
that FRAP analysis of tubulin-YFP can detect 
the changes in MT dynamics after paclitaxel 
treatment and that these changes are 
comparable throughout the entire cell. We 
used a high paclitaxel dose (10μM), which 
is important for interpreting the effect 
observed. Occupation of all paclitaxel-binding 
sites would allow MTs to continue growing 
but would not permit depolymerization of 
existing MTs. We thus interpret the changes 
in Mf to represent the decrease in MT 
turnover due to the absence of catastrophe. 
However, the remaining dynamic processes 
have similar half-life times as before treat-
ment with paclitaxel. These data validated 
that our modified FRAP-based assay using 
tubulin-YFP, and allowed us to apply it as 
a tool for monitoring global changes in MT 
dynamics. 
VHL stabilizes the MTs at the cell 
periphery
To further investigate the change in MT 
dynamics induced by VHL we compared 
KC12RN cells treated with or without 
doxycycline for 16hrs. Using the same 
two regions as before in a series of FRAP 
experiments, we determined the change of 
MT dynamics after the induction of VHL. We 
observed that in the presence of VHL, the 
Mf does not significantly change between 
the different regions. However, when com-
pared to cells lacking VHL region B showed 
significant changes; the Mf in region B 
decreased. The half-life time did not show 
significant changes between the different 
sub-cellular regions in the presence of VHL 
(Figure 3A, B). Furthermore in region A 
there is a trend towards faster kinetics and 
lower Mf in the presence of VHL (Figure 3B). 
The variation of MT-turnover throughout 
the cell as observed in the absence of VHL 
is no longer present. These data suggest 
that the most profound effect of induction 
of VHL on MT dynamics is localized towards 
the cell periphery. The dynamics found in 
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the VHL-proficient cells correlate better with 
previously published data on MT dynam-
ics as measured by FRAP in cultured cells. 
The cumulative half-life time we measured 
in cells expressing VHL was comparable to 
previously published data (330+/-170 sec. 
vs 200+/-85 sec) and no differences for sub-
cellular localization were noted (7). There 
also seem to be changes in region A, which 
show an increase in MT dynamics near the 
centrosome (Figure 3B). This effect could be 
a direct destabilizing effect of VHL, however 
we favor the hypothesis that this effect is 
secondary to the plus-end stabilizing func-
tion of VHL. A change in the MT dynamics 
at the cell periphery would result in altered 
MT organization, which could be captured in 
high-resolution confocal images. These im-
ages show the thickening and stabilization 
of the MTs towards the cell periphery and 
modified cell shape (Figure 3C). Note that in 
VHL-proficient cells, the cell shape is flatter 
and there appears to be a more even dis-
tribution of organelles. Together these data 
suggest that VHL’s influence in MT dynamics 
in interphase KC12RN cells is most promi-
nent at the cell periphery. Furthermore, we 
confirmed that the microtubule stabilizing 
function of VHL is independent from its role 
in regulating the HIFα levels. 
Here we directly measure MT turnover as a 
read-out for quantitatively assessing the role 
of VHL in MT stability. This assay comple-
ments the standard nocodazole resistance 
assay, but has many additional benefits. 
This assay does not introduce experimen-
tal artifacts through cell fixation and allows 
real-time evaluation. The extra information 
obtained by using this assay is useful in as-
sessing the localized change in MT dynam-
ics by endogenous proteins and drug treat-
ments. 
VHL appears to have a localized effect at the 
cell periphery. Physiological processes that 
involve changes in stability of MTs often re-
quire localized changes in MT dynamics. For 
example, these sorts of MT dynamics might 
be essential for the formation of parallel 
MT-arrays such as those observed in polar-
ized epithelial cells or polarizing the MT net-
work in migrating cells (18). It is tempting 
to speculate that VHL could have a role in 
processes that require localized changes in 
MT dynamics such as cell polarization, cell 
migration and cell-cell interaction. Another 
interesting finding from this study is that, 
although VHL is present throughout the cy-
toplasm (19), it can have a localized effect 
on MT-stability implying the existence of a 
signal transduction pathway in which VHL is 
involved to locally stabilize MTs.  
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The von Hippel-Lindau tumor suppressor binds kinesin-2 and 
regulates primary cilia function 
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In patients with von Hippel-Lindau (VHL) disease, VHL-/- kidney cysts degener-
ate into clear-cell renal carcinomas (ccRCC) through unknown mechanisms. The 
VHL gene product regulates the ubiquitination and subsequent degradation of 
hypoxia inducible factor (HIF), an important transcriptional activator of the genetic 
program triggered by hypoxia. Dysregulation of HIF is, however, not sufficient to 
induce cancer which suggests the presence of alternative functions of VHL. We 
show here that wild-type VHL binds KIF3A, a component of molecular motor 
kinesin-2 regulating the assembly and maintenance of primary cilia. We demonstrate 
that binding KIF3A is important for VHL-mediated microtubule stabilization. 
Because renal inactivation of any component of kinesin-2 causes cilia defects 
subsequently leading to cystic kidneys, we investigated the role of VHL in ciliogen-
esis. VHL localizes to primary cilia in cultured kidney cells. We demonstrate that 
cultured VHL-/- renal cell carcinoma cells do not tend to develop cilia; however, 
thick stubby cilia are rapidly assembled upon ectopic re-expression of wild-type 
-but not mutant alleles of- VHL in those same cells. These data show that VHL 
interacts with the kinesin-2 complex and that this interaction has a functional con-
sequence on ciliogenesis.
Introduction
The rare hereditary von Hippel-Lindau (VHL) 
disease is caused by heterozygous germ-
line mutations in the VHL gene located on 
chromosome band 3p25-26 (1). Mutations in 
VHL kindreds predispose patients to a variety 
of tumors including renal cell carcinomas, 
haemangioblastomas of the central nervous 
system and retina, and phaeochromocytomas. 
These patients also frequently develop mul-
tiple cysts in the kidney, pancreas and liver. 
The occurrence of biallelic somatic VHL 
mutations in about 70% of sporadic renal cell 
carcinomas fits with Knudson’s two-hit model 
for tumor suppressor genes and suggests 
that VHL functions as a global gatekeeper of 
cellular growth in the kidney (1,2).
Many lines of research support a role for VHL as 
the target recognition moiety of a multiprotein 
ubiquitin E3 ligase complex, the so-called 
VHL-EloC-EloB-Cullin2 (VEC) complex. Under 
normoxic conditions, oxygen-dependent 
prolyl hydroxylation of hypoxia inducible 
factor (HIF)-α facilitates VHL binding, fol-
lowed by ubiquitination, and subsequent 
proteasomal degradation of HIFα subunits 
(reviewed in: (3,4)). Two protein products 
encoded by VHL equally participate in the E3 
ligase complex to regulate HIFα, a 30 kDa full-
length protein (p30), and a 19 kDa protein 
(p19) generated by alternative translation 
initiation of an internal methionine at 
position 54 (Fig. 1a) (5,6). The first 53 residues 
of p30 constitute an acidic domain of unknown 
function, forming an N-terminal extension to 
p19. The vast majority of VHL mutations are 
downstream of residue 54 thereby inactivating 
both isoforms, however, the existence of VHL 
patient mutations in the acidic domain that 
do not affect p19 suggest a specific role for 
p30 in tumor suppression (Giles et al., sub-
mitted). Furthermore, phosphorylation of the 
acidic domain by casein kinase-2 is important 
for the full tumor suppressor function 
of VHL (7). Recently, the inactivation 
of JunB by VHL alleles capable of normal 
HIF regulation has been implicated in the 
development of pheochromocytoma associ-
ated with type 2C VHL disease (8). Thus, 
while the highly vascularized lesions associ-
ated with VHL disease are a result of HIF-
induced gene expression of pro-angiogenic 
factors such as VEGF, careful genetic and 
functional analysis of the VHL gene suggests 
that the tumor suppressor function of VHL 
is not solely restricted to its function in 
regulating HIF.
The heterotrimeric kinesin-2 complex has 
been implicated in the anterograde ATP- 
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dependent transport of various cargos along 
the microtubule (MT) cytoskeleton. Genetic 
disruption of individual components of the 
kinesin-2 complex (KIF3A, KIF3B, and KAP3) 
invariably results in dysfunction of specialized 
tubulin sensory structures known as pri-
mary cilia (9). Moreover, local disruption of 
KIF3A in the kidney results in ciliogenesis 
defects and the subsequent development of 
renal cysts, much like those present in VHL 
patients (10).
Here, we report that the acidic domain and the 
MT-binding domain of VHL regulate binding 
to KIF3A. This binding could be disrupted us-
ing a dominant negative KAP3 construct (ΔN-
KAP3) unable to bind the kinesin-2 complex 
(11). The interaction between VHL and 
KIF3A does not influence the known function 
of VHL in regulating HIFα levels nor is KIF3A 
a target for the VEC complex mediated poly-
ubiquitination. Our data suggest that KIF3A 
mediates the binding of VHL to MTs. Moreover, 
disrupting the interaction between VHL and 
kinesin-2 influences the mobility of VHL. 
Furthermore, we show that the interaction 
between VHL is essential for the function of 
primary cilia. This interaction not only assigns 
the first function of VHL in which the acidic 
domain is implicated, but it provides a 
molecular mechanism for the MT-stabilizing 
function of VHL and suggests a role for VHL 
in ciliogenesis.
 
Materials and Methods
Construction of plasmids 
The VHL bait for Yeast-two-Hybrid was gen-
erated by cloning VHL cDNA by one-step 
PCR in the Gal4 DNA-binding domain con-
taining vector pMD4 (kind gift of Dr. L. van ’t 
Veer). All eukaryotic expression constructs 
were generated using pcDNA3-derived vec-
tors (Promega, Madison, WI) containing 
either a N-terminal Myc- or Vsv-tag and 
standard cloning techniques. GFP-fusion 
constructs were generated by cloning into 
pEGFP-C1 (Clontech, Palo Alto, CA). The 
KIF3A construct (kind gift of Dr. L. Gold-
stein), ΔN-KAP3 construct (kind gift of Dr. 
T. Akiyami), the VHL-Δ95-123, VHL-Y112H 
construct (kind gift of Dr. W. Krek), the 
dsRED-γ-tubulin construct (kind gift of Dr. J. 
Ellenberg) were requested and cloned into 
the appropriate vectors.
Yeast-Two-Hybrid Screen
The Yeast-two-Hybrid screen was performed 
according to the Matchmaker protocol (Clon-
tech, Palo Alto, CA) using a human fetal brain 
cDNA library (Matchmaker, Clontech, Palo 
Alto, CA). The library was co-transformed 
with the VHL bait plasmid into Saccharomy-
ces cerevisiae strain Hf7c. Library plasmids 
were recovered from His+/LacZ+ clones and 
tested for the absence of interaction with ir-
relevant baits and sequenced.
Immunoprecipitations
Approximately 1*106 cells were lysed in 400 
ml Triton lysis buffer (20 mM TRIS; 1% Tri-
ton-X-100; 140 mM NaCl; 10% Glycerol; 
at pH 8.0) containing ‘complete’ cocktail of 
protease inhibitors (Roche, Basel, Switzer-
land). Cell remnants were spun down by 5 
min centrifuging at 4°C. α-VHL (1.5 μg of 
IG32; BD-Pharmingen, San Diego, CA) was 
coupled to protein A/G agarose beads (7.5 
μl; Santa Cruz Biotechnology, Santa Cruz, 
CA) and added to 200μl of cleared lysate. 
For endogenous IPs, 2 ml cell lysate (10*106 
cells) was used with 25 μl protein A/G aga-
rose beads pre-coupled to 7.5 μg α-VHL or 
7.5 μg α-KIF3A (BD-Transduction Labs, San 
Diego, CA). The IP reactions were incubated 
overnight at 4°C, washed three times with 
Triton lysis buffer and analyzed by western 
blotting. All IPs were repeated in at least 
three independent experiments.
Western blot
Specific protein bands were visualized using 
the following antibodies: α-Myc (9E10, hy-
bridoma supernatant 1:5), α-Vsv (P4D5, hy-
bridoma supernatant 1:5), α-KIF3A (1:500; 
BD-Transduction Labs, San Diego, CA) or α-
MAPK (1:3000) (polyclonal Ab, kind gift of 
Dr. O. Kranenburg) as indicated in the text. 
All antibodies were diluted in PBS contain-
ing 5% milk and 0.1% Tween-20. Rabbit 
α-mouse HRP (1:20,000; Pierce, Rockford, 
IL) or Swine α-Rabbit HRP (1:3000; DAKO, 
Glostrup, Denmark) provided the secondary 
antibody after which enhanced chemilumi-
nescence (Perkin Elmer Life Sciences, Bos-
ton, MA) was used for detection.
Reporter assay
To generate the HRE-luciferase reporter con-
struct, we used the following wild-type HRE 
oligonucleotide (W18) of the 3’-enhancer of 
the human erythropoietin gene (12) in trip-
licate in front of a minimal TK promotor and 
the Luciferase Gene in the vector pBlLuc: 
C(TACGTGCT)GC(TACGTGCT)GC(TACGTGC
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T)G (where the HRE is in parentheses and 
the core bases essential for HIF binding are 
underlined). The vector pBlLuc is derived 
from pBlCat2 (13) in which the Cat gene has 
been replaced by Luciferase out of pTopFlash 
(14). As a negative control, a similar con-
struct with the M28 fragment (12) was con-
structed in which three altered nucleotides 
completely abrogate HIF-binding: CTCAAT-
GCTGCTCAATGCTGCTCAATGCTG 3’ (where 
the mutated core bases are underlined). 
HEK293T cells were plated 18 hours prior 
to transfection by Fugene6 (Roche, Basel, 
Switzerland) according to the manufactur-
er’s instructions. The following amounts of 
plasmids were transfected in HEK293T cells: 
50 ng HRE-Luc or Mut-Luc in combination 
with 5 ng of the renilla internal control CMV-
pRNL (Promega, Madison, WI), and 100 ng 
wild-type HIF1α as indicated in the text. The 
total amount of DNA transfected in all re-
porter assays was adjusted to 500 ng with 
pcDNA3. Luciferase activities were mea-
sured 24-36 hours after transfection using 
the DUAL luciferase system according to the 
manufacturer’s protocol (Promega, Madison, 
WI).  Luciferase activity was normalized rel-
ative to renilla.
Microtubule co-sedimentation assay
Transfected HEK293T cells were lysed in PTN 
buffer (10 mM Pipes, 30 mM TRIS, 50 mM 
NaCl, 1 mM EGTA, 1.25 mM EDTA, 1 mM 
DTT, 1% Triton-X-100, and protease inhibi-
tors at pH 6.3). The lysates were pre-cleared 
by centrifugation at 100,000g for 45 min. at 
25ºC. The co-sedimentation assay was per-
formed using the MAP Spin-down Biochem 
Kit (Cytoskeleton, Denver, CO), with the fol-
lowing adjustments: after polymerization, 
microtubules were spun down at 100,000g 
for 30 min at 25ºC. The pelleted microtu-
bules were resuspended in the pre-cleared 
lysates containing 50 μM paclitaxel and in-
cubated at room temperature for 30 min. 
The samples were then loaded onto 100 μl 
of the kit’s cushion buffer and centrifuged at 
100,000g for 40 min. Pre-cleared total ly-
sates, supernatant and pellet fractions were 
analyzed by western blotting.
Live cell imaging 
Transfected N1E-115 neuroblastoma cells 
were visualized on a Zeiss LSM 510 confocal 
scanning microscope (Carl Zeiss, Jena, Ger-
many) fitted with a climate control chamber 
maintaining humidified 37°C and 5% CO2. 
A circular region of interest with 10 mm ra-
dius was photobleached with 80 pulses of 
approximately 15 mW laser intensity after 
which the cell was followed by time-lapse 
imaging (every 0.25 sec, total 400 frames). 
The pre-bleach fluorescence intensity (Fi) 
was defined as the mean of 15 images be-
fore photobleaching. Total cell fluorescence 
was measured over time and used to nor-
malize the data as described before (15). All 
values were calculated as percentage Fi. The 
recovery fluorescence (Fw) was defined as 
the mean of the 15 last scans. The mobile 
fraction (Mf) was calculated using the fol-
lowing equation: Mf=(Fw-F0)/(Fi-F0) (15). 
All experiments were repeated indepen-
dently on at least three separate days. For 
co-transfection assays we used equivalent 
doses of the co-transfected plasmids unless 
otherwise stated in the figure legends. 
Immunofluorescent staining
Cells were washed once with PBS and fixed 
with 100% ice-cold methanol for 2 minutes 
at RT, then washed again with PBS. Primary 
antibodies for staining were used as indicat-
ed in the text: α-VHL (Ig32; BD-Pharmin-
gen, San Diego, CA), α-acetylated tubulin 
(Sigma-Aldrich, St.Louis, MO) and α-gluta-
mylated tubulin (GT335, Gift from B. Edde 
and C. Janke, 1:2000). Secondary antibody 
was goat-anti-mouse Alexa 568 (1:200) 
(DAKO, Glostrup, Denmark). All incubations 
were done in PBS containing 1% BSA at 
room temperature in a dark chamber. Stain-
ing was visualized on a Zeiss LSM510 confo-
cal imaging unit (Jena, Germany). 
Ca2+ microfluorimetry
We grew kidney epithelial cells on uncoat-
ed 24x60 mm glass coverslips for at least 
4 days to full confluence. The experimental 
setup for flow has previously been described 
in detail (16).  Briefly, we incubated cells for 
30 min with the Ca2+ sensitive probe Fura2-
AM (5 μM) at 37°C. We then washed cells 
three times to remove excess Fura2-AM and 
placed them in a perfusion chamber with 
a thickness of 0.025 cm. in HEPES buffer 
(pH 7.4) containing 132 mM NaCl, 4.2 mM, 
NaHCO3, 5.9 mM KCl, 1.4 mM MgSO4, 1.2 
mM Na2HPO4, 1.6 mM CaCl2, 11 mM dex-
trose and 10 mM HEPES buffer. We captured 
paired Fura images every 4s at excitation 
wavelengths of 340 nm and 380 nm. After 
equilibration in the microscopy media for at 
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least 5 min, we then stimulated the primary 
cilia of these cells at a fluid shear stress of 
0.75 dyne cm-2. We radiometrically calculat-
ed the Ca2+ level relative to the baseline val-
ue using Rmin and Rmax values of 0.3 and 
6.0, respectively. Freshly diluted thrombin 
(1μM) produced a robust [Ca2+] response in 
these cells and was used to determine the 
maximum response (upper baseline). Cells 
were incubated with 10μM nocodazol for 30 
minutes at 37oC prior to microfluorimetry as 
indicated.
 
 
Results
KIF3A and VHL are interacting proteins
We performed a yeast-two-hybrid screen of 
a human fetal brain cDNA library with the 
full-length VHL protein as bait. Among the 
8 clones that appeared to robustly bind VHL 
in this assay we found chaperonin CCTh, a 
chaperone protein known to bind to VHL and 
is involved in the correct folding of VHL into 
the elongin B/C complex (17). These results 
indicated that we had detected possible VHL 
binding proteins and we selected a cDNA en-
coding the C-terminal portion of the kinesin-
2 subunit KIF3A for further analysis. We re-
transformed yeast with the KIF3A construct 
with 4 different VHL bait constructs: full 
length (VHLfl), β-domain: ranging from aa 1-
Figure 1: VHL binds KIF3A and other members of the kinesin-2 complex.
(A) Yeast-two-Hybrid assay. Left panel shows the schematic representation of the VHL constructs 
that were used as bait in a Yeast-two-Hybrid assay with KIF3A as prey. Above this panel, a schematic 
representation of the VHL protein is given showing the acidic domain (left box), β-domain (middle box) 
and α-domain (right box) and the translation initiation sites for the two different isoforms of VHL: p30 
and p19. Right panel shows the colony growth of transformed yeast under increasing stringency, which 
is achieved using increasing concentrations of 3AT on agar plates without histidine. The first lane in the 
right panel (c) shows the control colony in the presence of histidine. Gal4 DNA binding domain fused to 
(from top to bottom) full-length VHL (VHLfl), a deletion construct of containing only the HIF-binding VHL 
β-domain (VHLβ), a deletion construct of containing only the elongin-C binding VHL α-domain (VHLα), 
or a deletion construct of VHL lacking exon 2 (VHLΔ2). -HIS, without histidine; 3AT, 3-aminotriazole. (B) 
Overexpression IP of lysates of transfected HEK293T cells. The cells were co-transfected with Myc- 
KIF3A, Myc-KIF3B, GFP-KAP3 or Myc-hHR23A and Vsv-p30 as described under the different lanes. Top 
two panels show western blot of whole cell lysates for respectively GFP-tagged and Myc-tagged pro-
teins. The third and fourth panels show recovery for respectively GFP-tagged and Myc-tagged proteins 
from the anti-Vsv IP. The fifth panel shows recovery of Vsv-VHL from the anti-Vsv IP. The lower panel 
shows the recovery for the aspecific IP using α-RPTPμ antibodies. Irrelevant lanes were removed for 
clarity. Wcl, whole cell lysate; IB, immunoblot; IP, immunoprecipitation. (C) Endogenous IP in HEK293T 
cells. Upper panel shows western blot stained for endogenous KIF3A after recovery of an aspecific IP 
using α-RPTPμ (lane 1), an IP for VHL (lane 2) and an IP for KIF3A (lane 3).  Lower panel shows the 
same samples on western blot stained for VHL. IB, immunoblot; IP, immunoprecipitation.
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178 (VHLβ), α-domain: ranging from aa 178-
213 (VHLα) and Δexon2: lacking the region 
from aa 137-178 (VHLΔ2). In this assay the 
major determinants for binding of VHL to 
KIF3A seem to be located in the first exon of 
VHL ranging from aa 1-136 (Fig. 1a).
Interaction was validated by co-immuno- 
precipitation (IP) using cell lysates containing 
exogenous Vsv-tagged VHL (p30) and Myc-
tagged KIF3A (Fig. 1b; first lane). As a 
specificity control, we used a Myc-tagged 
cDNA from hHR23A (Rad23A), a nucleotide 
excision repair protein with no known link 
to VHL (18). Indeed, IP using an antibody 
against Vsv-VHL specifically co-immuno-
precipitated the Myc-tagged KIF3A protein 
whereas the Myc-tagged hHR23A was not 
detected (Fig. 1b; fourth lane). Moreover, IP 
using an antibody for an irrelevant protein 
in this system: RPTP-μ, a transmembrane 
protein with phosphatase activity that is not 
expressed in these cells, does not retrieve 
any of the overexpressed proteins (Fig. 1b; 
lower panel). IP of exogenous VHL resulted 
in co-precipitation of the other two compo-
nents of the kinesin-2 complex: KIF3B and 
KAP3, suggesting that VHL is able to bind 
all three members of the kinesin-2 com-
plex either directly or indirectly (Fig. 1b; 
second and third lane). Although it seems 
from the data shown here that KIF3B binds 
less to VHL than KIF3A, repeated experi-
ments showed that this effect is dependent 
on transfection efficiency of KIF3B (data not 
shown). Because overexpressed proteins do 
not represent physiological circumstances, 
we performed IPs using cell lysates of 
untransfected cells to determine whether 
these proteins are present in an endogenous 
complex. Using an α-VHL antibody we read-
ily pulled down KIF3A from HEK293T cells 
and using an α-KIF3A antibody we readily 
pulled down VHL, while an irrelevant anti-
body did not retrieve either VHL or KIF3A 
(Fig. 1c). As compared to overexpression IPs 
(Fig. 1b) the retrieval of both VHL and KIF3A 
in the endogenous IP are remarkably high. 
This supports the notion that the binding of 
Figure 2: Characterization of binding between VHL and KIF3A
(A) Overexpression IP of lysates of transfected HEK293T cells. Cells were transfected with p30, p19, 
Δ95-123 or Y112H and KIF3A as indicated under the lanes. The upper panel shows the western blot 
of the whole cell lysates as a control for the transfection efficiency of KIF3A. The second panel shows 
the recovery of the IP for VHL using an α-Vsv antibody, stained for KIF3A using an α-Myc antibody. 
The third panel shows recovery of the different VHL mutants after IP for the Vsv-tag. The lower panel 
represents the recovery of an aspecific IP using α-RPTPμ antibodies stained for KIF3A using the α-Myc 
antibody. Irrelevant lanes were removed for clarity. IB, immunoblot; IP, immunoprecipitation; HC, im-
munoglubulin heavy chain. (B) Overexpression IP of lysates of transfected HEK293T cells. Cells were 
transfected with p30 and KIF3A or ΔN-KAP3 as indicated under the lanes. The upper panel shows a 
western blot analysis of the transfection efficiency for KIF3A and ΔN-KAP3 in which ΔN-KAP3 runs 
slightly higher than KIF3A. The second panel shows the recovery of KIF3A and ΔN-KAP3 after IP for VHL 
using an α-Vsv antibody. The third panel shows the recovery of VHL after an IP using the α-Vsv anti-
body. The lower panel shows the recovery after aspecific IP using an α-RPTPμ antibody. Irrelevant lanes 
were removed for clarity. IB, immunoblot; IP, immunoprecipitation; HC, immunoglubulin heavy chain.
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VHL to KIF3A is strong in the endogenous 
situation. These data argue for the participa-
tion of VHL in a protein complex containing 
KIF3A, KIF3B and KAP3, otherwise known as 
the kinesin-2 complex.
Characterizing the binding of VHL to the ki-
nesin-2 complex
We further characterized the binding of VHL 
to KIF3A by testing two deletion variants of 
VHL: the naturally occurring p19 isoform of 
VHL, generated by an alternative translation 
initiation site at residue 54, and the Δ95-123 
mutant of VHL (Δ95-123) described by Her-
govich et al. defining the region regulating 
MT stabilization (19). Overexpression IP of 
either the p19 or Δ95-123 both significantly 
diminished co-precipitation of KIF3A, indi-
cating that the acidic domain as well as the 
MT-binding domain are important regions for 
KIF3A binding (Fig. 2a; first and third lanes). 
These data suggested that the microtubule 
stabilizing function of VHL could be mediated 
by KIF3A. Therefore, we tested the mutant 
Y112H VHL allele reported to be deficient in 
stabilizing microtubules; this mutations is as-
sociated with type 2A VHL disease. We found 
that this type 2A mutation was less able to 
bind KIF3A (Fig. 2a; fourth lane). This led us 
to hypothesize that the microtubule stabiliz-
ing function of VHL could be due to its inter-
action with the kinesin-2 complex.
Interfering with the binding of VHL to the 
kinesin-2 complex: the ΔN-KAP3 construct
To further study the nature of the binding of 
VHL to the different subunits of the heterotri-
meric kinesin-2 complex, we tested whether 
the ΔN-KAP3 construct described by Jimbo 
et al. could bind to VHL. ΔN-KAP3 binds to 
APC, a target for kinesin-2-dependent trans-
port, but fails to bind to the other members 
of the kinesin-2 complex, thereby disrupting 
the functional interaction between APC and 
the kinesin-2 complex (11). We immunopre-
cipitated exogenous Vsv-VHL and specifical-
ly recovered Myc-tagged ΔN-KAP3 (Fig. 2b; 
second lane), allowing us to similarly employ 
this construct as a dominant negative inhibi-
tor of VHL-kinesin-2 binding. Furthermore it 
indicates that VHL binds KAP3 independent 
of its binding to KIF3A.
The kinesin-2 complex mediates MT-binding 
of VHL
Next we addressed the possibility that as-
sociation of VHL with the kinesin-2 motor 
complex mediates the binding of the full-
length VHL isoform (p30) to MTs. To this end 
we performed a MT co-sedimentation assay 
with lysates of HEK293T cells transfected 
with Vsv-p30. Our data indeed demonstrate 
binding of p30 to MTs (Fig. 3a, upper panel), 
supporting data produced by Hergovich et al 
(19). To determine whether the binding of 
VHL to MTs is direct or indirect we performed 
a similar assay using highly purified tubu-
lin and in vitro translated VHL. In this assay 
we were not able to show direct binding of 
p30 to microtubules (Fig. 3a, middle panel). 
However, Hergovich et al. (19)  proposed 
that the binding of VHL to MTs is direct. The 
discrepancy between our data and the prop-
osition that VHL binds directly to MTs might 
be explained by different protocols used in 
the two studies; we used an additional su-
crose cushion in the co-sedimentation as-
say. This sucrose cushion serves as a den-
Figure 3: VHL binds to microtubules through 
its interaction with the kinesin-2 complex.
(A) MT co-sedimentation assay. Upper panel, 
Vsv-p30 transfected into HEK293T cells recovered 
from supernatant (S, left lane) or pellet (P, second 
lane) without the addition of MTs (- MT) and 
supernatant (S, third lane) or pellet (P, last lane) 
in the presence of MTs (+MT). Middle panel, same 
assay performed using in vitro translated (IVTT) 
p30. Lower panel, same assay repeated with-
out the recommended cushion buffer using the 
IVTT p30.(B) MT co-sedimentation assay using 
lysates of transfected HEK293T cells. Upper panel 
shows recovery of Vsv-p30 using HEK293T cells 
transfected with only Vsv-p30 (similar organiza-
tion as described Fig. 2A). Lower panel, recovery 
of Vsv-p30 using HEK293T cells transfected with 
both Vsv-p30 and ΔN-KAP3.
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sity gradient separating the lysate from the 
pellet and increasing the specificity of the 
spun down fraction. To address the different 
outcomes, we directly compared the two 
methods with in vitro translated p30 in the 
presence or absence of a sucrose cushion 
separation. In the absence of the sucrose 
cushion we found more VHL in the pellet 
with MTs than in the pellet without MTs (Fig. 
3a, lower panel). However, using the more 
stringent assay (with sucrose cushion) we 
found no direct interaction between MTs and 
VHL (Fig. 3a, middle panel). These data in-
dicate that an endogenous factor present in 
the cell lysates of the first experiment (Fig. 
3a, upper panel), e.g. endogenous kinesin-
2, enhances the binding of VHL to MTs as 
measured by this assay.
To specifically address whether kinesin-2 
mediates VHL-MT binding, we tested the 
ability of ΔN-KAP3 to disrupt the binding 
of p30 to MTs. We co-transfected VHL and 
ΔN-KAP3 in HEK293T cells and found that 
the MT co-sedimentation of p30 was greatly 
reduced in the presence of ΔN-KAP3 (Fig. 
3b). All relevant plasmids were expressed as 
detected by western blot (data not shown). 
In conclusion, our data suggest that p30 -
at least in part- binds MTs via its interaction 
with the kinesin-2 complex.
As Hergovich et al. suggested that the binding 
between VHL and MTs results in increased 
stability of microtubules we determined 
whether ΔN-KAP expression would abrogate 
the increased stability of MTs induced by 
VHL. Using a previously described method of 
measuring MT-stability using live cell imaging 
and fluorescence recovery after 
photobleaching (FRAP) (15) we determined 
that indeed ΔN-KAP specifically inhibited VHL 
mediated MT-stability (supplemental Figure 
1). These data support the notion that the 
interaction between VHL and the kinesin-2 
complex indeed regulates the interaction 
between VHL and MTs.
VHL is a highly mobile protein
We next sought to determine whether the 
kinesin-2 complex actively transports VHL. 
To this end we constructed fusions of the 
green-fluorescent protein (GFP) to p30 (GFP-
p30) and to p19 (GFP-p19), which were 
transfected into N1E-115 neuroblastoma 
cells as these cells express detectable 
levels of endogenous KIF3A (data not shown). 
To validate our construct, we performed IPs 
and confirmed that GFP-p30 bound to KIF3A 
(data not shown). Furthermore, examin-
ing methanol-fixed coverslips of GFP-p30 
expressing cells revealed the same perinuclear, 
vesicular structures as described by Hergov-
ich et al. (data not shown) (19). However, 
in living cells we observed that GFP-p30 lo-
calizes predominantly to the cytoplasm and 
has a seemingly random distribution (Fig. 
4a, second panel, left image). To study the 
dynamics of VHL localization we performed 
live cell imaging and fluorescence recovery 
after photobleaching (FRAP) experiments 
(20). The FRAP pattern of GFP-p30 differed 
only slightly from that of GFP indicating that 
GFP-p30 is a highly mobile protein much like 
GFP (Fig. 4a and b). 
The binding of VHL to KIF3A alters its mobil-
ity after ATP depletion
As the processive movement of kinesin-2 
molecules along microtubules is dependent 
on the presence of ATP, we performed the 
same FRAP assay after intracellular ATP-
depletion using sodium azide and 2-deoxy-
glucose. As opposed to GFP, we found that 
GFP-p30 acquired a dramatic decrease in its 
mobility after ATP depletion as seen by time-
lapse photography (Fig. 4a). The degree of 
mobility can be determined by calculating 
the mobile fraction (Mf), which represents a 
ratio of absolute fluorescence recovery after 
photobleaching (Fig. 4c). Next, we made a 
construct fusing GFP to KIF3A (GFP-KIF3A) 
and examined its mobility before and after 
ATP depletion. Like GFP-p30, GFP-KIF3A had 
a dramatic decrease in Mf after ATP depletion 
(Fig. 4c). In the absence of ATP, a large 
portion of the GFP-p30 redistributed to a 
perinuclear site resembling the microtubule- 
organizing center (MTOC). To confirm this 
observation we co-transfected GFP-p30 with 
ds-RED-labeled γ-tubulin, a major component 
of the MTOC, and found that after ATP 
depletion, GFP-p30 co-localizes with 
ds-RED-γ-tubulin in living cells (Fig. 4d). We 
thus concluded that after ATP-depletion a 
large portion of the GFP-p30 is immobilized 
at the MTOC. GFP-KIF3A responded in an 
identical manner after ATP depletion (data 
not shown). ATP depletion did not change 
the viability of the cells. After reconstitution 
with normal medium, mobility of GFP-p30 
was fully recovered as measured by FRAP 
(data not shown) as well as the random 
cytoplasmic localization.
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We next asked whether the VHL variants un-
able to bind KIF3A (Fig. 2a) would display 
similar behavior in this assay. We began by 
measuring the mobility of GFP-p19 and GFP-
Δ95-123 before and after ATP depletion and 
found the Mfs for these VHL constructs were 
not reduced (Fig. 4b). We subsequently 
tested whether the type 2A patient-derived 
Y112H mutation would react differentially to 
ATP depletion. For these purposes we gener-
ated GFP-Y112H. Like GFP-p30, GFP-Y112H 
is a highly mobile protein under normal 
conditions. However, unlike GFP-p30, GFP-
Y112H was less responsive to ATP depletion, 
with an Mf of 0.70 +/- 0.21 (S.D.) which is 
significantly higher than GFP-p30 at 0.42 +/- 
0.16 (p<0.01) (Fig. 4e). We conclude from 
these experiments that the binding of VHL to 
KIF3A correlates with a decrease in mobility 
after ATP depletion. We next asked whether 
binding of VHL to the ΔN-KAP3 construct 
would interfere with the decrease in mobility 
of GFP-p30 after ATP depletion. Interesting-
ly, upon depleting ATP from cells that were 
transfected with both the ΔN-KAP3 construct 
and GFP-p30, the Mf of GFP-p30 did not sig-
nificantly change (Fig. 4e).
The interaction between VHL and the kine-
sin-2 complex does not affect proteasomal 
degradation
To determine the consequence of VHL/kine-
sin-2 interaction, we examined VHL’s well-
known function as an E3 ubiquitin ligase. 
We found that KIF3A is not a target for pro-
teasomal degradation by poly-ubiquitina-
tion, as cellular levels do not accumulate 
after treatment with MG132, an inhibitor of 
proteasomal degradation (Fig. 5a). Further-
more, disrupting the binding between VHL 
and KIF3A using the ΔN-KAP3 construct did 
not change the expression levels of HIF1α 
in HEK293T cells in the presence or absence 
of desferoxamine (DFO), an iron chelator 
known to stabilize HIF1α (Fig. 5b). Next, we 
tested whether the HIF mediated transcrip-
tion would be affected by the overexpression 
of ΔN-KAP3. We transfected HEK293T cells 
with a reporter construct with 3 HRE se-
quences in front of a luciferase reporter and 
its control with 3 mutated HRE sequences. 
In this assay we were unable to detect any 
changes in HIF reporter activity as a conse-
quence of ΔN-KAP3 overexpression although 
we tested three different concentrations of 
ΔN-KAP3 (Fig. 5c/d). Therefore, we con-
cluded that the interaction between VHL and 
the kinesin-2 complex is not involved in HIF 
regulation, nor does the kinesin-2 complex 
undergo VHL-mediated polyubiquitination.
VHL localizes to cilia and is important for 
ciliogenesis
The kinesin-2 complex has been implicated 
in the generation and function of primary cil-
ia (9). Primary cilia protrude from the apical 
surface cells into the tubular lumen contain 
ordered microtubules that are composed of 
acetylated α-tubulin, detyrosinated tubulin, 
and glutamylated tubulin (21). To examine 
whether VHL could be involved in ciliogenesis 
we performed immunofluorescence studies 
on KC12TR/VHL-TO and KC12 parental cells. 
The KC12TR/VHL-TO renal cell carcinoma 
cell line has previously been described and 
carries a doxycycline-inducible plasmid en-
coding the full length VHL cDNA (15). These 
cells were grown to confluence in the pres-
ence or absence of doxycycline and stained 
for VHL. The stable microtubule network 
was counterstained with a monoclonal anti-
body recognizing acetylated or glutamylated 
tubulin. We found that KC12 parental cells 
(with or without doxyxycline) and KC12 TR/
VHL-TO cells not treated with doxycycline do 
not generally form primary cilia; however, a 
striking increase in the number of cilia was 
observed after induction with doxycycline. 
Furthermore, VHL was clearly located in the 
cilia (Fig. 6a). We next evaluated the cellu-
lar architecture of MDCK and freshly isolated 
baby mouse kidney cells by co-staining for 
acetylated tubulin and VHL. In addition to 
general cytoplasmic staining, cilia localiza-
tion of endogenous VHL was confirmed for 
both cell types (Fig. 6b). Because KC12 cells 
devoid of VHL appeared to have so few cilia, 
we screened for the frequency of primary cil-
ia in confluent KC12TR/VHL-TO and KC12TR 
cell cultures in the presence or absence of 
doxycycline using immunofluorescence anti-
body against acetylated tubulin and confo-
cal microscopy. Induction of VHL expression 
by doxycycline treatment was confirmed by 
western blot and immunofluorescence (not 
shown). One thousand interphase cells (de-
termined by DAPI) were examined for each 
cell type. Low numbers of cilia were ob-
served in the KC12TR cell line irrespective of 
doxycyline treatment: 44 cilia (no doxycline) 
vs 61 (doxycycline). Similarly, of 1000 KC-
12TR/VHL-TO interphase untreated cells, 83 
60
cilia were counted. However, inducing these 
cells with doxycycline, thereby inducing 
VHL, elevated the frequency of 
primary cilia to 566/1000 interphase cells 
(Fig. 6c). This experiment was performed 
twice independently and the data pooled. 
No signal was detected when cells were 
incubated with the secondary antibody 
alone.
Cilia induced by VHL overexpression are 
functional: intracellular calcium influx.
In the kidney, urine flow bends primary cilia 
on the luminal surfaces of renal tubule cells, 
rapidly resulting in a localized influx of cal-
cium through ion channels, which is subse-
quently amplified by calcium-induced release 
of calcium from intracellular stores (22). We 
measured calcium signalling in KC12TR and 
KC12TR/VHL-TO cells to explore whether 
the mechanotransduction events triggered 
by flow are sensitive to levels of VHL. To 
this end, confluent cultures of KC12TR cells 
and KC12TR/VHL-TO treated with or without 
doxycycline were incubated with Ca2+- 
sensitive fluorescence probe Fura-2/AM. 
The cells were then placed in a perfusion 
chamber under steady flow as previously 
described (16). Spectrofluorometric analysis 
allows a quantitative analysis of intra- 
cellular [Ca2+]. We observed that only KC12 
cells re-expressing VHL were capable of 
Figure 5: VHL-Kinesin-2 interaction does not involve ubiquitination or HIF signaling.
(A) Western blot of KIF3A an HIF1α before and after MG132 treatment. Upper panel shows western 
blot for KIF3A from 293T cells, left lanes 1-2 show endogenous KIF3A, lanes 3-4 show transfected 
KIF3A. Lanes 2 and 4 are treated for 8 hours with 5 μM MG132, a proteasome inhibitor. Lower panel 
shows similar experiment with endogenous vs. transfected HIF1α. (B) Western blot for HIF1α in the 
presence or absence of Myc-ΔN-KAP3. Upper panel shows endogenous HIF1α expression in HEK293T 
cells, lanes 1 and 3 are untreated; lanes 2 and 4 were treated for 4 hours with DFO. Lanes 1-2 were 
transfected with an empty plasmid and lanes 3-4 were transfected with the Myc-ΔN-KAP3. The middle 
panel shows the expression of the Myc-ΔN-KAP3. Lower panel is the loading control using MAPK. (C) 
Synthetic reporters containing a Hypoxic Response Element (HRE) in triplicate or its mutated vari-
ant were transfected in HEK293T cells either alone or in combination with DN-KAP3 and/or HIF1α. The 
amount of ΔN-KAP3 cDNA used was 30ng, 100ng and 300ng. Luciferase values were normalised against 
controle renilla values and plotted on the y-axis. Black bars represent the wildtype reporter of a Hypoxic 
Responsive Element (HRE) in triplicate in front of the minimal TK promoter. Open bars represent values 
using the mutated reporter. (D) Ratios of normalised mean luciferase values of wildtype promotor over 
the mutated promotor as are depicted in Fig. 5C.
61
Chapter 5: VHL binds Kinesin-2 and regulates primary cilia function
recapitulating the significant calcium 
response (77%) observed with thrombin 
stimulation as compared to the same cells 
transfected with empty plasmids and induced 
with doxycycline (1.6%) or cells uninduced 
with doxycycline (1.2%) (Fig. 6d). KC12TR/
VHL-TO cells induced with doxycycline and 
then treated with 10μM nocodazole neutralized 
this effect. These data indicate that VHL, 
as has been reported for kinesin-2, has 
a function in ciliogenesis and that the 
intracellular signaling derived from the 
primary cilia is dependent on the presence 
of VHL.
VHL regulation of primary cilia depends on 
kinesin-2
Kinesin-2-mediated anterograde intra- 
flagellar transport (IFT) is essential for the 
assembly and maintenance of cilia in various 
cell types. Because our results suggest that 
VHL also regulates cilia assembly, we sought 
to answer whether this function was de-
pendent on the interaction with kinesin-2. 
VHL-deficient KC12 cells were transiently 
transfected with constructs GFP-p30, GFP-
KIF3A GFP-Δ95-123, GFP-Y112H and GFP 
and cultured to confluence for 3-4 days. 
After methanol-fixation and counterstaining 
with anti-acetylated tubulin or anti- 
glutamylated tubulin, interphase cells were an-
alyzed by confocal microscopy for the presence 
of primary cilia in GFP-positive cells. If the 
tubulin staining clearly indicated the pres-
ence of a cilium, it was closely examined for 
GFP signal, to determine the presence of 
the GFP-labelled VHL allele. Two cilia were 
observed in the 55 KC12 cells transfected 
with GFP alone, which is consistent with 
the background cilia frequency observed in 
these cells. Neither of these cilia showed GFP 
staining in the tip of the cilia. In contrast, 
most cells transfected with GFP-KIF3A (49/60) 
had cilia, all of which showed clear GFP 
staining. Not surprising considering the 
response of the KC12TR/VHL-TO cells, more 
than half (64/104) of the KC12 cells transfected 
with GFP-p30 produced easily detectable cilia. 
Of the 236 GFP-Δ95-123 transfected cells 39 
cilia (17%) were observed, with no positive 
staining for GFP and of 108 GFP-Y112H 
positive cells analysed, 12 cilia (11%) were 
observed, and only one of these cilia had 
green staining. These data suggest that the 
binding between VHL and kinesin-2 is impor-
tant for ciliogenesis and targets VHL to the 
tip of the cilia. 
Discussion
The data presented here provide evidence 
that VHL binds the MT-based heterotrimeric 
kinesin-2 motor complex by interacting 
directly with KIF3A and possibly KAP3. 
Furthermore the third component of the 
kinesin-2 complex: KIF3B, could also be 
found in a complex with VHL, indicating that 
VHL probably interacts with a functional 
kinesin-2 complex. The acidic domain of 
VHL and the MT-binding region ranging from 
residues 95-123 within the first exon of VHL 
are important for this binding.  The type 2A 
mutant Y112H is deficient in binding KIF3A. 
These findings correlate well with the regions 
and mutations described by Hergovich et al. 
as being deficient in stabilizing microtubules 
(19). A significant portion –if not all- of the 
binding of VHL to MTs is mediated through 
this interaction. Kinesin-2 binding does not 
involve the ubiquitin ligase-associated func-
tion of VHL, but instead regulates VHL mobil-
ity. Similar to the kinesin-2 family members, 
VHL seems to play a role in the generation 
and/or maintenance of functional primary 
cilia. 
Patients suffering from the von Hippel-Lindau 
disease develop multiple cystic manifestations 
especially in the kidney, pancreas and in 
rare instances in the endolymphatic sac (1). 
Most patients demonstrate multiple renal 
cysts (23), which is almost invariably cor-
related with the “second hit” inactivating the 
wild-type VHL gene (24). Renal cysts are 
common in the general population and are 
rarely clinically significant; however, in VHL 
patients they have a significant predilection 
to degenerate to conventional clear cell RCC, 
the leading cause of death in patients with 
VHL disease (35-75% prevalence in one 
autopsy series) (25). In VHL patients, there 
is considered to be progression from simple 
cysts with a single layer of tubular epithelium, 
to atypical cysts demonstrating diffuse 
epithelial hyperplasia with stratification to 
three or more cell layers, to either cystic or 
solid RCCs (23). Uncovering the cause for 
the cystic phenotype in VHL patients would 
increase our understanding of an important 
event in the development of ccRCC.
Primary cilia extend like antennae from 
the surface of most eukaryotic cells, where 
they function as environmental sensors. 
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These specialized microtubule organelles 
contain an axoneme core, which 
serves as scaffolding for microtubule- 
based molecular motors. Mechanical 
forces bending primary cilia in response 
to fluid flow in kidney tubules elevate 
cellular [Ca2+] and activate signal transduction 
(22). Mutations in at least a dozen different 
genes involved in cilia assembly or mainte-
nance have now been implicated with the 
development of cystic kidneys in humans, 
mice, rats, and zebrafish (26), including 
components of kinesin-2. Known genes 
leading to polycystic kidney disease like 
PKD1 and PKD2 have been implicated in cilia 
function and generation (27). Therefore the 
cystic phenotype of VHL patient could be 
explained by our finding that VHL affects 
ciliogenesis. 
Targeted deletion of Kif3a in murine renal 
epithelium results in polycystic disease char-
acterized by lack of primary cilia (10). A simi-
lar experiment inactivating VHL in the kidney 
has been performed for the VHL coKO mice, 
however these mice developed a phenotype 
of hemangiomas and overexpression 
of hypoxia dependent factors such as EPO 
and VEGF, and only in a low frequency they 
developed renal cysts (28). These data 
seemingly contradict a prominent function 
for VHL in the development of renal cysts 
in mice. However, the clinical findings in 
patients might clarify this apparent 
discrepancy. Type 2A patients have a low pre-
disposition for ccRCC and the corresponding 
mutated alleles produce VHL mutants that 
are deficient in stabilizing microtubules and 
localizing to cilia. A possible explanation 
for these observations is that there are at 
least two independent functions for the VHL 
gene: regulating ciliogenesis and controlling 
HIF levels. In the majority of patients where 
missense mutations are introduced (e.g. type 
2B patient mutations), in vitro studies have 
shown that these VHL mutants retain some 
microtubule stabilizing function but lose 
their ability to regulate HIF. Alternatively, 
type 2A mutations such as Y112H lose 
both functions simultaneously (19,29). It is 
conceivable that a total loss of VHL-mediated 
ciliogenesis could fail to confer survival benefit 
in the kidney environment. We believe that 
these data collectively suggest a model 
whereby residual VHL-mediated ciliogen-
esis is important for generating the cystic 
phenotype observed in VHL patients and 
consequently affects their risk for developing 
ccRCC. 
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Figure 4: Decreased mobility after ATP depletion of GFP-p30 correlates with binding to the 
kinesin II complex
(A) Time-lapse photographs of N1E-115 cells transfected with GFP (upper row) or GFP-p30 (middle and 
bottom rows) and submitted to fluorescence recovery after photobleaching FRAP) experiments. Im-
ages were acquired 0.25 seconds before bleaching (left column), directly after bleaching (t=0, middle 
column), and 50 seconds after bleaching (right column). White arrows indicate approximate region of 
bleaching. Cells in bottom row were subjected to ATP depletion for at least 30 minutes using sodium 
azide and deoxyglucose. (B) Fluorescence recovery after photobleaching (FRAP) experiment. This graph 
depicts the %Fi, which represents the percentage of initial fluorescence as calculated from 3 independ-
ent measurements pooled into 1 line. The error bars represent the standard error of the mean of each 
time point. The open squares represent the data generated using GFP transfected into NE1-115 cells 
and the closed squares represent the data generated using GFP-p30 transfected into NE1-115 cells.  
(C) FRAP-derived mobility (Mf) values of GFP-tagged variants of VHL (top of graph) in transfected 
N1E-115 cells. Each square represents an individual measurement before (filled squares) or after ATP 
depletion (open squares). Horizontal line in each experiment represents the mean value. Significance of 
mobility decrease after ATP depletion was calculated using a two-tailed Students T-Test, and is depicted 
below the graph. Mf, mobile fraction; N/A, not applicable (mobility did not decrease); NS, not signifi-
cant. (D) Live cell images of N1E-115 cells co-transfected with CFP-p30 (left panel) and dsRED-γ-tubu-
lin (middle panel) after ATP depletion. Right panel, image overlay. (E) FRAP-derived Mf values for GFP-
p30 in the presence or absence of ΔN-KAP3 overexpression as indicated above the graph. Each square 
represents an individual measurement before (filled squares) or after ATP depletion (open squares). 
Horizontal line in each experiment represents the mean value. Significance of mobility decrease after 
ATP depletion was calculated using a two-tailed Students T-Test, and is depicted below the graph. Mf, 
mobile fraction
Figure 6: VHL is necessary for cilia development and function in KC12 renal cell carcinoma 
cells.
(A) KC12TR/VHL-TO cells were induced to express VHL with doxycycline and grown to confluency. Cells 
were fixed using ice-cold methanol and stained for acetylated tubulin (red) and for VHL using Ig32 
(green). We show a maximal Z-projection of a Z-stack depicting a representative cell made using a 
Zeiss LSM510 confocal microscope. (B) MDCK cells were grown to confluency and stained for endog-
enous VHL using Ig32. In this sample no counterstain was used and the gray dots represent VHL stain-
ing. We show a 3D-image with 3 projections from different angles made using a Zeiss LSM510 confocal 
microscope. Arrows show the VHL staining in a cilium. (C) Primary cilia formation was counted in KC12 
parental and KC12TR/TO cells. Depicted is the number of cells positively identified as carrying intact 
cilia from 1000 counted cells that were identified using DAPI. Data was acquired at least 2 different 
time points for each cell type and pooled. (D) KC12TR cells and KC12TR/VHL-TO cells were induced to 
express VHL with doxycycline (top of graph) and grown to confluency and used in a Ca2+ influx experi-
ment. The graph depicts the % of the maximal Ca2+ influx as measured by thrombin response. As 
shown under the graph we measured in the presence or absence of flow. 
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Activation of the Wnt signaling pathway initiates the transformation of colorectal 
epithelial cells, although the transition to metastatic cancer requires angiogenesis. 
We have investigated the expression of VHL in intestinal epithelial derived cells 
and intestines from humans and mice. Here we show that VHL expression is 
regulated by TCF4 in colorectal cancer (CRC) cell lines and consistent with oth-
er Wnt targets, immunohistochemistry of VHL in normal adult intestine reveals 
restricted expression to the proliferative compartment at the bottom of intestinal 
crypts. VHL is overexpressed in intestinal polyps from Familial Adenomatous 
Polyposis patients. Accordingly, Vhl is completely absent from the proliferative in-
testinal pockets of Tcf4-/- perinatal mice. We observed complementary staining of 
the hypoxia inducible factor (HIF)1α to VHL in normal intestinal epithelium as well 
as in all stages of CRC. Although we observed upregulated levels of VHL in very 
early CRC lesions –presumably due to activated Wnt signaling- a clear reduction 
of VHL expression is observed in later stages of CRC progression, coinciding with 
stabilization of HIF1α. Because loss of VHL in later stages of CRC progression 
results in stabilization of HIF, these data provide evidence that selection for VHL 
down-regulation provides a pro-angiogenic impulse for CRC progression.
Introduction 
Colorectal cancer (CRC) is one of the most 
common causes of cancer in the Western 
world. The sequence of multiple genetic 
events that occur in the transition from normal 
mucosa to cancer cells is subject to extensive 
research. Greater than 90% of all CRCs have 
an activating mutation of the canonical Wnt 
signaling pathway, ultimately leading to 
β-catenin/TCF4-mediated gene transcription. 
Downstream targets of the Wnt signaling 
pathway, such as the Myc oncogene, 
collectively form a genetic program enabling 
an intestinal epithelial cell to transform to a 
cancer phenotype (1). In addition to the 
genetic changes within the cancer cell, expo-
nential growth requires a supportive micro- 
environment. In CRC, tumor-induced 
formation of new capillaries from pre-
existing vasculature –angiogenesis- 
often marks the adenoma/carcinoma 
transition (2,3). This angiogenic switch 
during tumor growth provides increased 
oxygen and nutrient supplies to the tumor 
and has been correlated with invasive tumor 
growth and progression to a metastatic 
phenotype. Because angiogenesis represents 
a powerful control point in tumor development, 
investigation of the physiological mecha-
nisms underlying this process in CRC has 
direct relevance to the development of 
future therapeutics. Both preclinical and clini-
cal evidence indicate that vascular endothelial 
growth factor (VEGF) plays an important 
role in the angiogenic switch of colorectal 
cancer. This insight has led to the widespread 
use of cyclooxygenase-2 inhibitors –which 
inhibit VEGF- to prevent the formation of 
polyps and cancer in familial adenomatous 
polyposis (FAP), hereditary non-polyposis 
colon cancer, and sporadic colorectal cancer 
(4). The recent approval of bevacizumab, an 
anti-VEGF antibody, for advanced colorectal 
cancer also underscores the relevance of 
VEGF in survival and progression of disease 
(5). In addition, several clinical trials with 
anti-VEGF approaches are underway both in 
the adjuvant and metastatic disease setting 
(5). Taken together these findings support 
the central role of VEGF in colorectal cancer 
progression. 
One of the best-documented transcriptional 
regulators of VEGF is the hypoxia inducible 
factor 1α (HIF1α). Under normoxia HIF1α 
is rapidly degraded, a process that occurs 
under the control of the tumor suppressor 
gene von Hippel-Lindau (VHL). VHL forms a 
multiprotein complex with elongin C, elon-
gin B, Cul-2, and Rbx-1 [(VEC), reviewed 
by Maynard and Ohh (6)]. VEC functions 
as an E3 ubiquitin ligase to target HIF1α 
for polyubiquitination and subsequent 
degradation by the 26S proteasome (7-9). 
VHL functions as the target recognition moiety 
of the VEC complex and specifically recognizes 
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prolyl-hydroxylated HIF1α subunit (10,11). 
This post-translational modification of HIF1α 
requires oxoglutarate, iron and oxygen (10-
12). Thus, ubiquitin-mediated destruction 
of HIF1α occurs selectively under normoxic 
conditions whereas hypoxia results in 
stabilization and transcriptional activity of 
HIF. Accordingly, biallelic inactivation of the 
VHL gene through mutation, deletion, or 
promoter silencing generally leads to the 
stabilization of HIF1α and thereby promotes 
the up-regulation of numerous HIF1-target 
genes, resulting in an inappropriate triggering 
of the hypoxic response under normal oxygen 
tension (6). This is best observed in 
patients with von Hippel-Lindau disease, 
an inherited autosomal dominant cyst and 
cancer syndrome. Clinically, tumors lacking 
VHL secrete high levels of VEGF and other 
pro-angiogenic factors and manifest as 
highly vascularized lesions (13,14) such 
as hemangioblastomas and clear cell renal 
cancer.
The observation that VEGF plays an important 
role in colorectal cancer progression together 
with our earlier findings that VHL is 
abundantly expressed in colonic mucosa 
(15) formed the basis for our hypothesis that 
aberrant regulation of VHL contributes to the 
angiogenic switch in colorectal cancer. Here 
we report that the VHL tumor suppressor 
gene acts as a physiological Wnt target 
in the intestines. Although we observed 
upregulated levels of VHL in very early 
CRC lesions –presumably due to active Wnt 
signaling- a very clear reduction of VHL 
expression is observed in later stages of CRC 
progression, coinciding with stabilization of 
HIF1α and induction of a hypoxic response 
in these tumors. Thus, correlative data and 
biological plausibility support a role for VHL 
down-regulation in the angiogenic switch in 
CRC progression. Furthermore, understanding 
the regulation of VHL levels may 
provide an alternative approach to inhibit 
angiogenesis.
Material and methods
Cell culture and treatment
LS174T  (ATCC number CL-188) were cul-
tured in RPMI 1640 supplemented with 10% 
FCS. The T-REX system (Invitrogen, Carls-
bad, CA) was used according to the man-
ufacturer’s instructions to generate doxy-
cycline inducible dn-TCF4 expressing cells 
(L8) as previously described (16). To inhibit 
GSK3β activity, 293T cells were grown to 
70% confluency and 20mM LiCl (Sigma) 
was added to the medium for 4 hours prior 
to lysis. Conditioned medium from parental 
(mock-transfected) and Wnt3a-transfected 
mouse fibroblast L cells was prepared as de-
scribed (17) and was used to stimulate 293T 
cells for 16 hours before harvesting cells.
Reporter assays
To generate the HRE-luciferase reporter 
construct (HRE-Luc), we used the follow-
ing wild-type HRE oligonucleotide (W18) of 
the 3’-enhancer of the human erythropoietin 
gene (18) in triplicate in front of a minimal 
TK promotor and the Luciferase gene in the 
vector pBlLuc: C(TACGTGCT)GC(TACGTGCT)
GC(TACGTGCT)G (where the HRE is in paren-
theses and the core bases essential for HIF 
binding are underlined). The vector pBlLuc is 
derived from pBlCat2 (19) in which the Cat 
gene has been replaced by Luciferase out of 
pTopFlash (20). As a negative control, a sim-
ilar construct (Mut-Luciferase, or Mut-Luc) 
with the M28 fragment (18) was constructed 
in which three altered nucleotides complete-
ly abrogate HIF-binding: CTCAATGCTGCT-
CAATGCTGCTCAATGCTG 3’ (where the mu-
tated core bases are underlined). 293T cells 
were plated 18 hours prior to transfection 
by Fugene6 (Roche, Basel, Switzerland) ac-
cording to the manufacturer’s instructions. 
The following amounts of plasmids were 
transfected in 293T cells: 50 ng HRE-Luc or 
Mut-Luc in combination with 5 ng of the re-
nilla internal control CMV-pRNL (Promega, 
Madison, WI), and 100 ng wild-type HIF1α 
as indicated in the text. The total amount of 
DNA transfected in all reporter assays was 
adjusted to 500 ng with pcDNA3.  Luciferase 
activities were measured 24-36 hours after 
transfection using the DUAL luciferase sys-
tem according to the manufacturer’s proto-
col (Promega, Madison, WI). Luciferase ac-
tivity was normalized relative to renilla.
Western blotting
Samples were examined by SDS-PAGE on 
10% acrylamide gels and subsequent west-
ern blotting. Specific protein bands on the 
western blots were visualized using super-
natant from an in-house produced anti-VHL 
monoclonal hybridoma specifically recogniz-
ing the C-terminus of VHL (1B3B11) gen-
erated using a protocol we have preciously 
described (21). Hybridoma supernatant was 
diluted 1:5 in PBS containing 5% milk and 
70
0.1% Tween-20. Rabbit anti-Mouse HRP 
(Pierce, Rockford, IL) (1:20,000) was used 
as secondary antibody after which enhanced 
chemiluminescence (Perkin Elmer Life Sci-
ences, Boston, MA) was used for detection.
RT-PCR
RNA from cell lysates was extracted using 
RNAbee reagent (Campro
Scientific, Veenendaal, The Netherlands) 
following the protocol of the manufacturer. 
cDNA was made using 2μg of total RNA and 
reverse transcribed using Superscript Re-
verse Transcriptase (Invitrogen, Carlsbad, 
US) and random hexamers. Gene-specific 
cDNA fragments were amplified by 25 cy-
cles of PCR consisting of 1 min. at 95 oC, 
1 min. at 55 oC and 2 min. at 72 oC. PCR 
fragments were analyzed by DNA gel elec-
trophoresis. We used the following primers 
in our assays: VHL-Fw: 5’-gctaccgaggt-
cacctttgg, VHL-Rev: 5’- tgtgtcagccgctccag-
gtc, VEGF-Fw: 5’-cgaaaccatgaactttctctgc, 
VEGF-Rev: 5’-ccacttcgtgatgattctgc, EphB2-
Fw:  5’- cgtgactgcagcagcatc, EphB2-Rev: 
5’- cagtagagcttgatgggtac , 18S-Fw: 5’-
agttggtggagcgatttgtc, 18S-Rev: 5’-tattgct-
caatctcgggtgg.
Tissue sample preparation and immunohis-
tochemistry
Samples of small intestine or colon were 
obtained immediately after excision biopsy 
procedures from patients treated at the Uni-
versity Medical Center Utrecht, The Neth-
erlands and fixed in neutral 4% buffered 
formaldehyde at 4°C for 24 hours. Individu-
al segments were embedded in paraffin and 
sectioned (4-5 μm). Informed consent to 
anonymously use leftover patient material 
for scientific purposes was a standard item 
in the treatment contract with the patients. 
None of the patients with colorectal cancer 
had received any preoperative therapy. Par-
affin sections were mounted on silane-coat-
ed slides and baked in an oven at 57ºC the 
night before the staining was performed to 
avoid de-attachment of the tissue. Follow-
ing dewaxing and hydration, sections were 
pretreated with peroxidase blocking buffer 
(1.5% H2O2 in methanol) for 20 minutes at 
room temperature. Antigen retrieval was 
performed by boiling samples in Na-citrate 
buffer (10 mM, pH 6.0). After 20 minutes, 
the boiling pan was allowed to slowly cool 
down to room temperature. Incubation of 
αVHL (Ig32, diluted 1:100, Transduction 
Labs/Pharmigen, Alphen aan den Rijn, the 
Netherlands) was performed in 10% nor-
mal goat serum in PBS overnight at 4°C. In 
all cases, the Powervision poly HRP goat-
anti-mouse IgG (Immunologic, Duiven, the 
Netherlands) was used as a secondary re-
agent. Stainings were developed using DAB 
(brown precipitate) and then counterstained 
with hematoxylin and mounted. To exclude 
cross-reactivity of Ig32 with other Wnt-sig-
naling targets, we pre-incubated this anti-
body for 30 minutes with 2.5μg recombinant 
VHL, which completely abrogated all signal 
in the intestine (not shown). Anti-HIF1α im-
munohistochemistry was performed as we 
have previously described (22). Samples for 
β-catenin staining were fixed in 10% neu-
tral buffered formalin for 12 hours at 4OC. 
Following dewaxing and hydration, sections 
were pretreated with peroxidase blocking 
buffer for 20 minutes at room temperature. 
Antigen retrieval was performed by boiling 
samples in Tris/EDTA (40 mM/1mM, pH 8.0) 
buffer for 50 minutes in a cooking pan. After 
this period, the pan was allowed to slowly 
cool down to room temperature. Samples 
were blocked with 1%BSA/PBS for 20 min-
utes, washed 3 times in PBS and incubated 
with anti-C-terminus β-catenin antibody (di-
luted 1:50, Transduction Labs/Pharmigen, 
Alphen aan den Rijn, the Netherlands) in 
0.05% BSA/PBS for 2 hours at room tem-
perature. Detection of the primary antibody 
was performed using the Powervision poly 
HRP goat-anti-mouse IgG (Immunologic, 
Duiven, the Netherlands) for 1 hour at room 
temperature. The stainings were visualized 
with DAB. Nuclei were counterstained with 
hematoxylin.
 
Results
VHL responds to Wnt signaling 
To investigate the role of the tumor suppressor 
VHL in colorectal cancer we checked 
whether CRC cell lines harbored muta-
tions in the VHL gene. For this purpose we 
sequenced the entire open reading frame of 
VHL in a number of CRC cell lines and found 
them all to be wild-type for VHL despite variable 
expression levels (data not shown). One cell 
line in particular was found to express high 
levels of VHL: LS174T. These LS174T CRC 
cells also show high levels of constitutive 
β-catenin/TCF-driven transcription due to 
stabilizing mutations in β-catenin (16). We 
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used LS174T cells that were engineered to 
express dominant-negative TCF4 (dn-TCF4) 
under the control of a doxycycline-inducible 
promoter (dubbed L8). dn-TCF4 does not 
bind b-catenin and acts as a potent inhibitor 
of the endogenous β-catenin/TCF complexes 
present in CRC cells. Thus upon induction 
with doxycycline, L8 cells abrogate all 
transcription mediated by β-catenin/TCF 
complexes (16), essentially shutting off the 
Wnt signaling cascade. To investigate the 
influence of Wnt signaling on VHL levels in 
these cells, we performed RT-PCR for VHL 
with RNA derived from L8 cells either at 
baseline or after stimulation with doxycycline 
for 16 hours. As has been previously published 
(23), transcript levels of the well-characterized 
Wnt target the tyrosine kinase receptor 
EphB2  were greatly diminished by treating 
this cell system with doxycycline (Fig. 1A, 
top panel). To our surprise, however, VHL 
transcript levels responded similarly (Fig. 
1A, second panel). Because numerous 
studies have established that VHL inactivation 
results in increased transcriptional activation 
of VEGF, we also performed RT-PCR for VEGF 
in the same experiment. Contrary to VHL, 
VEGF levels increased 3.3-fold after treatment 
of L8 cells with doxycycline (Fig. 1A, third 
panel), indicating an intact response to VHL 
downregulation. Doxycycline alone had no 
effect on VHL levels in LS174T cells transfected 
with empty vectors (not shown). We amplified 
18S as an appropriate control for cDNA input 
(Fig. 1A, fourth panel) because, unlike sev-
eral housekeeping genes, transcript levels 
are not influenced by fluctuating VHL or 
HIF1α levels (24,25), nor are they affected 
by b-catenin/TCF activity. Ample product 
was observed in RT-PCR using plasmids 
containing cDNA sequences as primer 
controls and no product was detected in the 
absence of cDNA template for each primer 
pair (not shown). To verify the induction 
of dn-TCF4 in this experiment we prepared 
protein lysates from a portion of the L8 cells 
and tested the expression of the Flag-tagged 
dn-TCF4 construct using western blot analysis. 
Anti-Flag staining shows a specific band 
at the expected height of 85 kDa only in 
the cells induced with doxycycline (Fig. 
1A, fifth panel) despite equal protein load-
ing as indicated by anti-β-actin staining of 
the same blot (Fig. 1A, lowest panel). We 
concluded from this experiment that blocking 
β-catenin/TCF affects VHL transcript levels in 
a manner suggestive of a Wnt signaling target. 
Figure 1. VHL is a β-catenin/TCF target in 
vitro.
(A) Top four panels show RT-PCR analysis of the 
expression levels of EphB2, VHL, VEGF, and 18S 
(input control) mRNAs in L8 cells. Cells were 
induced for 24 hours with doxycycline (dox; 1μg/
ml). Lower two panels show western blot analysis 
of the protein expression levels of FLAG-tagged 
dn-TCF4 (α-FLAG) and the loading control actin. 
This figure shows a representative image of 3 
independent experiments with similar outcome. 
WB; western blot.(B) Western blots of 293T cell 
lysates at baseline (-) or after 5 hr treatment with 
20mM LiCl (+). Top panel, VHL protein levels; 
middle panel, non-phosphorylated activated β-
catenin (ABC) as a positive control for activated 
Wnt signaling; lower panel, loading control actin. 
This figure shows a representative image of 2 
independent experiments with similar outcome. 
(C) Soluble Wnt3A stimulates VHL levels. Western 
blot of VHL protein levels in 293T cell lysates 
after 16 hrs cultured with conditioned medium 
from either mouse L fibroblasts transfected with 
an empty plasmid (-) or with a plasmid express-
ing soluble Wnt3A ligand (+). Middle panel shows 
the positive control for activated Wnt signaling: 
non-phosphorylated activated β-catenin (ABC). 
Lower panel shows the loading control actin. This 
figure shows a representative image of 2 inde-
pendent experiments with similar outcome. (D) 
The transcriptional activity of HIF1α is reduced 
by β-catenin. 293T cells were co-transfected with 
HIF1α luciferase reporter constructs with either 
three tandem HIF1α response elements (HRE-Luc, 
filled bars) or three HREs with a single mutation 
(Mut-Luc, empty bars) and with the combinations 
of empty vector (mock), HIF1α, VHL, stable domi-
nant positive S33 β-catenin and LiCL as indicated. 
Relative luciferase units (RLU) are normalized with 
renilla to take transfection efficiency into account. 
Experiments were performed in duplicate and 
repeated at three independent time points. Bars 
show the standard error of the mean.
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Figure 2:  VHL is an in vivo target of Wnt signaling.
(A) Immunohistochemical analysis of VHL and HIF1α in the small intestine reveals that VHL expres-
sion is restricted to the cells in the intervillus regions (left) while HIF1α (middle) is expressed in a 
complementary pattern by the adjacent cells in the villus. Stainings were developed using DAB (brown 
precipitate) and counterstained with hematoxylin (blue nuclei). A cartoon (right) illustrates the position 
of the putative Wnt signal, the amplification compartment with proliferating cells and the arrested and 
differentiated cells located toward the intestinal lumen. (B) VHL is expressed in the intervillus regions 
of Tcf4+/- embryos (left) but is completely absent in Tcf4-/- littermates stained in parallel (right). (C) 
Immunohistochemistry of VHL in a FAP patient polyp shows elevated expression of VHL. (D) Early le-
sions from FAP patients show overexpression of VHL by immunohistochemistry (left), but limited or no 
immunohistochemical staining for HIF1α (right). 
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We subsequently performed experiments 
to test whether VHL levels could respond 
to upstream Wnt signaling. Initially, 
we tested the effects of 20 mM LiCl on 
endogenous VHL levels in 293T cells; LiCl 
inhibits GSK3β and mimics Wnt signaling by 
allowing non-phosphorylated β-catenin levels 
to accumulate (26). Stimulation with LiCl for 
five hours markedly increased the amounts 
of endogenous VHL in 293T cells detected 
by immunoblotting (Fig. 1B, upper panel), 
and likewise increased expression of the 
active signaling pool of non-phosphorylated 
β-catenin (ABC, Fig. 1B, middle panel) 
as has been previously reported in these 
cells (27). To substantiate this finding, we 
determined whether soluble Wnt3a protein 
could also regulate VHL levels. To this end, 
we stimulated 293T cells overnight with 
conditioned medium derived from mouse 
fibroblast L cells secreting Wnt3a (17). 
Accumulation of non-phosphorylated 
β-catenin (Fig. 1C, middle panel) served 
again as control for activation of the pathway. 
Consistent with the previous data, 
Wnt3a stimulation also resulted in VHL 
accumulation (Fig. 1C, upper panel), 
indicating that VHL is downstream 
of an intact Wnt-signaling pathway. 
Actin levels were used as a control for equal 
protein loading for all experiments.  
Wnt signaling regulates VEGF through VHL 
and HIF1α 
The RT-PCR data (Fig. 1A) suggested that 
VHL regulation by b-catenin/TCF affects 
HIF1α transcriptional activity, as seen by 
VEGF induction. To investigate the direct 
influence of β-catenin/TCF on HIF activity, 
we performed a HIF1α reporter assay. We 
generated a luciferase reporter construct 
to carry three tandem hypoxia response 
elements derived from the promoter of the 
erythropoietin gene (HRE-Luc) or three 
HREs with three nucleotide mismatches 
(Mut-Luc). 293T cells were co-transfected 
with either the HRE-Luc or the Mut-Luc 
reporter plasmids and with the combinations 
of empty vector (mock), HIF1α, VHL, and 
constitutively active S33 β-catenin as indicated 
in Fig. 1D. All samples were co-transfected 
with renilla as an internal transfection control. 
The mock transfection illustrates the 
background levels of HIF1α activity in 293T 
cells which is increased by approximately 
4-fold upon transfection of HIF1α. As 
expected, co-transfection of VHL with HIF1α 
greatly reduced HIF1α activity, which was 
mirrored by co-transfecting constitutively 
active S33 β-catenin. Mut-Luc background 
levels remained low, indicating a HIF1a-
specific effect. These data suggest that 
upregulation of VHL by b-catenin/TCF reduces 
HIF1α activity. Furthermore we used LiCl as 
an activator of endogenous-Wnt signaling 
and as expected, the addition of LiCl to the 
HIF1α-reporter assay resulted in a similar 
downregulation of HIF1α activity compared 
to the overexpression of VHL (Fig. 1D). 
By deduction, our data suggest that Wnt 
signaling would fail to decrease HIF activity 
in VHL-/- cell lines. In an attempt to address 
this question, we stimulated renal cell 
carcinoma cell lines 786-0, KC12, or 
RCC4 (all VHL mutant) cell lines with LiCl; 
however, none of these cell lines upregulated 
activated β-catenin in response to LiCl as 
measured by western blot for anti-ABC or by 
TCF/β-catenin reporter assays (not shown). 
It is likely that these renal carcinoma cells 
lack some upstream Wnt component.
VHL is a physiological target of Wnt 
signaling
At the bottom of intestinal crypts, stem cells 
give rise to a transient population of undif-
ferentiated cells that vigorously proliferate 
as they migrate towards the lumen of the 
intestine (Fig. 2A, right panel). Epithelial 
cells that reside at the bottom-most position 
of the crypts, close to the putative Wnt 
source, accumulate nuclear β-catenin and 
accordingly show high levels of proteins 
positively regulated by Wnt (16). To determine 
whether VHL also demonstrates characteristics 
of a Wnt-target in physiological circumstances 
we performed immunohistochemical 
analysis of VHL staining in normal adult 
intestine. Consistent with the in vitro data 
and our previous observations (15), VHL 
expression is limited to cells at the bottom 
of crypts, near the Wnt source, and tapers 
off along the crypt-villus axis (Fig. 2A, left). 
Interestingly, expression of HIF1α inversely 
correlates with that of VHL; it is absent near 
the presumptive Wnt source at the bottom of 
the crypt, low at the intermediate positions 
in the crypt and peaks at the surface 
epithelium. This spatial division of the 
epithelium into two domains complementarily 
expressing either VHL or HIF1α (cartoon, Fig. 
2A) suggests that VHL efficiently regulates 
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HIF1α levels in the intestine. These findings 
represent the first positive staining for 
HIF1α in normal normoxic tissue and show 
that HIF1α expression could have a function 
in normal homeostasis in the intestine in the 
absence of hypoxia. 
The distribution of VHL and HIF1α in the 
gut prompted us to examine the intestines 
of mice deficient for Tcf4. In the intestinal 
epithelium, Tcf4 is the most prominently 
expressed TCF family member (20). In the 
late fetal small intestine Tcf4 expression is 
mainly confined to the intervillus pockets, 
the prospective crypts of Lieberkühn (28). 
To study whether the expression of VHL 
in the intestine is dependent on TCF4, we 
determined the expression pattern of Vhl 
in the small intestine of E18 Tcf4 mutant 
embryos (Fig. 2B); older mice could not be 
examined because these mice die perinatally 
as a result of tearing of the intestinal epithelial 
lining and fluid imbalance. These mice have 
a striking small-intestinal phenotype with a 
selective loss of cycling intestinal crypt cells 
(28). In the Tcf4+/- control mice, VHL ex-
pression (Fig. 2B, left) was readily detectable 
in the pseudostratified intervillous epithelium. 
In sharp contrast, the intestinal epithelium of 
Tcf4-/- mice did not show any VHL staining 
(Fig. 2B, right). Unfortunately, there are no 
available antibodies that recognize murine 
HIF1α, thus we were unable to examine 
the expression pattern of HIF1α in a Tcf4-/- 
background.
VHL is upregulated in FAP patient polyps
A large body of data supports a model in 
which mutational activation of β-catenin/
TCF in intestinal epithelial cells leads to 
polyp formation, the first morphological 
alteration that ultimately results in colorectal 
cancer [reviewed in (29)]. These polyps can 
be viewed as abnormal expansions of the 
crypts as far as gene expression patterns 
are concerned (16). To further explore our 
hypothesis, we studied the expression of 
VHL in the intestinal mucosa of patients 
with familial adenomatous polyposis (FAP), 
an uncommon colorectal cancer syndrome 
associated with germline mutations of the 
APC tumor suppressor gene. In all atypical 
crypt foci and polyps examined from 12 FAP 
patients, VHL was highly expressed (Fig. 
2C, D). Nuclear β-catenin was observed in 
all polyp and adenoma tissues (not shown). 
Accordingly, HIF1α could not be detected in 
these early lesions (Fig. 2D). The above data 
imply that both legitimate and illegitimate 
activation of Wnt signaling stimulate VHL 
expression in intestinal mucosa through 
TCF4/β-catenin.
Expression of VHL is lost in spontaneous 
CRCs 
In order to further support the notion that 
β-catenin/TCF signaling acts as a switch that 
inversely controls VHL and HIF1α expression, 
we performed immunohistochemical analyses 
on 19 spontaneous colorectal tumors of 
various pathological grades. Interestingly, 
it was immediately evident that the earliest 
lesions displayed heterogeneous expression 
of VHL (not shown and Fig. 3A) Upon 
closer inspection of early adenomatous 
lesions, clonal loss of VHL could be 
observed, suggestive of a selective mecha-
nism (Fig. 3A-B). In some adenomas loss 
of VHL expression was quite striking, and 
correlated perfectly with HIF1α stabiliza-
tion (Fig. 3A). Although a layer of dysplas-
tic cells expressing VHL surrounded HIF1α-
positive adenoma cells, intermingling of 
the two cell populations was never seen in 
normal or neoplastic epithelium. Examining 
CRCs further along the adenoma-carcinoma 
sequence, we never detected VHL expression 
in late adenomas and carcinomas, despite 
the increased levels of cytoplasmic and 
nuclear β-catenin in the tumor tissue (Fig. 
4A-B, top row). Relatively normal adjacent 
tissue expressed normal levels of VHL (Fig. 
4A-B, middle row). Loss of VHL expression 
coincided with accumulation of HIF1α 
expression (Fig. 4A-B, bottom row). In 
short, while nuclear β-catenin continues 
to accumulate during adenoma-carcinoma 
progression, at some point VHL levels 
become uncoupled from the Wnt pathway, 
perhaps through selection for clones 
downregulating VHL either by promoter 
methylation, by chromosome loss, or by 
gene mutation. 
Examining the HIF1α staining in our se-
ries of CRCs closely, we were able to iden-
tify two distinct patterns: in 9/19 samples, 
the nuclear HIF1α staining was prominent 
in perinecrotic regions (not shown), while 
in the remaining 10 samples it generally 
localized to well-vascularized regions (not 
shown). The presence of stabilized nuclear 
HIF1α in areas that should be well-oxygen-
ated (ie adjacent to blood vessels) suggests 
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a hypoxia-independent mechanism –such as 
VHL inactivation- for HIF1α stabilization. It 
will be interesting to determine whether the 
pattern of HIF1α staining in CRCs correlates 
with patient prognosis, as has been recently 
been established for breast cancer (30).
Discussion
In the past few years, multiple downstream 
genes of β-catenin/TCF have been identified 
(reviewed at www.standford.edu/~rnusse/
wntwindow.html), yet the role of such 
individual genes in gut physiology or 
tumorigenesis is not completely understood. 
In this study we provide evidence that 
the VHL tumor suppressor gene acts as a 
physiological Wnt target in the intestines of 
mice and humans. Large-scale analyses of 
the genetic program driven by β-catenin/
TCF in normal and neoplastic intestinal 
epithelium have demonstrated that measuring 
RNA or protein levels are at least as biologically 
relevant as promoter studies in 
characterizing putative Wnt target genes 
(16,31). Nevertheless, it is interesting to 
note that the TCF4 consensus binding site 
CTTTGA (32)  is found –468 nucleotides 
upstream of the transcriptional start of 
human VHL (GenBank AF010238), suggestive 
of direct regulation. Our data demonstrate 
that the proliferative cells residing in the 
intestinal crypts express VHL, whereas HIF1α 
is expressed in a complementary fashion in 
adjacent differentiated cells. Furthermore, it 
was recently shown that VHL/HIF signaling 
plays an important role in maintaining colonic 
integrity in a colitis model (33). Another report 
has suggested that the expression of a HIF1α 
target gene -the intestinal trefoil factor- at 
the intestinal lumen might be essential for 
barrier formation and injury repair in intestinal 
mucosa (34). 
Secondly, we demonstrate that while both 
pathways remain intact and coordinated 
in early neoplastic lesions, they become 
uncoupled from each other upon 
downregulation of VHL expression in CRC 
development. Heterogeneous expression of 
VHL in early adenomas suggests that clonal 
selection and subsequent expansion of cells 
with reduced VHL is already taking place. In 
human CRC samples a strict compartmental-
ization of adjacent VHL-expressing relatively 
normal tissue and HIF1α-expressing tumor 
tissue was evident. These findings suggest 
the presence of selective forces encouraging 
VHL inactivation at the adenoma stage of 
tumor progression. In the light of these 
observations, the function of VHL proposes 
an interesting hypothesis. VHL functions as 
the target recognition moiety of an ubiquitin 
E3 ligase complex, targeting HIF1α for 
ubiquitination and subsequent proteasomal 
degradation. Biallelic inactivation of VHL 
allows HIF1α to escape degradation, 
accumulate and stimulate expression 
of several genes encoding for growth fac-
tors, such as VEGF. Clinically, tumors lacking 
VHL secrete high levels of VEGF and other 
pro-angiogenic factors and manifest as highly 
vascularized lesions. Furthermore, the 
presence of nuclear HIF1α has been extensively 
associated with the advent of angiogenesis 
in many tumor settings (22,35,36). Thus, 
correlative data and biological plausibility 
support a role for VHL down-regulation in 
the angiogenic switch in CRC progression. 
This hypothesis is supported by the wealth 
of data on the regulation of HIF1α and VEGF 
by VHL [reviewed by Maynard and Ohh (6)], 
in addition to our findings that decreased 
VHL levels in colorectal cells correlated with 
increased HIF1α and VEGF. 
A number of studies support a role for VHL inac-
tivation/HIF1α stabilization in the progression 
of colorectal cancer. Firstly, loss or alteration 
of the VHL locus on chromosome 3p is 
commonly associated with the progression 
and poor prognosis of CRC (37-39). 
Accordingly, while allelic loss of VHL has not 
been detected in intestinal early adenomas, 
64% of carcinomas have been reported to 
harbor VHL deletions, indicating a role for 
VHL loss in later stages of tumor progression 
(40). Another recent study sequenced VHL 
in 88 paraffin-embedded CRC specimens 
and found 10 (11%) point mutations (41). 
A relationship between HIF levels, VEGF 
expression, tumor invasion, liver metastasis 
and microvessel density was recently 
demonstrated in colorectal cancer patients 
(36). Almost 60% of archived colorectal 
cancer samples expressed HIF1α protein 
at a high level. These findings support 
the notion that HIF1α may play a role in 
angiogenesis and tumor progression via 
regulation of VEGF in human colorectal 
carcinoma. Another study reported nuclear 
HIF1α overexpression in 22/22 colon adeno-
carcinomas examined (42). Lastly, HIF1α 
overexpression has been implicated in colon 
carcinoma cell invasion (43). 
It has been previously shown that β-catenin 
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Figure 3: Clonal loss of VHL in early adeno-
mas  
(A) Immunohistochemistry of VHL (left) and 
HIF1α (right) demonstrate complementary 
staining in early adenoma. (B) Single crypt from 
spontaneous adenoma reveals localized loss of 
VHL staining (marked with *), suggestive of clonal 
expansion.
Figure 4. Advanced colorectal carcinomas 
uncouple VHL regulation from Wnt signaling. 
(A and B) Sequential sections of two representa-
tive carcinomas (A and B, respectively) stained 
for β-catenin (upper panels), VHL (middle panels) 
and HIF1α (lower panels). Whereas β-catenin 
nuclear and cytoplasmic staining increases in the 
carcinoma tissue, VHL stains only the adjacent 
normal tissue, whereas nuclear HIF1α stains in a 
purely complementary fashion to VHL. 
signaling resulted in an upregulation of 
VEGF-A mRNA and protein levels by 250-
300% (44). The authors postulated that the 
upregulation of VEGF was mediated by a di-
rect binding of TCF/β-catenin to consensus 
binding sites within the gene promoter of 
VEGF. However, our data support the role 
of HIF1α in VEGF regulation in CRC cells 
reported by Semenza and colleagues (45). 
These two mechanisms of VEGF regulation 
are not mutually exclusive; our data simply 
suggest that an alternative pathway exists 
where Wnt signaling can induce VEGF and 
angiogenesis through VHL/HIF regulation.
It is tempting to speculate that downregula-
tion of VHL expression might be prevalent 
in other cancer types exhibiting illegitimate 
Wnt signaling.  For example, selective loss 
of VHL has been described in thyroid tumors 
(46), where Wnt signaling is thought to play a 
critical role (47). It would also be interesting 
to examine VHL in other tumors commonly 
associated with activating mutations of the 
Wnt pathway, including breast, pancreatic, 
and liver tumors (1). Interestingly, these 
tumor types have already been significantly 
associated with HIF1α overexpression (42). 
Lastly, our data demonstrate a role for Wnt 
signaling in VHL regulation; manipulation of 
this pathway might be instrumental in the 
future design of therapeutic interventions 
for tumors associated with loss of VHL.  
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Lolkema MP
Understanding the function of tumor sup-
pressor genes is an important way to 
understand how tumors arise from normal 
tissue. In this thesis we studied the effects 
of the von Hippel-Lindau tumor suppres-
sor gene (VHL) involved in tumor suppres-
sion in the kidney. In the Introduction we 
argue that there is a function for VHL, which 
is as yet unknown. HIF regulation is a well 
established function ascribed to VHL (1-3) 
however there are at least two very compelling 
arguments for an additional function for VHL. 
The first argument is that there are two dif-
ferent isoforms of the VHL protein: p30 and 
p19, in which p19 lacks the N-terminal acidic 
domain (4,5). This acidic domain is not 
necessary for HIF regulation as p19 is fully 
capable of adequately regulating HIF levels 
but does contain tumorigenic mutations, 
implying a functional significance for this 
domain (6). Furthermore, von Hippel-Lindau 
disease patients can be classified into 
different subtypes of disease according to 
the genetic mutations that are found. Four 
different subtypes of disease can be classified 
with different risk for developing the 
different tumors associated with the VHL 
syndrome, in which the type 2C mutations 
are normally able to regulate HIF levels in 
vitro (7-9). A single function for VHL would 
not suffice to explain this complex genotype-
phenotype correlation.
The data represented in this thesis describe 
aspects of the biology of the VHL protein and 
suggest the presence of an alternative function 
for VHL in addition to the regulation of HIF 
levels. The concept of HIF-independent 
functions for VHL has been widely recognized 
and is represented in the international 
literature in a wide variety of publications; 
however the mechanism behind this function 
remains unknown (1,10-13). The approach 
of using differential expression profiling with 
microarray technology has been used in 
different set-ups and has shown in multiple 
experiments to reproduce VHL-regulated 
genes, which seem to be independent of HIF 
regulation (14-19). The data presented in the 
second chapter contributes to this knowledge 
and addresses another well known VHL 
phenomenon, namely altered fibronectin 
matrix formation. Ohh et al. described the 
binding of VHL to fibronectin and suggested 
that this binding is essential in the formation 
of a correct extracellular matrix (13). This 
binding of VHL to fibronectin seems to be 
disrupted in all tumorigenic mutants of VHL 
that have been tested thus far, in contrast 
to the HIF regulatory function of VHL which 
has been shown to be intact in the type 2C 
mutants of VHL (8). The expression of 
fibronectin however is also regulated by 
VHL; thereby strengthening the notion that 
fibronectin might be a major contributor to 
the tumor suppressor function of VHL. In a 
C. elegans genetic system, cross-breeding 
HIF-deficient worms with VHL-deficient 
worms revealed differential regulation of ex-
tracellular matrix genes by VHL that were in-
dependent of HIF function (12). These studies 
flesh out the above in vitro studies, confirm-
ing in vivo the transcriptional regulation 
of the extracellular matrix as an important 
–and HIF-independent-VHL function. 
The third, fourth and fifth chapters ad-
dress what the molecular mechanism of the 
VHL-mediated HIF-independent function 
could be. As discussed in the first chapter 
our “prime suspect” to determine the HIF- 
independent function for VHL lies within the 
N-terminal acidic domain, which has not 
previously been assigned a function. We 
show that the acidic domain of VHL can be 
phosphorylated and that this modification 
is essential for tumor suppression in vivo. 
The acidic domain is also involved in binding 
the kinesin-2 complex and this interaction 
between the kinesin-2 complex and VHL 
plays a role in promoting microtubule 
stability in the cell periphery. Furthermore, 
we show that the kinesin-2 complex and 
VHL cooperate in the formation of primary 
cilia. These data represent the first pieces of 
experimental evidence that the acidic 
domain has a function. The model that arises 
from the data presented in this thesis is that 
the acidic domain plays an important role 
in determining the HIF-independent role for 
VHL; however, the exact molecular 
mechanism needs to be elucidated. 
The most important question that these data 
evoke is: how do the extracellular matrix 
formation, microtubule stability and 
ciliogenesis affect the formation of tumors? 
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From literature we know that the interac-
tion of tumor cells with the extracellular 
matrix is an important regulator of various 
signal transduction events leading to more 
or less proliferation and migration (20), but 
could this be an explanation for the tumor 
suppressor effect of VHL? In the various in 
vivo models that have been studied, the 
major confounder to answering this ques-
tion has been the presence of two variables: 
higher levels of HIF expression and the 
mutation of VHL. However in studies performed 
by the groups of Kaelin and Klausner, 786-
O human renal cell carcinomas were tested 
in nude mice that expressed both VHL and 
a form of HIF that is insensitive to the VHL 
mediated ubiquitination and subsequent 
degradation (21,22). These experiments 
show that HIF2α can induce tumor formation 
in the presence of wild-type VHL in the 
background of the 786-O renal cell carci-
noma cell line. The reciprocal experiments 
where HIF2α was knocked down using RNAi 
in the absence of VHL in the same 786-O 
cell line showed that tumorigenesis in this 
model is dependent upon the presence of 
HIF2α (23,24). So in the background of the 
786-O renal cell carcinoma cell line the HIF- 
mediated tumor growth in nude mice 
induced by HIF2α is dominant over any oth-
er VHL-mediated effect. However, the in vivo 
experiments that were performed in chapter 
4 of this thesis showed that a mutant of VHL, 
that could not be phosphorylated, allowed 
tumor formation after 8-10 weeks, a time 
point after the in vivo experiments in other 
reports were terminated (25). The question 
remains whether HIF stabilization alone 
could be responsible for the tumor formation 
in VHL-deficient cells under more physiologic 
circumstances. The conditional VHL knock 
out mice that were bred using the Cre-Lox 
system could have answered this question 
but these mice do not develop tumors in the 
kidney (26). Therefore the role for the VHL-
dependent extracellular matrix deposition 
and the interaction of the tumor cell with its 
environment in vivo cannot be adequately 
judged from existing data.
The oncogenic potential of HIF-mediated 
transcription would be another way to show 
that VHL-dependent carcinogenesis depends 
on its function in regulating HIF levels. A role 
for HIF as an oncogene has not been de-
tected in human tumors. Whereas the muta-
tions in well defined oncogenes such as RAS 
have been detected in a large set of tumors, 
for HIF the mutational status has not shown 
activating mutations in human tumors. How-
ever, polymorphisms of HIF detected in re-
nal cell carcinomas, head and neck cancer 
and prostate cancer may result in more ac-
tive forms of HIF. These alleles are normally 
present in the general population and seem 
to increase the risk of developing these tu-
mors (27,28). This is a completely differ-
ent pattern of mutation compared to the 
classical oncogenes that undergo selection 
for mutations in the tumor that are not 
germline. Recent analysis of HIF expression 
in breast cancer has shown that the global 
expression of HIF inside tumors is associated 
with less aggressive behavior compared to 
expression in perinecrotic tumor tissue (29). 
Therefore, HIF activation alone does not 
correlate with aggressive tumor behavior; 
its expression pattern also influences the 
biological behavior of tumor cells. 
Experimental models such as transgenic 
mice bearing activated HIF genes have 
not been reported to date. The selective 
inactivation of HIF has been reported in 
different models and contradicting evidence 
has been shown using these approaches. 
Whereas one HIF knock out ES cell line has 
been shown to enhance teratoma growth, 
another with a somewhat different knock out 
allele was shown to be deficient in forming 
teratomas (30,31). However these models 
do not address the proper question of HIF-
dependent tumorigenesis as the teratoma 
model is too sensitive for developmental 
deficiencies. Teratomas may be deficient 
in their growth simply because of the fact 
that they are incapable of differentiating 
into tumors (e.g. APC-deficient teratomas) 
and could explain the smaller teratomas that 
developed from VHL deficient ES cells 
(32,33). So with the current evidence there 
is no indication that HIF functions as an 
independent oncogene in humans.   
The existence of a HIF-independent function 
for VHL is a plausible yet not fully proven 
and elucidated phenomenon. Recent data 
showed that JunB is up regulated in the 
presence of VHL and this seems to be in-
dependent of HIF as type 2C mutants that 
are capable of regulating HIF levels show 
defective JunB regulation (34). This is 
another link to a molecular mechanism of 
understanding how VHL influences the cellular 
behavior besides regulating HIF levels. 
JunB is known to play a role in promoting 
cell cycle arrest and apoptosis (35). These 
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features are mostly due to the antagonistic 
effect on c-Jun, which is a known oncogene. 
Could this be the link to the HIF-independent 
tumor suppressor effect of VHL? The authors 
of this recent paper suggest that in the 
development of pheochromocytoma the 
apoptosis after NGF withdrawal is the 
general mechanism behind the development 
of pheochromocytoma in all hereditary 
pheochromocytoma syndromes (34). 
These arguments are compelling for the 
development of pheochromocytoma but 
the development of these tumors probably 
has a different etiology within VHL disease. 
Type 2C mutations, only predisposing for the 
development of pheochromocytoma, could be 
seen as a different disease when compared 
to the other subtypes. The data acquired 
in this thesis suggests that the HIF- 
independent function of VHL we describe 
might have a role in the development of 
renal cell carcinoma, as the type 2A and 
type 2B mutations seem to be differentially 
affected. The cell biological behavior of cells 
that lack VHL seems to be characterized 
by the inability to communicate with the 
exterior of the cell. Defective extracellular 
matrix deposition in the form of deficiency 
in producing and depositing fibronectin and 
the defects in forming fibrillar adhesion 
increases the mobility of VHL defective cells 
(13,36,37). These changes will ultimately 
lead to less attachment to the basal 
membrane of kidney tubular cells creat-
ing a niche for autonomous development. 
Defective microtubule stability at the 
cell membrane will disturb the ability 
of epithelial cells to polarize properly 
as stable vertical microtubule arrays 
seem to be essential in directing the 
polarized distribution of cell surface 
molecules (38). Finally, defective cilia 
formation leads to a decreased ability of 
these cells to understand the stimuli from 
outside the cell (39). Clues like flow on the 
surface of the cell will no longer lead to the 
appropriate signals as could be seen in our 
experiments looking at flow-induced Ca2+ 
responses. I would like to propose a model 
in which VHL functions as a master-switch 
for cells to behave in a “social” fashion. Loss 
of function of VHL leads to cells incapable of 
communicating and simultaneously activates 
a strong survival program with the activation 
of HIF-dependent transcription. 
The interaction of VHL with the kinesin-2 
motor protein seems to play a central role 
in the mechanism behind this behavior of 
VHL deficient cells. The kinesin-2 motor 
protein complex has been shown to play an 
important role in the establishing proper 
polarization in neuronal cells and kidney 
epithelial cells (40,41). Illustrative of the 
function of kinesin-2 motor complex to 
target molecules to the cell-cell interaction is 
the effect of targeted deficiency of Kif3a in the 
kidneys of mice. In these kidneys not only the 
presence of cysts but also the mislocalization 
of beta-catenin was shown. The mice with 
targeted inactivation of Kif3a in the kidney 
did not develop tumors but cysts (41). It 
is tempting to speculate on an additive 
effect of both deregulation of kinesin 2 function 
and HIF activation in the pathogenesis 
of renal cell carcinoma with cysts as pre- 
malignant lesions and therefore the interac-
tion between VHL and the kinesin-2 complex 
deserves more attention in future research. 
Especially the functional correlation between 
VHL-kinesin-2 binding and phosphorylation 
and the link between kinesin-2 and 
fibronectin deposition are essential in 
determining whether indeed the interaction 
between VHL and kinesin-2 is central in the 
HIF-independent function for VHL. 
The second central question in this the-
sis and in the research field of VHL is the 
functional significance of the genotype- 
phenotype correlation. As discussed in the 
introduction, VHL disease predisposes to 
different tumors and the distribution of 
specific tumor development correlates with 
specific mutations. The first division is 
between type 1 and type 2 VHL disease 
in which patients with type 2 mutations 
and not type 1 mutations predispose to 
developing pheochromocytomas. This 
first and most important division defines 
pheochromocytoma as a separate entity 
within VHL disease and therefore one could 
assume that there should also be a functional 
dissection between type 1 and type 2 
VHL disease. The second argument for 
distinguishing pheochromocytoma as a 
functional separate entity is the existence of 
the type 2C disease in which mutations of 
VHL are included that uniquely predispose 
for pheochromocytoma. Important for 
this argument is the existence of different 
unrelated point mutations in different 
codons for different amino acid substitutions 
that lead to type 2C disease. This means that 
independent mutational events can lead 
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to the disruption of a function of VHL in 
preventing development of pheochromo-
cytoma. Moreover, the type 1 mutations 
comprise most of the large deletions of the 
VHL most likely to completely inactivate all 
VHL functionality. Therefore inactivation of 
all VHL functionality leads to hemangioblas-
tomas and RCC but does not lead to pheo-
chromocytoma development. This could be 
interpreted as an argument for residual VHL 
function in the development of pheochromo-
cytoma or a gain-of-function effect of the 
mutated type 2C VHL allele. So pheochromo-
cytomas are definitely a distinct entity within 
the clinical presentation of VHL disease. 
The second manifestation that could be 
considered to be a distinct entity within 
the VHL disease is ccRCC. Type 2A disease 
patients have a much lower chance of 
developing ccRCC without losing the chance 
of developing hemangioblastomas and pheo-
chromocytomas. These patients are distinct 
from the patients that develop type 2B 
disease, which are susceptible to all known 
VHL disease associated manifestations. So 
now should we consider type 2A mutations 
a different entity and ccRCC associated with 
yet another VHL function? Notably, type 
2A mutations are extremely rare. The true 
nature of the type 2A disease phenotype 
remains puzzling in light of the abundance 
of known mutations in the VHL gene and 
the low frequency of this particular type of 
disease. However, two recent lines of 
research do assign unique functions to the 
type 2A mutant alleles: type 2A alleles 
seem to be deficient in the microtubule 
stabilizing function of VHL and the type 2A 
mutants retain the ability to stabilize JADE-
1, a putative tumor suppressor gene in the 
kidney (43-45). A way of reconciling the 
available data would be that the loss-of-het-
erozygosity (LOH) targeting the normal al-
lele would lead to a remaining mutated allele 
with residual microtubule stabilizing function 
as would be the case with type 2B mutants, 
leading to a supposed survival benefit. If the 
remaining mutated allele lacks all microtubule 
stabilizing capacity as is the case with type 
2A mutants, the hypothesis would be that it 
does not confer survival benefit in the kid-
ney. This argument functionally separates 
renal cancer from the hemangioblastomas in 
the CNS and eyes. I believe that the data 
we and others have acquired favor a model 
of three separate VHL-mediated functions: 
HIF regulation with hemangioblastomas as 
clinical manifestation, impairing pheochro-
mocytoma development and a function 
which, in conjunction with HIF activation, 
leads to the development of ccRCC (Fig. 1).
These arguments lead to the proposed model 
of ccRCC development in VHL disease: the 
inactivation of VHL due to LOH in the kidney 
leads to the development of atypical cysts 
due to the relative insufficiency in sensing 
and adapting to extracellular signals. This 
phenomenon could be attributed to defi-
cient cilia formation. These atypical cysts in 
early stages upregulate HIF levels (personal 
communication Dr. P. Maxwell). These le-
sions remain silent or grow very slowly as 
HIF expression per se does not induce an 
“oncogenic program” but more likely induces 
Figure 1: Schematic overview of the VHL related functions.
This figure represents an hypothetical model for the VHL related functions published until now and 
reported in this thesis. We propose a trichotomy in the VHL related functions as depicted in the upper 
lane. Through different mechanisms these function cause disease phenotypes as can be observed in pa-
tients suffering from mutations in the VHL gene and their corresponding clinical subtype of VHL disease.
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a “survival program”. From the moment that 
these independent cell populations emerge, 
they will acquire additional mutational events 
but these will take some time to develop as 
these lesions have the tendency to grow 
slowly (Fig. 2). This model could explain a 
number of observations in patients with VHL 
disease: the relatively benign nature of the 
kidney lesions, the “pre-malignant” nature 
of cysts in VHL disease and the successful 
local resection of lesions with >3cm (42). 
Furthermore it explains the relative benign 
nature of ccRCC with VHL mutations and the 
relative large size of the tumors when they 
are detected in the general population (46). 
The sixth chapter deals with a somewhat 
different aspect of VHL biology being the 
regulation of VHL expression and its role in 
the physiology of the intestine. We found 
that the expression of VHL was regulated 
by active wnt-signaling and displays the 
expression pattern of a typical wnt-signaling 
target in the intestinal mucosa. Interestingly 
there was reciprocal expression of HIF un-
der normoxic conditions, which might rep-
resent the regulatory mechanism for HIF- 
mediated enhancement of barrier function 
in the intestinal villi (47) and the increase 
in oxygenation through stimulation of 
angiogenesis. These data show for the first 
time that regulation of expression of VHL 
has functional consequences and can lead to 
normoxic activation of HIF.
In colorectal tumor progression, a clear cut-
off point between non-invasive and invasive 
tumors could be seen with the loss of 
VHL. This suggests that loss of VHL could 
represent the molecular mechanism for the 
angiogenic switch in normal colonic tissue 
and colorectal cancer. Whereas the rest of 
this thesis has dealt with the functionality 
of the VHL tumor suppressor gene in the 
manifestations of patients with VHL disease, 
this chapter shows the relevance for dissecting 
the functions of VHL. Its role in regulating 
HIF, the best described and understood 
function now leads to a better understanding 
of tumor progression of colorectal cancer. 
With the novel anti-VEGF strategies that 
have shown benefit in trials for metastasized 
colorectal cancer we now show broad 
significance for VHL expression in tumors. 
Fully understanding the HIF-independent 
functions for VHL could also lead to 
improvement in our thinking about tumori-
genesis and lead to better therapies for 
patients with cancer in the future. 
Concluding remarks:
The experimental work in this thesis has 
generated a number of new insights into the 
biology of VHL. The role for HIF-independent 
functions might not have been elucidated 
fully, I believe its existence has been made 
probable. The unmasking of the molecular 
mechanism of this HIF-independent function 
has been made extremely difficult by 
evolution through the unconditional 
coupling of the HIF regulatory pathway 
to the other VHL functions. However, the 
genetic evidence for multiple functions 
for the VHL gene product lies within the 
genotype-phenotype correlations of VHL 
patients. Future research into this new area 
of tumor suppressor function will reveal the 
full functional consequence of VHL loss. 
Figure 2: Model for VHL mediated tumorigen-
esis in the kidney.
This model implies that tumorigenesis in the 
kidney is a multi-step chain of events in which 
atypical cyst formation is essential. These atypical 
cysts arise with the loss-of-function of VHL and 
differ from regular cysts because they loose cilia 
function and activate illegitimate HIF function. 
Additional oncogenic events will give rise to full 
blown renal cell carcinoma.  
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Introductie
Dit proefschrift behandelt de vraag hoe de 
uitschakeling van het von Hippel-Lindau 
tumor suppressor gen (VHL) kan leiden 
tot het ontstaan van tumoren. De erfelijke 
ziekte waarbij dit gen betrokken is, is 
ontdekt in het begin van de 20ste eeuw door 
Dr. Eugen von Hippel en later ook beschreven 
door Dr. Arven Lindau. Hen was opgevallen 
dat in een aantal patiënten tumoren 
voorkomen in de ogen, het centraal 
zenuwstelsel en de nieren. De patiënten 
met deze tumoren bleken allen familie van 
elkaar te zijn. Deze observatie suggereerde 
dat het ontstaan van deze tumoren een 
erfelijke of familiaire oorzaak heeft. Deze 
tumoren bestonden voor een groot deel uit 
zeer vaatrijke structuren. In de loop van de 
20ste eeuw is deze ziekte verder beschreven 
en de uitingen die ermee geassocieerd zijn, 
zijn:
- haemangiomen van de retina (bloedvaat-
woekering in het netvlies)
- haemangiomen van het centraal 
zenuwstelsel met name in het cerebellum 
(kleine hersenen) en het ruggemerg
- Grawitz tumoren van de nier (niercel 
tumoren)
- Pheochromocytoma (bijniertumoren die 
hormonen produceren)
- Zeldzamere tumoren: pancreastumoren, 
cystadenoma van de epidydimus bij 
mannen, endolymphatische zak tumoren 
(bij de oren)
De VHL ziekte kenmerkt zich door het 
vroege ontstaan van de bovengenoemde 
aandoeningen op meerdere plaatsen en 
kan door de gevolgen ernstig invaliderend 
zijn. Met name vele chirurgische ingrepen 
in de hersenen en aan de nieren geven 
functie verlies van de aangedane organen, 
daarnaast is de dreigende blindheid als 
gevolg van de oogaandoeningen een groot 
probleem. 
Het VHL gen: een tumor suppressor 
gen
Het VHL gen is een speciaal soort gen wat 
betrokken is bij de ontwikkeling van tumoren. 
Een tumor kan onstaan doordat een bepaald 
gen zijn functie meer of beter uitvoert, dit 
is dan een “onco-gen”. Voorbeelden hiervan 
zijn genen die de cel aanzetten tot celdeling. 
Hierbij is het vaak zo dat één gemuteerde 
kopie van dit gen dat “altijd” actief is, leidt 
tot ongebreidelde proliferatie. Daarmee kan 
dit het begin zijn van een tumor. VHL is 
echter een gen dat bij normale functie juist 
de ontwikkeling van tumoren onderdrukt. Dit 
zijn zogenaamde “tumor suppressor genen” 
waarvan wordt aangenomen dat voor de 
normale functie één goed functionerende 
kopie van zo’n gen voldoende is om tumoren 
te voorkomen. Echter, de inactivatie van een 
tumor suppressor gen leidt in het algemeen 
tot het actief worden van processen die tot 
tumoren kunnen leiden. Wanneer mensen 
een “foute” kopie van zo’n tumor 
suppressor gen van hun ouders erven, hoeft 
er nog maar één kopie te worden veranderd 
om een normale cel tot tumorcel te maken. In 
alle normale cellen die gedurende het leven 
celdelingen doormaken worden fouten 
gemaakt bij het “overschrijven” van de 
informatie in het DNA. Deze toevallige 
fouten leiden normaal gesproken niet tot 
problemen omdat de kans dat de twee 
kopieën van een tumor suppressor gen 
tegelijkertijd worden aangedaan uitermate 
klein is. Als men daarentegen al een 
verkeerde kopie bij zich draagt wordt 
de kans op inactivatie van een tumor 
suppressor gen een stuk groter. Deze 
“tweede hit” is een hypothese om te verklaren 
waarom mensen met één verkeerde kopie van 
tumor suppressor genen een verhoogde 
kans hebben om tumoren te ontwikkelen. 
Het VHL gen is geïdentificeerd en de 
sequence is bepaald in 1988 en sindsdien is 
er veel onderzoek gedaan naar de functies 
van dit gen. Een eerste en zeer opvallende 
observatie is dat dit gen niet alleen de VHL 
ziekte veroorzaakt maar ook betrokken is 
bij de ontwikkeling van andere spontaan 
ontstane Grawitz tumoren. Ongeveer 
50-70% van alle Grawitz tumoren vertonen 
een afwijking in beide kopieën van het VHL 
gen. Dit maakt het ontrafelen van de functie 
van VHL ook belangrijk voor het merendeel 
van de patiënten met Grawitz tumoren. 
De functie van het VHL gen: zuurstof 
meten in de cel.
Het VHL gen blijkt een rol te spelen in de 
normale reactie van cellen op een tekort 
aan zuurstof, zogenaamd hypoxie. Zuurstof 
is een van de essentiële bestanddelen voor 
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de stofwisseling van cellen. Met behulp van 
zuurstof kan de cel voedingsstoffen, met 
name suikerbestanddelen “verbranden” tot 
water en koolzuur en daarbij komt dan de 
energie vrij die nodig is voor het normale 
functioneren. Onder hypoxische omstandig-
heden moeten cellen zich aanpassen aan 
de hoeveelheid zuurstof die beschikbaar is. 
De respons op hypoxie bestaat onder an-
dere uit het proberen meer zuurstof aan-
bod te krijgen. Dit kan door de vaatnieuw- 
vorming te stimuleren. Daarnaast zal de cel 
zijn energie op een andere manier dan met 
behulp van zuurstof afhankelijke verbrand-
ing moeten opwekken om te voorkomen 
dat de cel dood gaat. Hiervoor is de 
zogenaamde anaërobe verbranding, zonder 
het gebruik van zuurstof, noodzakelijk. De 
enzymen die nodig zijn voor de anaërobe 
verbranding worden ook tijdens hypoxie 
aangemaakt. Daarnaast moet de cel alle 
niet-essentiële activiteiten uitschakelen en 
voorkomen dat er celdood optreedt. Deze 
complexe reactie op een verandering in 
de omgeving wordt gecoördineerd door de 
activatie van een transcriptie factor: hypoxie 
geïnduceerde factor (HIF). Transcriptie 
factoren zijn de “managers” van de cel die 
belangrijke processen, zoals de reactie op 
stimuli van buitenaf aansturen. HIF stimuleert 
de aanmaak van tal van eiwitten die nodig zijn 
voor de cellulaire reactie op hypoxie. Onder 
normale zuurstof spanningen is HIF een 
instabiel eiwit dat zeer snel wordt afgebroken. 
Dit gebeurt in de proteasoom: een 
gespecialiseerde structuur die eiwitten snel 
kan afbreken. VHL speelt een belangrijke 
rol in de respons op hypoxie. VHL stimuleert 
de afbraak van HIF door zgn. ubiquitine 
moleculen aan HIF te binden. Dit leidt tot 
afbraak van HIF door de proteasoom. Onder 
hypoxie bindt VHL niet meer aan HIF en 
daardoor kan het ook niet meer afgebroken 
worden. De ophoping van HIF geeft cellen 
een betere kans op overleving onder 
hypoxische omstandigheden. Als cel-
len zonder hypoxie HIF activeren, zoals 
bij de inactivatie van VHL, dan kan 
dat leiden tot gedragsveranderingen 
van de cel. Deze vaatnieuwvormingen 
kunnen goed verklaard worden door 
de aanmaak van groeifactoren, 
zoals de vaatgroeifactor VEGF. Echter het ont-
staan van kwaadaardige Grawitz tumoren kan 
niet alleen door de activatie van HIF worden 
verklaard. 
Is zuurstof meten de enige functie van 
VHL?
In de introductie van dit proefschrift 
beschrijven we een aantal redenen waarom 
wij denken dat VHL meerdere functies heeft. 
De eerste reden is dat het VHL gen uiteindelijk 
2 verschillende eiwitten maakt: een lange 
vorm: p30 en een korte vorm: p19. Het verschil 
tussen de twee eiwitten is een stukje van 
slechts 54 bouwstenen (aminozuren) zonder 
dat hiervoor een functie is beschreven. 
Beide vormen p30 en p19 zijn in staat om 
HIF te markeren voor afbraak maar in dat 54 
aminozuren grootte stukje van het eiwit 
kunnen wel fouten ontstaan die leiden tot 
tumoren. Deze fouten (mutaties van het 
gen) hebben geen invloed op de functie 
van p19 dus moet dat stukje haast wel een 
functie hebben. Het andere argument voor 
meerdere functies voor het VHL gen komt 
uit de kliniek. De patiënten met mutaties in 
het VHL gen kunnen worden geclassificeerd 
aan de hand van hun specifieke mutaties 
en hebben dan meer of minder kans op 
verschillende tumoren. Heel typisch zijn de 
zogenaamde type 2C mutaties die eigenlijk 
alleen een verhoogde kans geven op 
pheochromocytomen zonder een verhoogde 
kans op de andere tumoren. Er moeten dus 
minstens twee functies zijn voor het VHL 
gen.
Samenvatting van de conclusies uit dit 
proefschrift:
Het tweede hoofdstuk beschrijft een 
zogenaamde microarray studie waarbij in 
één experiment tot duizenden genen 
tegelijkertijd onderzocht kunnen worden 
op de hoeveelheid gen-product in een cel 
populatie. Met deze methode hebben we 
cellen met en zonder VHL vergeleken en 
gevonden dat VHL ook genen reguleert 
onafhankelijk van hypoxie. Dit was wederom 
een aanwijzing dat VHL ook een functie heeft 
die niet aan hypoxie is gerelateerd.
Het derde hoofdstuk gaat over het mech-
anisme van een HIF onafhankelijke 
functie van VHL. Hierin beschrijven we een 
nieuwe bewerking van VHL: fosforylatie. 
Fosforylatie is het proces waarbij zgn. fosfaat 
groepen aan een eiwit worden gekoppeld en dit 
beïnvloedt de activiteit van het eiwit. 
Fosforylatie van VHL leidt tot een betere 
export van fibronectine, een eiwit dat een 
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deel van de ondergrond vormt waarop cellen 
groeien. Deze fosforylatie van VHL vindt 
plaats in het eerder genoemde 54 aminozuren 
deel van VHL waarvoor nog geen functie was 
beschreven. Verandering van het VHL eiwit 
zodat het niet meer gefosforyleerd kan 
worden leidt tot een VHL eiwit dat 
normaal HIF kan afbreken maar toch 
niet kan voorkomen dat er tumoren 
gevormd worden. Dit is de eerste aanwijzing 
in de literatuur dat dit eerste deel van VHL 
daadwerkelijk een functie heeft.
Het vierde en vijfde hoofdtuk beschrijft de 
invloed die VHL heeft op de stabiliteit van 
microtubuli. Deze buisvormige structuren 
zijn als het ware het “skelet” van de cel wat 
moet zorgen voor de vorm, beweeglijkheid 
en stevigheid. Belangrijke processen zoals 
celdeling en de juiste communicatie van cellen 
met elkaar en met de ondergrond waarop 
ze groeien zijn afhankelijk van de juiste 
balans tussen stevigheid en dynamiek van 
microtubuli. In vele tumoren is die balans 
verstoord en nu blijkt dat ook voor VHL 
afhankelijke tumoren het geval te zijn. 
Daarnaast laten we zien dat bij deze functie 
wederom het 54 aminozuren grote domein 
van VHL belangrijk is. VHL bindt 
met behulp van dit domein aan 
een complex van eiwitten genaamd 
het kinesin-2 complex. Dit complex 
functioneert in de cel als “motor” eiwit 
en is in staat om andere eiwitten langs 
microtubuli te vervoeren. De interactie 
tussen VHL en het kinesin-2 complex is ook 
belangrijk voor de juiste aanmaak van 
zogenaamde cilia. Dit zijn een soort 
voel-sprieten die voornamelijk bestaan 
uit microtubuli die op de cellen groeien 
en belangrijk zijn voor het “voelen” van 
stroming buiten de cel. In de nieren is dit erg 
belangrijk omdat de cellen waaruit de VHL 
gerelateerde tumoren ontstaan tubulaire 
cellen zijn. Deze cellen vormen de bekleding 
van de buizen waardoor de urine stroomt 
en bewerkt wordt. Defecte cilia en 
dus onvoldoende signalering van cilia 
leidt in het algemeen tot het ontstaan 
van holtevormige afwijkingen ook wel cysten 
genoemd. Onze hypothese is dat het 
veelvuldig voorkomen van cysten  bij  VHL 
patiënten samenhangt met deze functie 
van het VHL eiwit. Normale cysten in de 
nier hebben slechts een hele kleine kans 
om een kwaadaardige tumor te worden. Bij 
VHL patiënten gebeurt dit wel. Dit verschil 
kan mogelijk  verklaard worden doordat in 
de cysten die bij VHL patiënten ontstaan 
ook HIF geactiveerd wordt. Beide factoren 
samen: het activeren van HIF en de formatie 
van cysten zou wel eens tot tumoren kunnen 
leiden.    
Het zesde hoofdstuk is een uitstap naar 
een functie van VHL in de darm. In dit 
hoofdstuk tonen we aan dat VHL ook in 
tumoren van de darm wordt uitgeschakeld. In 
tegenstelling tot de goedaardige voorlopers 
van deze tumoren waarin juist veel VHL 
eiwit aanwezig is. Het uitschakelen van de 
functie van VHL en daarmee het versterken 
van de functie van HIF geeft darmtumoren 
een groeivoordeel. Dit gaat gepaard met 
een toename van vaatnieuwvorming die de 
bloedtoevoer verhoogt. Dit hoofdstuk toont 
aan dat ook voor patiënten met andere 
tumoren dan Grawitz tumoren de functie 
van VHL belangrijk is.
Conclusie:
In dit proefschrift is de functie van een 
belangrijk tumor suppressor gen beter 
beschreven. VHL speelt niet alleen een rol bij 
het meten van zuurstof maar ook bij de vorm-
ing van cilia. De uiteindelijke betekenis van 
deze nieuw beschreven functie en de precieze 
achterliggende mechanismen zijn een belan-
grijk onderwerp van onderzoek. De rol van 
VHL en HIF in vaatnieuwvorming heeft geleid 
tot de ontwikkeling van  geneesmiddelen. 
Deze geneesmiddelen kunnen de tumorgroei 
vertragen door de vaatnieuwvorming af te 
remmen. Door inzicht in de HIF-onafhanke- 
lijke functie van VHL te verkrijgen, kan in 
de toekomst de behandeling van Grawitz 
tumoren ook gericht worden op de andere 
functies van het VHL gen. Om dit soort 
gerichte therapie te kunnen ontwikkelen 
is het noodzakelijk om precies de achter-
liggende mechanismen te ontdekken die 
van belang zijn voor de ontwikkeling en de 
groei van tumoren. In het geval van VHL 
is er hoogst waarschijnlijk meer dan alleen 
een rol in de regulatie van HIF en is er dus 
ruimte voor verdere ontwikkeling van 
therapieën voor Grawitz tumoren.  
Dankwoord
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Zoals velen voor mij hebben ervaren, is het 
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afhankelijk van de inzet van de promoven-
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afronden van dit werk en die wil ik graag in deze 
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geweest. Jij bent degene die mijn leven 
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vergeet ik Bob niet: onze rode kater die het 
slapen en spinnen tot kunst heeft verheven. 
Soms zou ik willen dat ik een kat ben, maar 
meestal niet.
Beste Emile, geachte promotor, jij hebt mij de 
afgelopen jaren naar dit moment toe begeleid 
en ik denk dat we samen trots kunnen 
zijn op de uitkomst van dit werk. Het 
combineren van onderzoek met klinische 
werkzaamheden is geen gemakkelijke 
combinatie maar jij weet als geen ander 
op beide vlakken te excelleren. Daarmee 
inspireer je jonge mensen zoals mijzelf om 
deze belangrijke combinatie uit te proberen. 
Je hebt me een bijna onvoorwaardelijke 
vertrouwen en de kans om mezelf te 
ontplooien gegeven. Daarnaast heb je 
op cruciale momenten de juiste richting 
gegeven aan ons onderzoek. Je bent 
onmisbaar geweest in het tot stand komen 
van dit proefschrift en voor het ontwikkelen 
van mijn verdere carrière.
Beste Rachel, geachte co-promotor, je kwam, 
je zag, nu moet je nog overwinnen. De 
frisse wind die uit Clevers lab kwam waaien: 
zo kwam je halverwege mijn promotie 
traject het laboratorium medische oncologie 
binnen. Met jou samen heb ik mijn 
gedachten over de inhoud van dit proefschrift 
kunnen vormen. Je stelde de juiste vragen 
en wist me te boeien met een intellectuele 
discussie. Je hebt me laten zien dat 
wetenschap meer is dan uitkomsten van 
proeven maar ook een stukje creativiteit 
vereist.
In mijn carrière heb ik nog twee sterke vrouwen 
ontmoet die aan mijn wetenschappelijke 
vorming een onuitwisbare bijdrage hebben 
geleverd: Claire Boog en Polly Matzinger. 
Claire, bij jou mocht ik mijn eerste stapjes in 
het lab zetten en daarbij heb je ontzettend 
veel geduld gehad. Samen met Benito heb je 
me de basisvaardigheden bijgebracht: ik was 
traag en onhandig. Desalniettemin heb ik 
met ontzettend veel plezier bij jou gewerkt. 
Je hebt nooit onder banken of stoelen 
gestoken dat je graag je bijdrage wilde leveren 
aan de wetenschappelijke ontwikkeling van 
artsen. Die gedachte en de uitvoering ervan 
waren mijn eerste echte aansporing om te 
gaan doen wat ik nu doe: wetenschap en 
geneeskunde combineren.
Dear Polly, as I have finished my thesis I 
would like to thank you for the contribution 
you made to my personal and scientific 
development. My 11-month stay in your lab 
has been a roller coaster ride: together 
with Steffi we performed experiments and 
talked about theories until late at night. You 
two showed me the energy that gifted and 
ambitious scientists can project on others. 
You also taught me to think as an 
independent person and gave me the 
confidence I could do so. Thanks to 
your supervision and the cooperation 
with Steffi I learned to appreciate the 
challenges of basic research.
Het laboratorium medische oncologie en de 
mensen die er werk(t)en ben ik veel dank 
verschuldigd. Martijn Gebbink en Moniek van 
Beest: jullie waren de moleculair biologen 
die mij hebben voorzien van alle moleculair 
biologische kennis die ik nu bezit. Dat moet 
voor jullie een hele opgave zijn geweest: 
de zoveelste arts die probeert wetenschap 
te doen! Gelukkig hebben jullie het nooit 
opgegeven. Er moeten momenten zijn geweest 
die jullie tot wanhoop hebben gedreven 
maar ook dan waren jullie er. Onno: ook jij 
hebt een bijzondere positie gehad. Als een 
van de weinigen ben je over van de mensen 
die in het lab werkten toen ik er begon. Je 
bent voor mij altijd de criticus geweest, de 
man die om controles vroeg. Daarmee ben 
je cruciaal geweest voor de kwaliteit van het 
werk dat hier wordt gepresenteerd, ook al 
sta je niet in de auteurslijsten. Dan zijn er de 
analisten die gedurende het tweede en derde 
jaar van mijn promotie ontzettend hard 
hebben gewerkt om een aantal artikelen 
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af te maken: Cristel en Anita. Ik heb het 
voorrecht gehad om als promovendus jullie 
hulp te krijgen. Van mijn mede promovendi 
verdient Niven een aparte vermelding jij 
hebt een belangrijke bijdrage geleverd aan 
het werk dat in dit boekje staat. Dan waren 
er nog de studenten: Michelle, Thomas en 
Mirjam. Jullie hebben een deel van jullie 
studie onder mijn begeleiding in het lab 
gewerkt. Dankzij jullie is het opleiden van 
mensen in het lab een ontzettend leerzame 
en inspirerende bezigheid voor mij geweest. 
Verder wil ik alle andere werknemers 
van het laboratorium medische oncologie 
waarmee ik heb gewerkt bedanken: we 
hebben de jaren die ik er nu werk tot een 
gedenkwaardige mix van gezelligheid, 
inhoudelijke discussies en mooie uitgaans-
momenten gemaakt.
  
Dan wil ik nog mijn paranimfen bedanken. 
Beste Dorus, de laatste jaren van mijn pro-
motie traject en zeker de tijd die ik al weer 
met klinische werkzaamheden heb gevuld, 
ben jij ontzettend belangrijk geweest voor 
het afmaken van de artikelen die nog af 
moesten. Jij hebt een belangrijk aandeel in 
dit boekje gehad.  Harald Jan, wij kennen 
elkaar vanaf onze studie geneeskunde en ik 
ben er trots op dat je nu op dit moment  
naast me staat. Je bent nu weliswaar chirurg 
in opleiding maar toch: ik waardeer je  
vriendschap.
Tenslotte wil ik twee mensen die erg belangrijk 
voor mij zijn noemen: papa en mama. Dankzij 
jullie heb ik dit bereikt en daarvoor ben ik 
jullie ontzettend dankbaar. Jullie hebben iets 
gedaan dat niet veel mensen jullie nadoen: 
mij en mijn broer uit Korea geadopteerd 
om ons hier in Nederland een warme en 
liefdevolle jeugd te geven. Daarnaast 
hebben jullie ook nog 4 pleegkinderen 
langdurig opgevangen en verzorgd. Hiervoor 
verdienen jullie alle lof van de wereld!
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